

Since
1954

ANNUAL REPORT 2020



*Good Health
Good Life*



Indo-Bangla Pharmaceuticals Ltd.

www.indo-banglapharma.com



“TO PROVIDE INNOVATIVE AND QUALITY MEDICINES TO IMPROVE THE HUMAN BEINGS IN ARENA OF HEALTH IN NEED FOR BEST TREATMENTS”



“BE ON THE FOREFRONT OF CHANGING HEALTHCARE ENVIRONMENT TURNING INNOVATIVE SCIENCE TOWARDS ESTEEMED NEW TREATMENT REFERENCES”

BANGLADESH ASSOCIATION OF PUBLICLY LISTED COMPANIES



Ref. No: CM-2020/274

Date of issue : November 25, 2020

Renewed Certificate

This is to certify that

INDO-BANGLA PHARMACEUTICALS LIMITED

is an Ordinary Member of Bangladesh Association of Publicly Listed Companies and is entitled to all the rights and privileges appertaining thereto.

This certificate remains current until 31st December 2020.




Secretary-General



Certificate of Registration

This is to certify that the
Quality Management System
of

INDO-BANGLA PHARMACEUTICALS LIMITED

College Road, Barisal-8200, Bangladesh

Has been independently assessed and is
compliant with the requirements of:

ISO 9001:2015

For the following scope of activities:

**Manufacturing, Marketing and Sales of Pharmaceutical Products
i.e. Tablets, Dry Powder, Syrup, Capsule etc.**

Certificate Number: INT-001812 2019

Date of initial registration	22 nd April 2019
Date of this certificate	25 th April 2019
Certificate expiry (subject to the company maintaining its system to the required standard)	24 th April 2022



Authorised Signatory

This certificate is the property of ACM Limited and shall be returned immediately on request.
ACM Limited, 4 Navigation Court, Harris Business Park, Hanbury Road, Stoke Prior, Bromsgrove, B60 4FD, UK
info@acmcertbd.com



ক্রমিক নং
3061

দি বরিশাল চেম্বার অব কমার্স এণ্ড ইণ্ডাস্ট্রী

গণপ্রজাতন্ত্রী বাংলাদেশ সরকারের বাণিজ্য মন্ত্রণালয়ের স্বীকৃতিপ্রাপ্ত

(১৯৬১ সনের ট্রেড অরগানাইজেশন অধ্যাদেশ অনুযায়ী)

স্বরোড (নাজিরের পুল), বরিশাল।

সদস্যপদ প্রত্যয়ন পত্র

এতদ্বারা প্রত্যয়ন করা যাইতেছে যে, মেসার্স ইন্দ্রা বাণেশ্বর ফার্মাসিউটিক্যালস্ লিমিটেড

কালড এন্ড বরিশাল

(মালিক / নির্বাহী অংশীদার / পরিচালক প্রতিনিধি / নির্বাহী পরিচালক জনাব এ. এফ. এম. আনোয়ারুল হক
ইন্দ্রা বাণেশ্বর ফার্মাসিউটিক্যালস্ লিমিটেড
একটি প্রকৃত ব্যবসায়ী প্রতিষ্ঠান এবং অত্র চেম্বারের সদস্য। প্রতিষ্ঠানটি অতি সুনামের সহিত উৎসর্গ

ব্যবসায় নিয়োজিত আছে। উক্ত প্রতিষ্ঠানের সদস্যপদ সংখ্যা ৫০ এবং উহার রপ্তানী / আমদানী / ইনভেস্টিং

নিবন্ধন সংখ্যা _____

প্রতিষ্ঠানটির সদস্যপদ ৩০শে জুন, ২০২০... পর্যন্ত বলবৎ থাকিবে।



সভাপতি

সচিব



বাংলাদেশ ঔষধ শিল্প সমিতি

BANGLADESH ASSOCIATION OF PHARMACEUTICAL INDUSTRIES
Navana Osman@Link (Level-4), 214/D Bir Uttam Mir Shawkat Avenue
Tejgaon-Gulshan Link Road, Dhaka-1208. Fax: 88-02-8823651
Phone: 88-02-58816767, 9889731, 8824163 E-mail: bdass@bol-online.com

CERTIFICATE NO.

1279

CERTIFICATE OF MEMBERSHIP

MEMBERSHIP NO.

BASS/MD-2020/69

This is to certify that *M/s*

Indo-Bangla Pharmaceuticals Ltd.

College Road, Barisal

is a member of *Bangladesh Ashad Shipa Samity*.

This Association is duly licensed by the Ministry of Commerce, Government of the People's Republic of Bangladesh under reference License No. 3 of 1973 and incorporated with the Registrar of Joint Stock Companies, Bangladesh bearing Certificate No. 3898-B of 1972-1973.

This Association is also affiliated with the Federation of Bangladesh Chambers of Commerce and Industry (FBCCI) Dhaka and International Federation of Pharmaceutical Manufacturers Associations (IFPMA) Geneva.

This Certificate is valid upto 31st December 2020

Ziaul Haq
Secretary
Bangladesh Ashad Shipa Samity

Given on this day of
17 FEB 2020

Naymul Hossain
President
Bangladesh Ashad Shipa Samity

TABLE OF CONTENT

Letter of Transmittal	06
Notice of the Annual General Meeting	07
Shareholders View of the 4th AGM	08-09
Company Profile	10-11
The Board of Directors	12-14
Management Apparatus	15
Chairman's Statement	16
Message from the Managing Director's	17-18
Corporate Governance	19-23
Manufacturing Capabilities	25-26
Corporate Social Responsibilities	27
Product Portfolio	28-33
Corporate Operational Results	34
Directors' Report to the Shareholders	35-43
Management's Discussion & analysis	44-45
Statement of Directors' on Financial Reports	46
Directors' Re-Appointment	47
Shareholding Pattern	48
Report on the Activities of the Audit Committee	49-50
Report on the Activities of the Nomination and Remuneration Committee	51-52
Managing Director & CFO's Declaration	53
Certificate on Compliance of Corporate Governance Guidelines	54
Corporate Governance Compliance Report	55-66
Independent Auditors' Report	67-70
Statement of Financial Position	71
Statement of Profit or Loss and Other Comprehensive Income	72
Statement of Changes in Equity	73
Statement of Cash Flows	74
Notes to the Financial Statements	75-101
Proxy Form	102

LETTER OF TRANSMITTAL

All Shareholders
Bangladesh Securities and Exchange Commission
Dhaka Stock Exchange Limited
Chittagong Stock Exchange Limited
Registrar of Joint Stock Companies & Firm

ANNUAL REPORT FOR THE YEAR ENDED JUNE 30, 2020

Dear Sir/Madam (s)

We are pleased to enclose a copy of the Annual Report containing Directors' Report, Auditors' Report along with Audited Financial Statements including Statement of Financial Position as at June 30, 2020, Statement of Profit or Loss and Other Comprehensive Income, Changes in Equity and Cash Flows for the Year ended June 30, 2020 along with notes thereon.

We in our endeavor have tried our best to make fair disclosures on our financial & non-financial matter as part of our integrated reporting for your kind perusal and record.

Thanking you.

Very truly yours:



Mohi Uddin QCS
Company Secretary
Dated: 20th November, 2020.



INDO-BANGLA PHARMACEUTICALS LIMITED

NOTICE OF THE 6TH ANNUAL GENERAL MEETING.

Notice is hereby given that the 6TH ANNUAL GENERAL MEETING of the Members of Indo-Bangla Pharmaceuticals Ltd. will be held on **Thursday 24th December, 2020 at 11:00 a.m.** Under virtual platform through the link <http://ibp2020.digitalagmbd.net> to transact the following business:

- Agenda-1:** To receive, consider and adopt the Audited Financial Statements for the year ended 30th June, 2020 together with the Report of the Directors' and Auditors' thereon.
- Agenda-2:** To declare dividend for the year ended 30th June, 2020.
- Agenda-3:** To elect Directors in terms of the relevant provisions of Articles of Association.
- Agenda-4:** To appoint Statutory Auditors for the year 2020-2021 and to fix their remuneration.
- Agenda-5:** To appoint Compliance Auditors for the year 2020-2021 and to fix their remuneration.
- Agenda-6:** To approve appointment of the Independent Director.
- Agenda-7:** To transact any other business with the permission of the Chair.

December 09, 2020

Note:

- I. The Record Date of the Company was Monday 23 November 2020.
- II. The Annual Report 2019-2020 and Form of Proxy will be available in the company' website: www.indo-banglapharma.com
- III. As per the Bangladesh Securities and Exchange Commission's Order No. SEC/SRMIC/94-231/25 dated 8 July, 2020, the Annual General Meeting will be conducted virtually by digital platform.
- IV. The link for the virtual AGM and detailed procedures to attend the meeting will be communicated to the shareholder's email ID in due course and it will also be available on Company's website: www.indo-banglapharma.com.
- V. The members are able to submit their question(s)/comment(s) and vote electronically 24 hours before commencement of the AGM and during the AGM.
- VI. The Form of Proxy (scanned copy), duly stamped must be sent through email to the Indo-Bangla Pharmaceuticals Ltd., at info@indo-banglapharma.com not later than 72 hours before the meeting.
- VII. Pursuant to Bangladesh Securities and Exchange Commission's Notification No. BSEC/CMRRCD/2006-158/208/Admin/81 Dated: 20 June 2018, the Annual report 2019-2020 of the Company shall be sent to the respective e-mail address of the shareholders mentioned in their Beneficiary Owners (BO) Accounts with the depository. In case of non-receipt of Annual Report 2019-2020 of the Company through e-mail shareholders may collect the same from the Corporate Office of the Company by submitting written request beforehand.

By order of the Board

(Mohi Uddin QCS)
Company Secretary.

PHOTO GALLERY



PHOTO GALLERY





ABOUT INDO-BANGLA PHARMACEUTICALS LTD.


Indo-Bangla Pharmaceuticals Limited, the prevalent pharmaceuticals company in the Country, is a reliable name in the pharmaceuticals sector of Bangladesh. Like most local concerns, it made its inauguration in a humble way in 1954, founded by Ramlal Vattracharjjo in the heart of Barisal in the name of Indo-Pak Pharmaceutical Works (IPW). At that time, Indo-Pak Pharmaceutical Works started its business aiming to fulfill the basic healthcare demand of the people of Bangladesh. After independence, the government took control of the company and it was registered in Bangladesh under the privatization act in the name of Indo-Bangla Pharmaceutical Works. Later in 1982, the government sold the company through auction to a reputed businessman of Barisal, late Alhaj Shamsuddin Talukder and late Alhaj Azizul Haque. They started commercial operations with producing high quality medicine at a reasonable price with a goal to reach healthcare services to the doorsteps of the common people of Bangladesh as well as all over the world.

On June 18, 2014, Indo-Bangla Pharmaceuticals Works converted into a Private Limited Company under the Companies Act 1994, vide registration no. C116665/14. Subsequently on 21 October 2014, it converted into a Public Limited Company and thereafter became a Publicly Listed Company listed with Dhaka and Chittagong Stock Exchange Ltd., in 2018.

Since established, Indo-Bangla committed to providing high quality medicines, business success with ensuring ethical standards and responsibility to valuable customers/patients. Our tradition and our values are the foundation of our mission to ensure health, heartiness and happiness for mankind.

We are an ISO 9001:2015 certified company and committed to improving the quality of human life by enabling people to do more, feel better and live longer. We also believe and adhere to values like Quality, Knowledge and Responsibility in all aspects of its operations and earned respect and recognition of its valued customers as well as to emphasize on the quality of product, process and services leading to the growth of the company imbued with good governance practices.

CORPORATE INFORMATION

Registered name of the company	Indo-Bangla Pharmaceuticals Ltd.
Company Logo	
Legal Form	A Private Limited Company incorporated in Bangladesh on June 18, 2014 under The Companies Act, 1994 (Reg. no. C-116665/14) and converted into Public Limited Company on October 21, 2014. The company was listed with Dhaka and Chittagong Stock Exchange on October 2018.
Converted Public Limited Company	21-Oct-14
Commencement of Commercial Operation	18-Jun-2014
Registered Office	729, College Road, Barisal Sadar, Barisal-8200.
Corporate Office	Plot No. # 183 (7th Floor), Block # B, Ahmed Akbar Sobhan Road, Bashundhara R/A, Baridhara, Dhaka-1229.
Factory Address	729, College Road, Barisal Sadar, Barisal-8200.
Tax Identification Number	681332543219
VAT Registration Number	15101029766
Website Address	www.indo-banglapharma.com
E-mail Address	info@indo-banglapharma.com,
Import Identification Number	260306120000319
Export Identification Number	260306210000519
Authorized Capital	BDT 1500 million
Paid-up Capital	BDT 1115 million
Nature of Business	The Company is engaged in manufacturing and selling of all kinds of medicine (excluding Antibiotic), medical preparations drugs & chemicals (Human Health). The Company applied for permission for production and selling of veterinary medicine also.
Statutory Auditor	Fames & R., Chartered Accountants
Compliance Auditor	Shafiq Basak & Co., Chartered Accountants
Membership	Bangladesh Association of Publicly Listed Companies (BAPLC) Bangladesh Association of Pharmaceutical Industries (BAPI) Barisal Chamber of Commerce and Industry (BCCI)



BOARD OF DIRECTORS



MRS. AZIZZA YEASMIN, is a Director of the Company since 2014 and has been appointed as Chairman in 2016. She is the daughter of late Azizul huq, Founder of Indo-Bangla Pharmaceuticals Works, converted into a Private Limited Company under the companies Act 1994, on 21 October 2014, after than converted into a Public Limited Company and become Publicly Listed Company in 2018. She has a rich experience of more than 12 years in the pharmaceuticals sector.

AZIZA YEASMIN
Chairman

MR. A F M ANOWARUL HUQ, is a Director of the Company since 2014 and has been appointed as Managing Director in 2014. Further that he has been appointed as Managing Director in 2019 for an another tenure. He is the son of late Azizul Huq, founder of Indo-Bangla Pharmaceuticals Works. Mr. Huq obtained Master's Degree in Chemistry, MBA in marketing & LLB from the National University and obtained certificate of completion on GMP Training in various countries conducted by WHO. Mr. Huq has a prosperous experience of more than 22 years in Pharmaceuticals, Shipping, apparels as well as others family Business.

Mr. Huq also a Sponsor Director in other private limited company namely HBS Apparels Limited., Talukder Dairy Firm Limited., IBP Agrovet Ltd., Sabila Sea Foods Ltd., & BD Pharmaceuticals Ltd.,

Mr. Huq was a Former President of Rotary club of Barisal Mid Town; Apex club of Barisal; Chairman of Employers Committee of UCEP, Barisal; Director of the Barisal Chamber of Commerce & Industry; Director of FBCCI;

At present he is the member of Ghatail Golf Club (GGC), Bangladesh Association of Publicly Listed Companies (BAPLC), Bangladesh Association of Pharmaceuticals Industries (BAPI), Barisal Chamber of Commerce and Industry (BCCI), lifetime member of Barisal Club Ltd, Barisal; Diabetic Hospital, Barisal; Red Crescent, Barisal; Heart Foundation, Barisal; Anjuman-E Hemayat-E Islam, Barisal.



A F M ANOWARUL HUQ.
Managing Director

BOARD OF DIRECTORS



MRS. SAYEDA HUQ is a Non-Executive and Sponsor Director of Indo-Bangla Pharmaceuticals Ltd., since 2014. She is the wife of late Azizul Haque, Founder of Indo-Bangla Pharmaceuticals Works. She has a rich experience of more than 18 years in the Pharmaceuticals and other sector. In addition, her present role, she is a member of Nomination and Remuneration Committee of the Company and has been playing role to assist the Board in formulation of the nomination policy for determining qualifications, positive attributes, experiences and independence of directors and top level executives as well as a policy for formal process of considering remuneration of directors & top level executives.

SAYEDA HUQ
Director

MR. MD. IFTIKHAR-UZ-ZAMAN, joined as Independent Director on the Board of Indo-Bangla Pharmaceuticals Limited in January 2020. He is the Chairperson of Audit Committee of Indo-Bangla Pharmaceuticals Ltd. He obtained B.A. (Hon's) and M.A. in Statistics from the University of Rajshahi.

Mr. Zaman has a rich experience of more than 33 years in corporate arena. He was appointed as the Managing Director (additional Charge) of Investment Corporation of Bangladesh (ICB) in December, 2015. Thereafter, he has been appointed as the Managing Director of Investment Corporation of Bangladesh (ICB) on 4 February 2016. He joined ICB in 1983 as Senior Officer. During his 33 years long professional career he rendered his duties as the CEO of ICB Capital Management Ltd. (ICML), GM of ICB, Chairman of ICB Securities Trading Company Ltd. (ISTCL) & ICB Asset Management Company Ltd. (IAMCL), DMD of Janata Bank Ltd. & ICB.



MD. IFTIKHAR-UZ-ZAMAN
Independent Director



MD. GOLAM RABBANI
Director

MR. MD. GOLAM RABBANI, has been appointed as a Director on the Board of Directors of Indo-Bangla Pharmaceuticals Limited in 2017 nominated by the Investment Corporation of Bangladesh. He is a Deputy General Manager of Investment Corporation of Bangladesh (ICB). He joined in ICB as a senior officer in 1989. He completed his B.Sc (Honors) & M.Sc degrees in Economics from Jahangirnagar University. Mr. Rabbani during his tenure in ICB served in different Departments, Divisions and Branches including Law, Documentation, Special Fund Management Unit, Public Relations, Investors' Department and contributed a lot for the Corporation as well as to the Investors. Mr. Rabbani during his long service in ICB took part in different training programs among them Investment Banking, Venture Capital, Laws, Rules and Regulations, Land Management and Documentation, Handling of Disciplinary Cases, Public Relations etc. He also took part in different computer training programs. He is the ICB nominated Director of ICB financed projects like Indo-Bangla Pharmaceuticals Ltd. He traveled in Japan, Singapore & India several times.

BOARD OF DIRECTORS



AYSHA SIDDIKA
Director

MRS. AYSHA SIDDIKA, has been appointed as a Non- Executive Director on the Board of Directors of Indo-Bangla Pharmaceuticals Limited in August 2020. Mrs. Siddika is also a sponsor of the company. She obtained Master's and has a rich experience of more than 13 years in Administration and Human Resource and pharmaceuticals sector.

MRS. FATIMA PARVIN is a Director of Indo-bangla Pharmaceuticals Ltd., since 2016, Daughter of Dr. Ali Akbar Mia. She obtained L.L.B (Hon's) and L.L.M from the Dhaka International University and has an experience of more than 13 years in the pharmaceuticals sector. In addition, her present role, she is a member of Audit Committee of the Company and has been playing role to review and recommend to the Board to approve the quarterly and annual financial statements prepared for statutory purpose. She is also the columnist of the Bangladesh Protidin, Daily Samakal, Daily JaiJai Din and Daily Aurthoniti protidin.



FATIMA PARVIN
Director



HAFIZA YEASMIN
Director

MRS. HAFIZA YEASMIN, is a Sponsor Director of Indo-Bangla Pharmaceuticals Ltd. since 2014. She is a daughter of late Azizul Huq, Founder of Indo-Bangla Pharmaceuticals Works. She has a business experiences of more than 13 years in the pharmaceuticals sector. After coming back from Denmark, she joined in Indo-Bangla Pharmaceuticals Ltd. as a Director and also director in other Private Limited Company.

MD. MIZANUR RAHMAN, is a Director of Indo-bangla Pharmaceuticals Ltd. since 2014 Mr. Rahman has a business experiences of more than 11 years in the manufacturing industry including Pharmaceuticals sector. He is also Director in other Private Limited Company.

MD. MONIRUJJAMAN, Joined as Independent Director on the Board of Director of Indo-bangla Pharmaceuticals Ltd. He is Advocate of Hon'ble High Court, son of Abdur Rab Khan. He obtained Master of law from Dhaka International University & started Advocate practicing at the High Court Division of Bangladesh Supreme Court. He has a rich experiences of more than 14 years. In addition, his present role, he is a Chairman of Nomination and Remuneration Committee and member of Audit Committee of the Company.

MANAGEMENT APPARATUS



Board of Directors

1. Mrs. Aziza Yeasmin	Chairman
2. Mr. A F M Anowarul Huq	Managing Director
3. Mrs. Hafiza Yeasmin	Director
4. Mrs. Aysha Siddika	Director
5. Mrs. Sayeda Huq	Director
6. Mr. Md. Golam Rabbani	Director
7. Mrs. Fatima Parvin	Director
8. Md. Mizanur Rahman	Director
9. Mr. Md. Iftikhar-Uz-Zaman	Independent Director
10. Mr. Md. Monirujjaman	Independent Director

Audit Committee

• Mr. Md. Iftikhar-Uz-Zaman	Chairman
• Mr. Md. Monirujjaman	Member
• Mrs. Fatima Parvin	Member

Nomination and Remuneration Committee

• Mr. Md. Monirujjaman	Chairman
• Mrs. Sayeda Huq	Member
• Mr. Md. Mizanur Rahman	Member

Company Secretary

• Mohi Uddin, QCS	Company Secretary.
-------------------	--------------------

Management Team

• Mr. A F M Anowarul Huq	Managing Director
• Mr. Md. Faruque Hossain	Chief Financial Officer
• Mr. Md. Abu Taleb	Head of Internal Audit and Compliance
• Mr. Shah E Azam	Plant Manager
• Mrs. Dilruba Begum	Head of Quality Assurance
• Mr. Mizanur Rahman	Head of Admin

CHAIRMAN'S STATEMENT



AZIZA YEASMIN
Chairman



"WE STRIVE ALL, FOR TOP QUALITY MEDICINES AT A LOW PRICE REACHING THE HEALTHCARE SERVICES TO THE DOOR STEP OF THE COMMON PEOPLE.

Bismillahir Rahamanir Rahim
The Beloved Shareholders,
Assalamu Alaikum Wa Rahmatullah.

With deep appreciation and respect, I on behalf of the Board of Directors welcome you all at this 6th Annual General Meeting of the Shareholders and thank you for attending this auspicious gathering which is being held as part of Compliance. It is a great pleasure for me to be empowered to submit, on behalf of the Board of Directors, before you the Annual Report 2019-2020 along with the Audited Financial Statements, the Auditors' Report and the Directors' Report thereon for the year ended 30th June, 2020 as required under the Companies Act 1994 and Regulations of Bangladesh Securities and Exchange Commission for your kind review and observation, if any and approval thereof by you at this 6th Annual General Meeting.

We in Indo-Bangla Pharmaceuticals Ltd., strive all, for top quality health care products at the low cost reaching the lowest rungs of the economic class of people in the country. Our business policy and our priority is to drive long term value for investors through renewed focus on innovation and improving performance of Company to ensure maximum shareholders return and believe that the future development of Indo-Bangla Pharmaceuticals Ltd., including overall function of the company alongside the management of the Company would be ensured by your dynamic cooperation and suggestion

We are pleased to notify you that in this year 2019-2020, Indo-Bangla Pharmaceuticals Ltd. passed another successful year maintained its sustainable achievement in terms of Earning Per Share (EPS), Net Operating Cash flow and profit earning as well. The Gross Profit, Operating Profit and Net Profit increased during FY 2019-2020 respectively over the previous year. However, the Cost of Goods Sold increased at 17% over previous year which helped increase Gross Profit and Operating Profit. The Net Profit After Tax, however, increased by 0.66% and Earning Per Share increased by 0.72% over the previous year reflect our efficiency in achievement of growth landmark, driven by implement of different business strategy like, to provide better medicine and healthcare services by enhancing the product portfolio with innovations as well as by efficient marketing policy and using the latest technologies in production plant.

Bangladesh is inching ahead in doing business climate index and other socioeconomic indices and had made remarkable progress in the growth rate of GDP and has already entered the socio-economic classification of Lower Middle Income Group targeting to reach higher Middle Income Group by 2021 and Higher Income Group by 2041. As a result GDP growth continues, the per capita income would rise leading to higher health care expenditures by families as well as the government. This is expected to augment the demand for pharmaceuticals at a higher rate than the existing level.

Based on the success of 2019-2020, on behalf of the Board of Directors, I would like to express my sincere acknowledgement to the contribution made by the management team and employees of all levels for their tireless efforts. I also would like to express my heartfelt gratitude to our valued Shareholders, Customers, healthcare professionals, Suppliers, Bangladesh Securities and Exchange Commission (BSEC), Dhaka Stock Exchange (DSE), Chittagong Stock Exchange (CSE), Central Depository Bangladesh Limited (CDBL), Registrar of Joint Stock Companies and Firms (RJSC), Government agencies and all concerned for their continued support. Thanking you all with best wishes and kindest regards.

Sd/-

(Mrs. Aziza Yeasmin)

Chairman

MESSAGE FROM THE MANAGING DIRECTOR



WE STRIVE FOR PROTECTION OF OUR SHAREHOLDERS CAPITAL AS WELL AS ENSURE HIGHEST RETURN AND GROWTH OF THEIR ASSETS.

16.13%
Rise in sales
BDT 125.38 million



20.04%
Rise in Net Margin Before Tax
BDT 36.23 million



92.61%
Rise in Cash Dividend
BDT 12.29 million



Bismillahir Rahamanir Rahim

Dear Shareholders, Colleagues, Ladies and Gentlemen
Assalamu Alaikum Wa Rahmatullah.

I am delighted to welcome you all at this 6th Annual General Meeting of Indo-Bangla Pharmaceuticals Limited and thank you for attending the auspicious gathering which is being held as part of Compliance of the Regulations of the Companies Act, Bangladesh Securities and Exchange Commission and other provisions of Corporate Culture. As required, the Audited Financial Statements pertaining to the FY 2019-2020 along with Independent Auditor's Report and related report from the Audit Committee of the Board which is Chaired by an Independent Director, Report of the Directors on the operation and management of the affairs of the Company, proposals of the Management/Board of Directors on statutory requirement as well as future outlook etc., as embodied therein, have been sent to you in advance, which I hope, has offered you the scope of screening of the performance of the Company.

I feel your review of the activities, operations and the resultant effect on the operating/financial results will present a picture of unbroken growth line in income and investment values as the efforts given by the Management, officers, employees and workers have greatly contributed to the success in this regard. On behalf of my fellow board members, I express my earnest thanks and profound gratitude to you for your enormous support and coordination. It is a great pleasure for me to be empower to submit, on behalf of the Board of Directors, the Annual Report 2019-2020 containing the Directors' Report and Financial Statements for your kind review and observation, if any and approval thereof by you at this 6th Annual General Meeting.

On this auspicious occasion, I would like to introduce the Annual Report 2019-2020 furnishing before you the Company's Financial Statements for the year ended 30 June 2020, the achievements and a review of gradual and sustainable progress of the Company. I am also delighted

to report you that the company achieved sales of Tk. 866,097,783 in 2019-2020 with growth of 16.93% as compared to last year. During the year, Indo-Bangla Pharmaceuticals Limited was able to maintain to continual development with regard to the earning per share, net operating cash flow and ensure net profit due to effective measures taken by Management in raw material purchase, utilization of expansion capacity, use of new infrastructure with GMP facilities, Financial cost, operating expenses and inventory management resulting in increase in EPS by the same level.

The Net Profit after Tax has increased to Tk. 156,243,664 Which 0.65% higher than the previous year. In 2019- 2020, the Company has maintained its growth in Profit comparing to the previous year. It is anticipated that positive momentum will continue in the coming year. Based on performance and business results the Board has recommended 2% Bonus Share (Stock dividend) in view to utilized its retained amount as capital for business expansion as well as working capital and 4.5% cash totaling 6.5% for the year 2019-2020.

You know that, Worlds' most of the country have been badly affected by the Corona pandemic and Bangladesh is no exception to that, for which Economy and Companies all are affected at certain ranges whether that is significant or insignificant. Indo-Bangla Pharmaceuticals Limited also effected by COVID-19 pandemic since its outbreak, is mostly dependent on India and China for raw materials, with 80 per cent of Raw Materials coming from these two countries.

In spite of all the challenges, we achieve 63.93% growth in sales and a good number of products have been added to our portfolio. This increase has been possible due to utilization of expansion capacity, use of new infrastructure with GMP facilities, manufacturing of more sophisticated new products having high profit margin, good management policies for reducing the overall manufacturing cost as well as our management team who are working for a better future for our stakeholders, buyers, employees and society at large.

Pharmaceuticals industry has been one of the success stories of Bangladesh in the last three decades. Bangladesh had to depend largely for medicines on multinational companies and imports in the 1970s and early 80s. Now local companies meet almost 98 percent of domestic demand worth around USD 2 billion or Tk.16,000 crore.


Domestic market of Pharmaceutical products in Bangladesh has shown an increasing trend over the past few years and the market size is increasing day by day. According to Bangladesh Association of Pharmaceutical Industries (BAPI) and Directorate General of Drug Administration (DGDA), approximately 257 licensed pharmaceutical manufacturers are operating in Bangladesh and about 150 are functional. These manufacturing companies meet around 98% of local demand.

IBPL is striving to upgrade and adopt new technology in production, quality control, distribution and administration of its products to produce new generation drugs as the faster growth of new and lifesaving drugs to customers/patients. the company invested a substantial amount in improving its Laboratory facilities, R&D Scale-up facilities etc.

I would like to promise you that, our hard effort to increase the company's growth, wealth as well as to maximize the shareholder's equity will continue as before. Our effective and efficient management with skilled labor stands the main value drivers force of company. We strongly believe that the growth of the company, market stability as well as exercise good corporate governance of the Company will gradually rise in future by utilizing our optimum capacity through better corporate strategy.

I conclude by expressing my thanks to all employees of IBPL for the hard work they have put in during the last year. On behalf of the Board, I convey my sincere appreciation to our valued Business Partners, the Healthcare Professionals and Institutes, Suppliers and Government Authorities for their trust and continued support to the Company.

Finally, I pray to Almighty Allah to bless us with success and help us in our endeavor marching towards a bright future and benevolence to our people as a whole.



(Mr. A F M Anwarul Huq)
Managing Director



The Board of Directors of Indo-Bangla Pharmaceuticals Limited and the Management of the Company are committed for achieving high standards of Corporate Governance through increasing transference, accountability and compliance with Bangladesh Securities and Exchange Commission’s Notification dated 03 June, 2018. Corporate Governance involves decision making processes for any corporate body as a going concern for the benefit of all concerned, present and future. These decisions may be categorized as policy & strategic, operational and executing, performance & evaluation and sharing of the accretion assets between present & future cohorts. The involvement of the entrepreneur in all these areas invokes decision making governance on a continuous basis, the degree of involvement being variable with the extent of delegation of authority top down and reporting for accountability bottom up of the Management echelon. These aspects of governance are shared by the Board of Directors, Executive Management, operational participants and workers and others in fulfillment of the common goals that converge in increasing the benefits of all stakeholders. To this end entire corporate governance efforts are blended with "good governance practices" as ethically and morally acceptable standards under a given socio politico environmental phenomenon of our society in which we work, live and exist. The organisms through which the corporate governance functions are carried out are:

BOARD OF DIRECTORS

The Board of Directors consist of Ten (10) members including the Independent Directors with versatile knowledge, professional skills and experience which provides a balancing character in decision making process. There is a clear division of responsibilities between the Chairman's functions and that of Managing Director. The Chairman is mainly responsible for chairing the Board Meeting as well as the AnnualGeneral Meeting.

On the other hand, the Managing Director is responsible for implementing and coordinating the Company's corporate and commercial programs to achieve its business objectives.

The present members of the Board of Directors are as follows:

Name	Position
Mrs. Aziza Yeasmin	Chairman
Mr. A F M Anowarul Huq	Managing Director
Mrs. Aysha Siddika	Director
Mrs. Sayeda Huq	Director
Mrs. Hafiza Yeasmin	Director
Mr. Md. Golam Rabbani	Director
Mrs. Fatima Parvin	Director
Mr. Mizanur Rahman	Director
Mr. Md. Monirujjaman	Independent Director
Mr. Md. Iftikhar-Uz-Zaman	Independent Director

During the year under review the board held 10 (ten) meetings to transact various agenda. The Board is re-constituted every year at each Annual General Meeting when one-third of the members retire and seek re-election. A director is liable to be removed if the conditions of the Articles of Association and the provisions of the Companies Act 1994 are not fulfilled.

ROLE AND RESPONSIBILITIES:

The main role of the Board of Directors, which is the highest level of authority, is to provide general superintendence, oversee the operations and control the affairs of the company through appropriate delegation and accountability processes via the lines of command. However, the Board of Directors hold the ultimate responsibility & accountability with due diligence for conducting the activities of the company as per provisions of law in the interest of the shareholders, the stakeholders, the state

and the society. The Board of Directors, in fulfillment of its responsibility hold periodic meetings, at least once a quarter and provide appropriate decisions/ directions to the Executive Management. Such meetings usually consider operational performance, financial results, review of budgets, capital expenditure proposals for BMRE or new projects/divisions/product lines, procurement of funds by issue of shares or borrowing, procurement of raw materials, plant & machinery, pricing of products/ discounts, recruitment, training and promotion of officers, approval of audited accounts and distribution of dividends and other interest of the stakeholders including the employees and workers. The Board of Directors take special care in designing and articulating productivity and compensation plans of employees and workers and rewarding them appropriately on the basis of quality and quantity of performance as an incentive. Board also remains responsible for removal of operational hazards to life and health of workers, friendly environmental work condition and social relationship as demanded of good citizen in a country. The Board has authorized the formation of a number of Committees to implement the stated policies and activities. The Committees are: Audit Committee, NRC Committee. The Audit Committee ensures that adequate internal checks & balances supported by adequate MIS are in place for detection of errors frauds and other deficiencies. The other responsibilities include inter alia, not being limited to, the prevention of conflict of interest between the company and its Directors officials, customers, suppliers, government and any other interest groups and detect or remove any scope of insider trading in the company's stock. The Audit Committee also ensures compliance of requirements of BSEC and other agencies. The details about Audit Committee including composition, responsibilities, meetings, reporting and activities carried by the Audit Committee is disclosed in the Annual Report in "Report of the Audit Committee".

RELATIONSHIP WITH SHAREHOLDERS AND GENERAL PUBLIC:

The shareholders as owners, are required to be provided with material information on the company's operation quarterly, half-yearly and annually, the latter at the AGM. They are also provided routine services by the Company Affairs Division in matters of their various queries, shares related queries, payment of dividends etc. The Board is however responsible to the public for publication of any price sensitive information as per BSEC regulation. A qualified Chartered Secretary is in charge for all these responsibilities as Company Secretary.

RELATIONSHIP WITH SUPPLIERS:

As the company has to import plant and machinery and almost all the raw materials from abroad, it maintains cordial and mutually beneficial interest with its international as well as local suppliers. This has enabled the company to avoid any legal disputes in international/local courts and enhanced the company's image as a good customer.

CORPORATE SOCIAL RESPONSIBILITIES (CSR):

The Board of Directors is also awoken of the Corporate Social Responsibilities (CSR) especially in the areas of gender equality, race, religion, regional equality, non-employment of child labour, human rights, environmental pollution, social-marketing, social activities.

DISTINCTIVE ROLE OF THE CHAIRMAN & MANAGING DIRECTOR:

The positions of Chairman of the Board and the Managing Director of the Company are filled by different individuals who are member of the Board. The Chairman of the Board elected from the non-executive directors of the company as per requirement of Bangladesh Securities and Exchange Commission (BSEC).

CHIEF FINANCIAL OFFICER, HEAD OF INTERNAL AUDIT AND COMPANY SECRETARY FILLED BY DIFFERENT INDIVIDUALS:

The Company has appointed Mr. Md. Faruque Hossain as Chief Financial Officer, Mr. Mohi Uddin, QCS as Company Secretary and Mr. Md. Abu Taleb as Head of Internal Audit of the company as per requirement of Bangladesh Securities and Exchange Commission (BSEC).

BOARD OF DIRECTOR'S COMMITTEE: AUDIT COMMITTEE

The Board has formed an Audit Committee of the Board consisting of three (3) member to assist the Board in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and ensuring a good monitoring system within the business.

The Board of Directors has formed an Audit Committee of the Board, the committee comprised of Mr. Md. Iftikhar-Uz-Zaman, Independent Director, Mr. Md. Monirujjaman, Independent Director and Mrs. Fatima Parvin, Director. All the members of the Committee are Non-Executive Directors and the Chairman of Audit Committee is an Independent Director.

The Audit Committee carries out its responsibilities as per the provisions of law and submits its report to the Board of Directors from time to time. The Audit Committee shall also co-ordinate with the Internal and external Auditors as and when required. The Audit Committee ensures that adequate internal checks & balances supported by adequate MIS are in place for detection of errors frauds and other deficiencies. The other responsibilities include inter alia, not being limited to, the prevention of conflict of interest between the company and its Directors officials, customers, suppliers, government and any other interest groups and detect or remove any scope of insider trading in the company's stock. The Audit Committee also ensures compliance of requirements of BSEC and other agencies. exercise such other powers as may be delegated/directed by the Board of Directors from time to time.

The Audit Committee of Indo-Bangla Pharmaceuticals limited is comprised of 3 (three) Members of the Board of Directors including 2 (two) Independent Directors. The composition of the present members of Audit Committee as follows:

Name	Position
Mr. Md. Iftikhat-Uz-Zaman Independent Director	Chairman
Mr. Md. Monirujjaman Independent Director	Member
Mrs. Fatima Parvin Director	Member

Mr. Mohi Uddin, QCS Company Secretary is the Secretary to the Audit Committee. The number of the meeting held during year ended June 30, 2020 were 4 (four). The details of the Audit Committee including background, composition, responsibilities, meeting, reporting and activities carried out by the Audit Committee is disclosed in this Annual Report in "Report of the Audit Committee".

NOMINATION AND REMUNERATION COMMITTEE:

The Board of Directors formed a Nomination and Remuneration Committee of the Board comprising of three Non-Executive Directors namely MD.Monirujjaman, Independent Director, Mrs. Sayeda Huq, Director and Mr. Md. Mizanur Rahman, Director. The Chairman of the Committee is an Independent Director. The terms of reference of the Nomination & Remuneration Committee inter alia include to determine the Company's policy on specific remuneration packages for executive directors, to review, recommend and/or approve remuneration to

whole-time Directors, to review and approve the Remuneration Policy of the Company, to formulate criteria for evaluation of Independent Directors and the Board, to devise a by the Board of Directors from time to time.

The Nomination and Remuneration Committee of Indo-Bangla Pharmaceuticals limited is comprised of 3 (three) Members of the Board of Directors including 1 (one) Independent Directors. The composition of the present members of Audit Committee as follows:

Name	Position
Md. Monirujjaman Independent Director	Chairman
Mrs. SayedaHuq, Director	Member
Md. Mizanur Rahman Director	Member
In attendance	- Chairman - Managing Director External - - Advisers – by invitation Any - - Non-Executive Director shall be entitled to attend the Committee's meetings.

Mr. Mohi Uddin, QCS Company Secretary is the Secretary to the nomination & Remuneration Committee. The number of the meeting held during year ended June 30, 2020 were 2(two).

EXECUTIVE MANAGEMENT

The Executive Management is led by the Managing Director who is appointed by the Board of Directors for a term of 5 years (renewable) with the approval of shareholders in the Annual General Meeting. The Managing Director is supported by professional, well educated, trained and experienced team consisting of Directors, General Managers and a host of Senior Executives in the hierarchy of management. The Board has approved an organogram with modern features ensuring clear lines of delegation of authority and reporting for accountability for effective decision making evaluation of performance on merit for both rewarding and disciplinary action. The Executive Management is responsible for preparation of budgetary segment plans/ sub segment plans for every cost/profit centers and are held accountable for performance therefore. The Executive Management is aided by committee(s)/sub-committee(s) in carrying out its functions. policy on Board Diversity, to identify persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down and recommend to the Board the appointment or removal of such persons and to discharge such other functions

OTHER GOVERNANCE APPARATUS

The Company, in its efforts for Corporate Good Governance Practices, uses a series of top ranking professional service providers including Legal experts, Bankers, Insurers and Technical experts who continuously assist the Board of Directors and the Executive Management in properly discharging their duties to all the shareholders, stakeholders, the Government and the public as highlighted below:

INDEPENDENT DIRECTOR

In compliance of the BSEC Regulations on Good Governance, the Board of Directors as empowered by the Regulations, appointed Mr. Md. Iftikhar-Uz-Zaman, former Managing Director of Investment Corporation of Bangladesh (ICB). He joined ICB in 1983 as Senior Officer. During his 33 years long professional career he rendered his duties as the CEO of ICB Capital Management Ltd. (ICML), GM of ICB, Chairman of ICB Securities Trading Company Ltd. (ISTCL) & ICB Asset Management Company Ltd. (IAMCL), DMD of Janata Bank Ltd. & ICB. And Mr. Md. Monirujjaman Advocate of Supreme Court of Bangladesh as the non-shareholding Independent Director with an expectation that their expertise would help contribute to the further disclosure and protect the interest of the stakeholders, investors in general and smaller investors in particular.

FINANCIAL AUDITOR

The role of the auditors in certification of the financial statement is the most significant aspect of Corporate Governance and protection of interest of investors. As evident from the Annual Reports, the company rigidly follows the Companies Act, Rules of Bangladesh Securities and Exchange Commission, listing regulation, code of International Financial Reporting Standards (IFRS), International Accounting Standards (IAS) and International Standard of Auditing (ISA) with legally required disclosures of Accounts and Financial Statements.

All this has been possible due to the high level capability and integrity of M/s. MahfelHuq & Co., Chartered Accountants whose unchallenging performance has played a very trustworthy role in the protection of interest of the investors. Pursuant to the Companies Act-1994 every Company shall, at each Annual General Meeting appoint an auditor to hold office from conclusion of the Annual General meeting until the next Annual General Meeting. As per Regulation-15 (2) Dhaka & Chittagong Stock Exchange (Listing) Regulation-2015, The issuer of listed securities shall not appoint any firm of chartered accountants as its statutory auditors for a consecutive period exceeding three years. In this connection, M/s. MahfelHuq, Chartered Accountants, the present Statutory Auditor of the company has been completed a consecutive period of

three years, thus M/s. Mahfel Huq, Chartered Accountants, being not eligible to re-appointment for performing the auditing of financial statements of the Company. Therefore, the Board of Directors recommended the appointment of M/S. FAMES & R. Chartered Accountants, as the Statutory Auditor of the Company for the Financial Year 2020-2021, and to continue the next Annual General Meeting subject to approval of the shareholders at the forthcoming 6th Annual General Meeting of the company."

COMPLIANCE AUDITOR

The compliance auditors is responsible in certification on compliance of conditions of Corporate Governance Code 2018 of Bangladesh Securities and Exchange Commission as well as the provisions of relevant Bangladesh Secretarial Standards of Institute of Chartered Secretaries of Bangladesh. M/s. Shafiq Bask & Co., Chartered Accountants is the compliance auditors of Indo-Bangla Pharmaceuticals Ltd. appointed by its shareholders in general meeting.

LEGAL ADVISERS:

In order to avail the best legal services for Good Corporate Governance, the company has appointed Mr. Shahadat Hossain and Mr. Humayun Kabir to support the Company's Good Governance efforts.

BANKERS:

The degree of efficient business operation largely depends on the quality of efficiency of banking services received by the company. Efficient banking service brings down cost of operations. On the other hand, cost of financial services and interest on the lending by the banks are also required to be the minimum. With this end of view, the company has established long term business relationship with the banks namely First Security Islami Bank Ltd., Sonali Bank Ltd., Dutch-Bangla Bank Ltd., Pubali Bank Ltd., Mercantile Bank Ltd., and Islami Bank Ltd., who provide most efficient service at minimum cost that benefit the shareholders.

INTERNAL AUDIT AND CONTROL:

The Indo-Bangla Pharmaceuticals Limited. Considers that internal audit is one of the important regular function of the Company. The Company has an independent internal audit department under control of the Audit Committee of the Board. Department of Internal Audit and Control gives effort to bring a methodical disciplined approach to evaluate and improve the effectiveness of the organization's risk management process, system of the internal control and governance.

SHAREHOLDERS' RELATIONSHIP:

Corporate Governance issues include how major policy decisions are made in business corporations, how various stakeholders can influence the process, who is held accountable for performance and what performance standards are applied. In a nutshell power and influence are crucial in corporate governance.

. As shareholders belong to the most important stakeholders, ownership structure has an impact on the balance of power among shareholders. Though sponsors usually hold majority shares required for ordinary resolutions, public shareholders have a definite role and influence in the passing of special resolutions required for changes in the business object, sale of business/productive assets, merger and amalgamation, winding up or dissolution and amendments to Memorandum and Articles of Association for protection of minority interest up to 51.35% of the shareholdings. The position of shareholders as on 30th June, 2020 indicates that the sponsors of the company do not hold the required shareholdings (75%) for passing special resolutions. This allows the public shareholders (individuals & institutions) to play an effective role in protecting their legal corporate rights. The Company holds regularly as per law the Annual General Meeting with adequate notice and disclosures in the Directors' Report and the Auditors' Report on Accounts/Notes and resolutions are passed with consensus and unanimity. All reasonable and practicable suggestions are implemented with good grace. Special Resolutions are passed in General Meeting with due notices periods. All enquiries are attended by the Company Secretary. Where necessary, Internal Audit Committee investigates matters of significant merit for consideration by the Management Committee/Managing Director/Audit Committee of Board/Board of Directors as the case may be. The Shareholders as owners are provided with material information on the Company's operation quarterly and annually. They are also provided routine services by the Company Secretary in any company matters which is permissible. The Board is however responsible to the Shareholders as well as investors for publication of price sensitive information as per regulations of Bangladesh Securities and Exchange Commission.

Total No of Shares	11,15,07,000	100%
Sponsor & Director	5,46,95,982	49.05%
General Public	4,71,23,534	42.26%
Foreigners	64,792	0.06%
Institutions	96,22,692	8.63%

The Company has also a web site to provide permissible information, notices, price sensitive information, financial reports, disclosures and others for the Shareholders and interested investors.

DIVIDEND POLICY

Ethics is an ingredient of Good Governance and involves a determination of what is right and what is wrong and deals with things to be sought and things to be avoided with way of life and the end of life. Ethics invokes the management of the environment within which we function from a perspective broader than, but obviously inclusive of, the current cohort. Since the corporate environment is in theory an infinitely lived entity owned by finitely lived shareholders,

a governance ethic must represent a system that serves the needs of the current ownership while preserving the ability of the corporation to sustain itself and benefit future cohorts.

The corporate ethic must necessarily promote efficiency in coexisting with the environment to generate the quality of life for a current cohort and yet also provide an equity that does not disadvantage a future cohort by the decisions of a current cohort.

As an environmental ethic analogy, those living today naturally believe in dividend payouts today with less regard for the consequence tomorrow and those living tomorrow would prefer dividend payouts tomorrow without regard for the sacrifices we make today to allow their greater consumption tomorrow.

Based on the above concept, the company is committed to show a stable policy of distribution (cash outlay) of the accretion wealth (profits) between the current and the future generation of shareholders. This would enable the company to enhance its capital wealth and sustain for perpetuity of existence, benefiting both the present cohorts and the progeny. Future generation of shareholders. This would enable the company to enhance its capital wealth and sustain for perpetuity of existence, benefiting both the present cohorts and the progeny.

CORPORATE SOCIALIZATION

In order to play a model role for Good Governance characteristics in the corporate sector, the company has become members of chamber

- Barisal Chamber of Commerce & Industries (BCCI).
- Dhaka Stock Exchange Ltd. (DSE)
- Chittagong Stock Exchange Ltd. (CSE)
- Bangladesh Association of Publicly Listed Companies (BAPLC)
- Central Depository Bangladesh Limited (CDBL).
- Bangladesh association of Pharmaceutical Industries (BAPI)

These memberships have provided scope to the company for improvement of Corporate Governance Practices for the benefit of the shareholders as well as stakeholders.

SECRETARIAL STANDARD

Indo-Bangla Pharmaceuticals Ltd., try their best maintaining of the Secretarial Standard on meetings of the Board of Directors, Members (shareholders), Minutes and Dividend issued by the Institute of Chartered Secretaries of Bangladesh. A qualified Chartered Secretary is in charge for maintaining of the Secretarial Standard.

COMPLIANCES

Indo-Bangla Pharmaceuticals Ltd., has an established procedure to ensure compliance with all applicable statutory and regulatory requirements. Respective officers are responsible for ensuring proper compliance with applicable laws and regulations.



Since 1954 Indo-Bangla is working for the healthcare development of Bangladesh to ensure health, heartiness and happiness for mankind.

www.indo-banglapharma.com



WE OFFER

Indo- Bangla Pharma currently produces more than 90 brands and applied for 15 new Brand. Indo-Bangla Pharma's portfolio encompasses various the categories, including analgesics, respiratory, cardiovascular, central nervous system, dermatology, gastrointestinal etc. The company has sound expertise with specialized and advanced drug delivery systems that have created strong differentiation. Many of its brands remain consistent leaders in their respective therapeutic categories and the company continuously reviews and expands its product portfolio in order to ensure that people have access to newer, better treatment options at affordable cost. The expanding portfolio, including high value, differentiated, and difficult to copy products will continue to drive strong growth in the coming days.



MANUFACTURING CAPABILITIES

In line of International standards, our state of the manufacturing facilities is spread across a 37.40 decimals area located near the heart of Barisal city, Barisal, which houses facilities for manufacturing tablets, capsules, intravenous fluids, liquids, suppositories, injectable as well as the bulk paracetamol production unit. There are also water purifying and liquid nitrogen generation facilities. Currently being Constructing with large capacity to provide to the emergent demand.



Total Quality Management

QUALITY COMPLIANCE:

To preserve and improve patient health by consistently delivering high quality, safe and effective specialty pharmaceutical products and services, that meet or exceed customer expectations. IBPL is committed to successful deploying our company's Quality Policy to all aspects of our activities - assuring continued high quality, usefulness and effectiveness of products for our customers. Having an experienced workforce, equipped with continuing education and training in emerging Quality techniques and philosophy.

QUALITY CONTROL:

We have a separate Galenical laboratory for R & D, equipped with all the necessary machineries & equipment of current GMP standard in small scale for the team to develop products.

IBPL Quality Control Department guide and support in analytical development. Quality Control Department is equipped with highly sophisticated instruments like UPLC, Gas Chromatography, Atomic absorption spectrophotometer, FTIR, etc. A highly sophisticated microbiology laboratory has been setup to cater to the need for quality control of regular products as well as control of all the different biological products that the company produces.

RESEARCH & DEVELOPMENT

“As commitment to discovery and development of drug, IBPL has an ironic and unique pipeline that is persistently surfacing.”

A part from the hundreds of different drug contenders and new technologies under our investigation in our laboratories, we significantly identify and strictly prioritize those with the greatest potential to deliver new standards of care-critical for our commitment to produce the best therapies.

our intent to develop drugs that accurately target biological processes in patients with specific disease profiles, with companion diagnostics to identify those people who will receive most benefit.

We proactively utilize external resources and specialist excellence at every stage of the R&D process – enabling us to deliver as many innovative new drugs as possible. In the drug discovery & development phase, we partner and collaborate with public and private organizations to harness complementary capabilities to medical science.



OUR PEOPLE

Indo-Bangla Pharmaceuticals' success and accomplishments story lies on 219 strong & skilled workforces, who have stood by the company through thick and thin. The IBPL workforce is charged with the life-force from highly skilled and dedicated professionals. People are our most valuable assets and we always recognize that the essence of this company and their collective resolve to excel - will propel us forward to reach new heights. We seek to provide a workplace that inspires people to be the best they can be. Our ability to transform ourselves is driven by a strong emphasis on employee empowerment at every level.

PRODUCT MANAGEMENT:

The Product Management Department lies in the center of all marketing activities. A dedicated team with excellent professional background comprising Pharmacists, Biochemists, MBAs and Microbiologists work in this department. They formulate the strategies to uphold the market share of company's products, select and introduce new products to keep the company growing and develop promotional materials for the sales people to win in the market.

MARKETING:

The marketing Department plays an important part, as they do the implementation part of all strategies. A large team with highly skilled sales people work throughout the country to bring in success for the company. Team spirit remains as the key to success of the sales department of Indo-Bangla Pharmaceuticals Ltd.

Corporate Social Responsibility

Contributing to the advancement and development of humankind and society through practice of the Kyocera Philosophy



CORPORATE SOCIAL RESPONSIBILITIES

As our strategic commitment; corporate social Responsibility (CSR) is an integral part of our company and continually guided by ethical values to operate responsibly in socio-economic context. We truly believe one can only be affluent if one generates value not just for the company but also for the society. We contribute to society by supporting the communities to achieve sustainability and growth by improving the health and well being.




The company believes in enriching the lives of people by providing innovative high quality medicines with affordable price. We strongly believe in stirring the lives of people of employees by giving them the scope of growth and achievement, providing fair employment conditions and having a safe & health environment.

We support charitable projects in area of healthcare through Rotary, support various Mosque, School and NGOs in selected programs, arrange & participate medical camps and consistently reach out beyond the boundaries of our company to touch societies in which we work. We assist and provide aid in the event of disasters and other emergency situations.

We demonstrate our commitment towards environment by following environment friendly practices across the organization and ensuring manufacturing facilities continuously reducing impact on the environment.

PRODUCT PORTFOLIO



Group	Trade Name	Generic Name
Antiulcerants & Antacids	 Capsule Protobit V 20 (In HPMC Capsule Shell)	Omeprazole BP (Enteric Coated Pellets)
	Protobit-20	
	Tablet Trialugel 250mg & 400 mg	Aluminium Hydroxide Dried Gel BP Magnesium Hydroxide BP
	Tablet Ranitidine-150	
	Capsule Indonix 20	Esomeprazole Magnesium Trihydrate USP equivalent to Esomeprazole 20mg (as enteric coated pellets)
	Tablet Indonix 20	Esomeprazole Magnesium Trihydrate USP
	Tablet Indonix 40	
	Tablet Pantoprazole 20	
	Tablet Pantoprazole 40	
Analgesics-Antipyretics	 ParamolPlus 500mg & 65mg .	Paracetamol BP Caffeine BP
	Tablet Paramol 500 mg	Paracetamol BP
	Suspension Paramol	Paracetamol BP
		
Antifilariasis	Tablet Indo -Fila 100mg	Diethylcarbamazine Citrate BP
Antihistamine &Antiallergic Preparations	Elixir Arromin	Promethazine Hydrochloride BP
	Tablet I -Cet 10mg	Cetirizine Hydrochloride BP
	Syrup I -Cet	Cetirizine Hydrochloride BP
	Tablet Indosin	Chlorpheniramine Maleate BP
	Syrup Indosin	Chlorpheniramine Maleate BP

Group	Trade Name	Generic Name
Anti -Anaemia	Syrup Auriotone	Ferrous Sulphate BP
	Capsule I Need Z	Ferrous Sulphate, Folic Acid, Zinc Sulphate USP
	Tablet I -Fol	Ferrous Fuma rate & Folic Acid
	Tablet I -Fol Plus	Ferrous Fuma rate & Folic Acid




Anthelmintic	Tablet Mebendox 100 mg	Mebendazole BP
	Suspension Mebendox	Mebendazole BP
	Tablet Albendox 400mg	Albendazole USP
Anti-Asthmatic Preparations	Syrup Sulbumol	Salbutamol Sulphate BP
	Tablet Sulbumol 2.0mg	Salbutamol Sulphate BP
	Tablet Sulbumol Plus 4.0mg	Salbutamol Sulphate BP
	Tablet Indophylline 100mg	Aminophylline BP
	Tablet Indokast 10	Montelukast Sodium



Group	Trade Name	Generic Name
Antibacterials & Antimicrobials: Macrolides	Capsule Indoith 250mg	Azithromycin Dihydrate USP
	Tablet Indoith 500 mg	Azithromycin Dihydrate USP
	Indoith Powder for Suspension	Azithromycin Dihydrate USP
Quinolones	Tablet Cipro -I 750mg	Ciprofloxacin Hydrochloride USP
	Tablet Cipro -I 500mg	Ciprofloxacin Hydrochloride USP
Penicillins	Indomoxin Powder for Suspension	AmoxycillinTrihydrate BP
	Capsule Indoflox 250mg	AmoxycillinTrihydrate BP
	Capsule Indoflox 500 mg	AmoxycillinTrihydrate BP
	Indoflox Powder For Suspension	AmoxycillinTrihydrate BP
	Indomoxin Powder for Paediatric Drops	Flucloxacillin Sodium BP
	Capsule I -Cillin 250mg	Flucloxacillin Sodium BP
	Capsule I -Cillin 500mg	Flucloxacillin Sodium BP
	I-Cillin Powder for Suspension	AmoxycillinTrihydrate BP
	Tablet Indomox250mg	AmoxycillinTrihydrate BP
	Capsule Indomoxin250mg	AmoxycillinTrihydrate BP
	Capsule Indomoxin 500mg	AmoxycillinTrihydrate BP
Tetracycline Group of Drugs	Capsule Indotetra500mg	Tetracycline Hydrochloride BP
	Capsule Indox	Doxycycline Hydrochloride BP
Sulphonamides	Tablet Cotrimox400mg & 80mg	SulphamethoxazoleB PTrimethoprim BP
	Tablet Cotrimox-DS 800mg & 160mg	SulphamethoxazoleBP Trimethoprim BP
	Suspension Cotrimox	SulphamethoxazoleBP Trimethoprim BP
Cephalosporins & Cephamycins	Capsule Indocef	Cephradine Monohydrate BP
	Indocef DS Powder for Suspension	Cephradine Monohydrate BP
	IndocefPowder for Suspension	Cephradine Monohydrate BP
	IndocefPowder for Paediatric Drops	Cephradine Monohydrate BP
Gastroprokinetic & Antiemetic Preparations	Tablet I-Pedom 10mg	Domperidone Maleate BP
	Suspension I-Pedom	DomperidoneBP


Antifungal (Dermatological) Preparations	Tablet Gyfusin 500 mg	Griseofulvin BP
	Capsule Fluconazole-50	Fluconazole BP
	Capsule Fluconazole-150	Fluconazole BP
Antiprotozoal Preparations	 Tablet Metrol 400 mg	Metronidazole BP
	Tablet Metrol 200 mg	Metronidazole Benzoate BP
	Suspension Metrol	Metronidazole BP
	Tablet Metrol 500 mg	Metronidazole BP
Bone Calcium Regulator	Tablet Caltab 300 mg	Calcium Lactate BP
	Tablet Indocal 1250 mg	Calcium Carbonate BP
Opioid Analgesics	Tablet Tramadol-50	Tramadol Hydrochloride BP
	Tablet Tramadol-100	Tramadol Hydrochloride BP
Antiseptic	Indo-Sol Faster Hand Rub	Chlorhexidine Gluconate Solution (20% w/w)
Urinary Anti -Infective	Tablet Naldic 500mg	Nalidixic Acid BP
Non-Hormone Sex Stimulant Drugs	Tablet Makmaul Sanagra -50mg	Sildenafil Citrate BP
	 Tablet Makmaul Sanagra -100mg	Sildenafil Citrate BP

Diuretics Preparations	Tablet Frusidin 40 mg	Frusemide BP
Non-steroidal Anti-inflammatory Drugs Preparation	Tablet Inket	Ketorolac Tromethamine USP
	Tablet Indoprox 250 mg	Naproxen Sodium USP
	Tablet Indoprox 500 mg	Naproxen Sodium USP
	Capsule I-Cin 25 mg	Indomethacin BP
	Tablet Relise 100 mg	Aceclofenac BP
	Tablet Indoflam 400 mg	Ibuprofen BP
	Suspension Indoflam	Ibuprofen BP
	Capsule Indofenac-TR	Diclofenac Sodium BP Timed Release Pellets
	Tablet Indoprox E Plus	Naproxen BP & Esomeprazole Magnesium Trihydrate BP
	Tablet Indofenac-50	Diclofenac Sodium BP
ORS Preparations	I-B Oral Saline	Sodium Chloride BP Trisodium Citrate Dihydrate BP Potassium Chloride BP Glucose Anhydrous BP
STEROIDS	Tablet Daxtrin 0.5 mg	Dexamethasone BP
	Tablet I-Solone 5 mg	Prednisolone BP
Tranquillisers	Tablet Diazepam 5 mg	Diazepam BP
	Tablet I-Zam 10 mg	Clobazam BP
Water Purificants	Tablet Clear 7.5 mg	Sodium Thiosulphate USP
	Tablet Clear-Plus 15 mg	Sodium Thiosulphate USP
	Tablet Puretab 7.5 mg	Halazone USP
	Tablet Puretab-Plus 15 mg	Halazone USP
Vitamins & Minerals	Tablet V-Complex	Thiamine Hydrochloride BP Riboflavine BP Pyridoxine Hydrochloride BP Nicotinamide BP
	Syrup Indoplex	Riboflavin BP
	Tablet Riboflavine	Vitamin C, Vitamin E & Betacarotene
	Tablet BCE	Zinc Sulphate Monohydrate BP
	Syrup Zins	Calcium Carbonate & Vitamin D3
	Tablet Indocal -D	Calcium Carbonate BP, Vitamin D3, Magnesium Oxide BP, Zinc Oxide BP, Cupric Oxide Ph.Gr., Manganese Sulphate Monohydrate BP, Boron Citrate Ph.Gr.
	Tablet Calfresh-M	

CORPORATE OPERATIONAL RESULTS

Summary of key operating and financial data for the least preceding 5 (Five) years are as follows:

Financial Highlights.



Operational Result	Amount in Taka				
	2019-20	2018-19	2017-18	2016-17	2015-16
Turnover	866,097,783	740,714,183	659,971,100	616,711,210	444,777,724
Gross Profit	346,450,050	296,550,952	260,400,732	234,910,917	182,248,732
Profit from Operation	222,667,522	178,281,873	153,178,111	132,222,600	94,497,109
Net Profit before tax	217,005,550	180,778,346	151,529,230	135,957,956	90,807,238
Net Profit after Tax	156,243,664	155,226,689	98,493,999	88,372,671	59,024,705
Net Operating Cash Flow per Share	1.57	1.70	1.20	1.09	0.19
Financial Position	2019-20	2018-19	2017-18	2016-17	2015-16
Non-Current Assets	1,126,809,674	818,523,321	654,019,821	536,553,973	330,469,857
Current Assets	612,456,404	767,224,351	565,947,614	541,115,957	614,908,956
Shareholder's Equity	1,517,598,176	1,374,627,332	1,036,100,643	937,606,643	849,233,972
Current Liability	126,947,217	144,361,259	116,617,191	101,883,096	82,321,162
Non-Current Liability	94,720,685	66,759,081	67,249,601	38,180,191	13,823,879
Key Financial Ratio	2019-20	2018-19	2017-18	2016-17	2015-16
Current Ratio	4.82	5.31	4.85	5.31	7.47
Quick Ratio	1.89	2.36	2.40	2.75	4.29
Debt to Equity Ratio	-	-	-	-	-
Net Income Ratio (%)	18.04%	20.96%	14.92%	14.33%	13.27%
Return on Equity (%)	10.80%	12.88%	9.98%	9.89%	11.71%
Earnings Per Share	1.40	1.39	1.35	1.21	2.62

DIRECTOR'S REPORT TO THE SHAREHOLDERS

To the Members for the 12th months period ended 30 June, 2020



Bismillahir Rahmanir Rahim
Distinguished Shareholders,
Assalamu Alaikum Wa Rahmatullahi Wa Barakatuhu,

In terms of provisions of section 184 of the Companies Act 1994, Rule 12 (and the Schedule there under) of the Bangladesh Securities and Exchange Rules, 1987, BSEC Notification dated 3 June, 2018, International Accounting Standards-1 as adopted by The Institute of Chartered Accountants of Bangladesh and Finance Act, it is the pleasure of the Board of Directors to submit the Audited Financial position, Statements of Profit or Loss & other Comprehensive Income, Statement of Cash Flows and Statement of Changes in Equity along with the Auditors Report thereon Report to the Shareholders for the reporting period ended June 30, 2020 for your valued consideration in the following paragraph:

OPERATIONS AND STATE OF AFFAIRS OF INDO-BANGLA PHARMACEUTICALS LIMITED

The Indo-Bangla Pharma's Standalone Revenues from Operations Were Tk. 866.09 million for the year ended 30th June, 2020 as compared to Tk. 740.72 million for the previous year, an increase by 16.93%. Net Profit after tax increases 0.65% to Tk. 156.24 million on standalone basis for the year under review as compared to Tk. 155.23 million for the previous year. Earnings Per Share (EPS) stood at Tk. 1.40 against Tk. 1.39.

INDUSTRY OUTLOOK AND POSSIBLE FUTURE DEVELOPMENT.

Manufacture of pharmaceuticals is now one of the largest capital-intensive white-collar industries in the country, which has grown tremendously over the past few decades. So that the country can continue to produce a wide range of medicines at competitive costs and enjoys comparative advantage in the sector as cheap labor and raw materials, a favorable World Trade Organization (WTO) regime and adequate supply of skilled manpower.

A few decades ago, the country was dependent on imported medicines as well as drugs produced by multinational companies for meeting domestic demands. But now around 97 per cent of medicines are produced locally

while imported medicines mainly belong to hi-tech genres. And the market share of the local manufactures is currently around 90 percent and 10 percent is controlled by foreign companies. It also mentioned that current export of Bangladeshi medicines to 147 countries, including Europe.

PHARMACEUTICALS INDUSTRY GEARING UP FOR THE FUTUR

According to the Department of Drug Administration currently the number of Pharmaceuticals companies stands at 273 and the market size stood worth TK. 205.12 billion with a growth rate of 15.36 percent. The figure for the year 2017 and 2016 were Tk. 287.56 billion and Tk. 156.40 billion along with growth rate of 19.92 per cent and 30.82 percent respectively. The country's domestic pharmaceutical market size has been expanding during the current decade at a rate of around 15% and is expected to be worth Tk. 400 billion and 500 billion by the year 2022-2023 as Bangladesh's economy is growing with increased per capita income in 2019-20 of \$2064, while life expectancy increased to 73 years, Life expectancy of people has significantly increased — the average life expectancy of 66.4 years in 2002 rose to 72.72 years in 2020. Improved healthcare facilities and diagnosis with modern technology and rapid growth of chronic diseases due to change in lifestyle and environment factors are other reasons for the growth of domestic drug market.

OPPORTUNITIES IN PHARMACEUTICALS SECTOR

According to the Export Promotion Bureau (EPB) figures, medicine worth U\$\$ 130 million have been exported so far in 2019 which was \$103.46 million the previous year, the growth rate being 25.56 per cent. The export volume during 2018 was U\$\$ 103.46 with a growth rate of 7.10 per cent. Global certification and adoption of new technologies along with efforts to make local medicine familiar abroad and cash incentives against exports of medicine are the key reasons for the sharp rise in exports earnings. The export earnings to a new high, exports to the United States of America played an important role and it is a great achievement and milestone for Bangladesh. According to Bangladesh Association of Pharmaceutical Industries (BAPI), approximately 1,200 pharmaceutical products received registration for export in the last two years.

OPPORTUNITIES FOR BANGLADESH IN GLOBAL GENERIC DRUGS MARKET



Rising healthcare cost, namely drug prices, now a global concern



Current global generic drug market value: **\$1.06 trillion**



Projected to be **\$1.30 trillion** by 2020



Developed countries increasingly promoting **generic drugs**



Major generic drug hubs India and China losing cost advantages




Drugs worth **\$150 billion-plus** will become unpatented by 2020

BANGLADESH PHARMACEUTICAL INDUSTRY



Exempted from **WTO** patent protection until **2033**

PRODUCED DRUGS



Source: Bangladesh Association of Pharmaceutical Industries

All the associated factors are in favor for the rapid growth Bangladesh pharmaceutical market and it is expected to grow with a CAGR of more than 12% during 2019-2025 period. The share of generic drugs is expected to surpass 85% by the 2025, which will further strengthen the dominance of local pharmaceutical companies in the market. In addition to this, the presence of leading multinational pharmaceutical companies is also increasing in Bangladesh, which is indicating towards the competitive landscape in upcoming years.

- **Bangladesh Pharmaceutical Market Opportunity: More Than US\$ 6 Billion by 2025**
- **Share of Local Pharmaceutical Companies: >90%**
- **Share of Generics Drugs in Pharmaceutical Market: >75%**
- **Leading Drugs Market Insight by Availability, Dosage & Price Analysis**
- **Number of Ongoing Clinical Studies: > 300 Clinical Studies**
- **Pharmaceutical Exports Opportunity: > US\$ 450 Million by 2025**
- **Contribution to GDP 1.33%**

SCOPE TO GROW IN FUTURE

According to Business Communications Company (BCC) Inc, a US-based research organization, the global market for generic drugs is expected to reach \$533 billion by 2021 from \$352 billion in 2016 at a compound annual growth rate (CAGR) of 8.7%. "Bangladesh is going to be a major global hub for high quality low cost generic medicine and vaccine. In reaping the benefits, Bangladesh needs to develop the knowledge and capacity to grab a bigger share of the global pharmaceutical market. Local drugs manufacturers of Bangladesh mainly produce generic drugs of the total amount, 80.0% are generic and 20.0% patented drugs.

INDO-BANGLA LOOKS FOR A BETTER FUTURE

Indo-Bangla Pharmaceuticals Ltd, is a reliable name in the pharmaceuticals sector of Bangladesh, works relentlessly to move forward with a targeted vision to be on the forefront of changing healthcare environment turning innovative science towards esteemed new treatment preferences. Indo-Bangla steps forward with the pre-determined vision to achieve excellence in manufacturing and marketing of pharmaceuticals products and trying to extending its business in abroad as well. New technology, new invention, new products as well as new project are the rhythm of life of pharmaceuticals Company. Since, Indo-Bangla Pharmaceuticals Ltd., is well aware of the adoption new technology and has taken a number of ambitious initiatives and business strategy to meet the upcoming.

TECHNOLOGY AND QUALITY CONTROL

Indo-Bangla Pharmaceuticals Ltd. is striving to upgrade and adopt new technology in production, quality control, distribution and administration of its products to produce new generation drugs as the faster growth of new and lifesaving drugs to customers/patients During the year (2019-2020). the company invested a substantial amount in improving its Laboratory facilities, R&D Scale-up facilities etc.

Indo-Bangla Pharmaceuticals Limited places total emphasis on maintaining and improving of quality of its products following GMP standards of WHO by following strictly laid down criterion at every level of production and handling. Indo-Bangla Pharmaceuticals Limited also follows-up withdrawals from market of all expiry dated products through close inspection and surveillance. The quality control facilities include a high standard laboratory, computerizing equipment's and tools and a team of high qualified research personnel who are able maintain high standards.

RISK AND CONCERNS

Different types of risk and concern in Pharmaceuticals industries are- Tariffs and international trade restrictions, Insufficient raw material production facilities, Absence of bioequivalence test facility, Lack of modern drug testing laboratory.

Marketing strategy- Pharmaceutical industries are now in high-end development trend that is being carried out by leading companies. Increasingly, many companies are competing with new pharmaceutical industries. As a result, the success of pharmaceutical industries largely depends on the efficiency and effectiveness of the highly trained and qualified medical promotion officers.

Problems regarding export, Contest in the Bangladeshi pharmaceutical market, Rivalry among existing firms, Threat of new entrants, Threat of substitute products, bargaining power of buyers, Bargaining power of suppliers. Changes in the existing global or national policies can have either positive or negative impacts for the company. Any insufficiency or price hike of raw materials due to change in policy in the international market might hamper the production and profitability. Changes in currency exchange rates might also affect the pricing and thereby the profitability of the Company.

Similarly, risks factors of the industry depend on the Government policies as well. However, the industry is also exporting abroad. Currently, formulations are exported to 92 countries around the world. The major destinations for Bangladeshi medicines are Myanmar, Sri Lanka and Kenya, while nearly 50 countries import Bangladeshi medicines regularly.

PROJECT AT KALIAKOIR, GAZIPUR.

In order to meet increased demand of existing products as well as to achieve long term sustainable growth of the Indo-Bangla Pharmaceuticals Ltd. by including new technology and produce new generation drugs, Indo-Bangla Pharmaceuticals Ltd. has undertaken a courageous step in setting up of a new production plant at kaliakoir, Gazipur.

OPERATIONS AND STATE OF AFFAIRS OF THE COMPANY: FINANCIAL RESULTS

The operating financial results of the Company for the year 2019-2020 as compared to previous year are summarized hereunder:

Particular	2019-2020 Taka	2018-2019 Taka	% ↑ ↓
Turnover	866,097,783	740,714,183	16.93% ↑
Gross Profit	346,450,050	296,550,952	16.83% ↑
Financial Expenses	-	-	-
Non-Operating Income	5,188,305	11,535,389	55.02% ↓
Net Profit Before Tax (NPBT)	217,005,550	180,778,346	20.04% ↑
Provision for Taxation	60,761,886	25,551,656	137.80% ↑
Net Profit After Tax (NPAT)	156,243,664	155,226,689	0.65% ↑
Gross Margin (Turnover)	40.01%	40.04%	0.03% ↓
Net Margin Before Tax	25.05%	24.41%	0.64% ↑
Net Margin After Tax	18.04%	20.96%	2.92% ↓
Earnings Per Share (EPS) BDT.	1.40	1.39	0.71% ↑

The Gross Profit and Net Profit (BT) increased during FY 2019-2020 at 16.83% and 20.04% respectively over the previous year. However, the Cost of Goods Sold increased at 16.83% over previous year which helped increase Gross Profit and Operating Profit of the Company. The Net Profit After Tax, however, increased by 0.65% over the previous year.

The Earning per Share of Tk. 1.40 is the basic earning dividing by the weighted average number of shares outstanding at the end of the Period.

DISCUSSION ON EPS & NOCFPS


The Company's Standalone Revenues from operations were TK. 866.09 million for the year ended 30th June, 2020 as compared to TK. 740.72 million for the previous year, an increase by 16.93%

The company has made Net Profit of TK. 156.24 million on standalone basis for the year under review as compared to TK. 155.23 million for the previous year. Earnings Per Share (EPS) of Tk. 1.40, NAV per share of Tk. 13.61, and NOCFPS of Tk. 1.57 for the year ended on June 30, 2020 as against Tk. 1.39, Tk. 13.44 and Tk. 1.70 respectively for the same period of the previous year.



DISCUSSION ON COST OF GOODS SOLD, GROSS PROFIT MARGIN AND NET PROFIT MARGIN SHOWN BELOW:

Profit from Operation	30-June-2020		30-June-2019	
	Amount	Percentage	Amount	Percentage
Turnover	866,097,783	100.00	740,714,183	100.00 ↑
Cost of Goods Sold	519,647,733	59.99	444,163,230	59.96 ↑
Gross Profit	346,450,050	40.01	296,550,952	40.04 ↓
Net Profit for the year	156,243,664	18.04	155,226,689	20.96 ↓




APPROPRIATION OF PROFIT.

The Board of Directors recommended the appropriation of the net profit earned during the year 2019-2020 in the following manner:

Details	Tk.	Tk.
Net Profit after Tax year ended 30 June, 2020	156,243,664	
Minimum Dividend Pay Out Ratio 30% on Net Profit as per IT Ordinance, 1984	46,873,099.2	46,873,099.2
Total Paid Up Capital as at 30 June 2020	1,115,070,000	
Less: Director & Sponsors 49.05%	(546,959,820)	
General Public other than Directors & Sponsors of the Company	568,110,180	
2% Stock Dividend for all Shareholders (1115070000*2%)	22,301,400	
4.5% Cash Dividend only for General Shareholders (568,128,165*4.5%)	25,564,958.10	
Dividend (6.5%) Payable for the Year ended 30 June 2020		47,866,358.10
Net Un appropriate Profit		108,376,497

DIVIDEND

The Company has invested a substantial amount for expansion of capacity as well as diversification of products and business. However, the Board of Directors at its Board meeting held on 27 October, 2020 has recommended 4.5% Cash excluding Sponsors & Directors (including ICB) of the company and 2% Stock Dividend for all shareholders for the year ended on June 30, 2020 the Sponsors/Directors hold 5,46,95,982 shares out of total 111507000 shares of the Company and the cash Dividend to be payable to the General Shareholders of TK. 25,564,958.10 (25.56 million.)



SEGMENT WISE REPORTING

The company operates only in one segment, which is manufacturing and selling of all kinds of medicine (excluding Antibiotic), medical preparations drugs & chemicals (Human Health). The Company applied for permission for production and selling of veterinary medicine also.

DISCUSSION ON CONTINUITY OF EXTRAORDINARY GAIN OR LOSS

Extraordinary gains or losses refer to irregular and infrequent gain or loss and which is not part of the Company's ordinary/day to day operations. As for the Company, there was no such gain or loss during the year ended June 30, 2020

RELATED PARTY TRANSACTION

Related parties Transactions:

The company carried out a number of transactions with related parties.

The following are the related parties transactions of the Indo-Bangla Pharmaceuticals Ltd has been disclosed as required by BAS 24 Related Party Disclosures.

(a) Remuneration:

Name	Designation	Nature of Transaction	Amount in (BDT)	
			2019-2020	2018-2019
Mr. A F M Anwarul Huq	Managing Director	Remuneration	2,400,000	1,800,000

(b) Board meeting fee:

Name	Designation	Nature of Transaction	Amount in (BDT)	
			2019-2020	2018-2019
Mrs. Aziza Yeasmin	Chairman	Board Meeting Fee	50,000	50,000
Mr. A.F.M Anwarul Huq	Managing Director		50,000	55,000
Mrs. Hafiza Yeasmin	Director		-	20,000
Md. Amin-Ur-Rashid	Director		15,000	50,000
Sayeda Huq	Director		45,000	50,000
Fatima Parvin	Director		50,000	55,000
Mst. Shanaz Akter	Director		15,000	40,000
Md. Mizanur Rahman	Director		45,000	50,000
Md. Golam Rabbani	Director (Represented of ICB)		30,000	20,000
S.M. Harun Or Rashid	Independent Director		15,000	50,000
Md. Monirujjaman	Independent Director		45,000	45,000
Md. Firoz Khan	Independent Director		10,000	40,000

STATEMENT OF UTILIZATION OF PROCEEDS RAISED THROUGH IPO

Indo-Bangla Pharmaceuticals Ltd. has received Tk. 200,000,000 (Taka Twenty Crore) only as Initial Public Offering (IPO) proceeds through subscription from 09 August to 16 August. And the expenses/utilization has been made in the line with the provision of Initial Public Offering (IPO).

Fund utilization period had extended to 24 months instead of 18 months for construction and other civil works due to change of new project place and subsequently approved by the Board of Directors and Shareholders in 4th Annual General Meeting.

Fund utilization fixed for Construction and other Civil works has been changed to Machinery and subsequently approved by the Board of Directors and Shareholders in 5th Annual General Meeting.

The breakup of Utilization Position of IPO proceeds up to 30 June, 2020 was as under:

Purpose Mentioned in the Prospectus	As per the Prospectus	As per the Prospectus and 5th AGM	Utilization for the year ended 30 June 2019	Utilization up to the month of March, 2020	Total Utilized amount
Construction and other civil works	58,580,000	-	-	--	
Machineries	124,720,000	183,300,000	89,463,090	93,836,910	183,300,000
IPO expenses	16,700,000	16,700,000	16,700,000	-	16,700,000
Total IPO Proceeds	200,000,000	200,000,000	106,163,090	93,836,910	200,000,000

The company raised Tk. 200,000,000 divided into 20,000,000 ordinary shares of Tk. 10 each through IPO on September 13, 2018. The company utilized Tk. 200,000,000 in total up to March 30, 2020 for the purposes described above as certified by independent auditor, Shafiq Basak & Co, Chartered Accountants.

SIGNIFICANT VARIANCE OF FINANCIAL STATEMENTS

No significant variation occurred between quarterly and final results of the Company during the year ended June 30, 2020.

BOARD SIZE

The number of members of the Board of Directors stands at 10 (including Two Independent Director) which are within the limits given by the BSEC Notification.

SL	Name	Position
1.	Mrs. Aziza Yeasmin	Chairman
2.	Mr. A F M Anowarul Huq	Managing Director
3.	Mrs. Hafiza Yeasmin	Director
4.	Mrs. Aysha Siddika	Director
5.	Mrs. Sayeda Huq	Director
6.	Mr. Md. Golam Rabbani	Director
7.	Mrs. Fatima Parvin	Director
8.	Md. Mizanur Rahman	Director
9.	Mr. Md. Iftikhar-Uz-Zaman	Independent Director
10.	Mr. Md. Monirujjaman	Independent Director

ELECTION OF DIRECTORS

Mrs. Fatima Parvin, Director and Mrs. Sayeda Huq, Director retires as per Article-55, 56, 57 of the Articles of Association of the company, being eligible, Mrs. Fatima Parvin, Director and Mrs. Sayeda Huq, Director have offered themselves for re-election. Brief resume and other information of the above mentioned directors are depicted in Annexure-II

DIRECTOR'S REMUNERATION

Director's remuneration is shown in the note no. 32(a) of the notes to the Financial Statements. There is no remuneration for Independent Directors.

Name	Designation	Nature of Transaction	Amount in (BDT)	
			2019-2020	2018-2019
Mr. A F M Anowarul Huq	Managing Director	Remuneration	24,00,000	1,800,000

DIRECTORS INVOLVED IN OTHER COMPANIES

SL	NAME	POSITION	DIRECTORSHIP/OWNERSHIP WITH OTHER COMPANIES.	
			COMPANIES	POSITION
1	Mrs. Aziza Yeasmin	Chairman	-	-
2	Mr. A F M Anowarul Huq	Managing Director	-IBP Agrovat Ltd. -Sabila Sea Foods Ltd., -HBS Apparels Ltd. - BD Pharmaceuticals Ltd.	Director
3	Mrs. Hafiza Yeasmin	Director	-	-
4	Mrs. Aysha Siddika	Director	-	-
5	Mrs. Sayeda Huq	Director	-	-
6	Mr. Md. Golam Rabbani	Director	-	-
7	Mrs. Fatima Parvin	Director	-	-
8	Md. Mizanur Rahman	Director	-	-
9	Mr. Md. Iftikhar-Uz-Zaman	Independent Director	-	-
10	Mr. Md. Monirujjaman	Independent Director	-	-

APPOINTMENT OF INDEPENDENT DIRECTOR

The Board of Directors has appointed Mr. Md. Iftikhar-Uz-Zaman as an Independent Director in its meeting dated 31st January, 2020 for the period of three years which will be approved by Shareholders in AGM. Brief resume and other information of the above mentioned director is depicted in Annexure-II.

APPOINTMENT OF DIRECTOR

The Board of Directors has appointed Mrs. Aysha Siddika as a Director for the in its meeting dated 16th August, 2020 on the Board of Directors of the Company which will be approved by Shareholders in AGM. Brief resume and other information of the above mentioned director is depicted in Annexure-II.

APPOINTMENT OF AUDITORS

The existing Auditors of the company M/s MahfelHuq& Co., Chartered Accountants, will retire at the conclusion of the 6th Annual General Meeting. Pursuant to the Companies Act-1994 every Company shall, at each Annual General Meeting appoint an auditor to hold office from conclusion of the Annual General meeting until the next Annual General Meeting. As per Regulation-15 (2) Dhaka & Chittagong Stock Exchange (Listing) Regulation-2015, The issuer of listed securities shall not appoint any firm of chartered accountants as its statutory auditors for a consecutive period exceeding three years. In this connection, M/s. Mahfel Huq, Chartered Accountants, the present Statutory Auditor of the company has been completed a consecutive period of three years, thus M/s. Mahfel Huq, Chartered Accountants, being not eligible to re-appointment for performing the auditing of financial statements of the Company. Thus, the Board of Directors unanimously recommended the appointment of M/S. FAMES & R Chartered Accountants, as the Statutory Auditor of the Company for the Financial Year 2020-2021, and to continue the next Annual General Meeting at a fees of tk. 2,50,000.00, subject to approval of the shareholders at the forthcoming 6thAnnual General Meeting of the company.

APPOINTMENT OF COMPLIANCE AUDITORS

As per the requirement of Bangladesh Securities and Exchange Commission (BSEC) Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June, 2018, the Company shall obtain a certificate from a practicing Professional Accountant or Secretary other than its Statutory Auditors or Audit firm on yearly basis. Since, the existing Auditors of the company M/s Shafiq Basak& Co., Chartered Accountants retires at this Annual General Meeting and being eligible, have offered themselves for reappointment as Compliance Auditors of the company for the year 2020-2021 subject to approval at the 6th Annual General Meeting to be held on December 24 by the members of the company.

COMPANY SECRETARY, CHIEF FINANCIAL OFFICER, HEAD OF INTERNAL AUDIT

As per corporate governance code of BSEC, the company has allocated the responsibilities of the officials as follows:

SL	Name	Position
1.	Mohi Uddin QCS	Company Secretary
2.	Md. Faruque Hossain	Chief Financial Officer
3.	Md. AbuTaleb	Head of Internal Audit

AUDIT COMMITTEE

Indo-Bangla Pharmaceuticals Limited has an Audit Committee as a sub-committee of the Board of Directors in order to assist the Board of Directors in ensuring and fulfilling its oversight responsibilities in compliance with Condition-5 of the Notification of Bangladesh Securities and Exchange Commission (BSEC) No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June, 2018. All members of the audit committee are “financially literate” and having the ability to read and understand the financial statements like statement of financial position, statement of comprehensive income, statement of changes in equity and cash flows statement.

The Audit Committee carries out its responsibilities as per the provisions of law and submits its report to the Board of Directors from time to time. The Audit Committee shall also co-ordinate with the Internal and external Auditors as and when required. The Audit Committee ensures that adequate internal checks & balances supported by adequate MIS are in place for detection of errors frauds and other deficiencies. The other responsibilities include inter alia, not being limited to, the prevention of conflict of interest between the company and its Directors officials, customers, suppliers, government and any other interest groups and detect or remove any scope of insider trading in the company's stock. The Audit Committee also ensures compliance of requirements of BSEC and other regulatory. During the year 2019-2020 under review, the Committee held four meetings.

The Audit Committee of Indo-Bangla Pharmaceuticals limited is comprised of 3 (three) Members of the Board of Directors including 2 (two) Independent Directors. The composition of the present members of Audit Committee as follows:

SL	Name	Position
1.	Md. Iftikhar-Uz-Zaman (Independent Director)	Chairman
2.	Md. Monirujjaman (Independent Director)	Member
3.	Mrs. Fatima Parvin (Director)	Member
4.	Mr. Mohi Uddin, QCS	Secretary

NOMINATION AND REMUNERATION COMMITTEE

The Board of Directors of Indo-Bangla Pharmaceuticals Ltd. has duly constituted a Nomination and Remuneration Committee (NRC), as per the requirement of the Corporate Governance Code of Bangladesh securities and Exchange Commission (BSEC) to shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executives as well as a policy for formal process of considering remuneration of directors, top level executives.

The Nomination and Remuneration Committee has performed its duties as assigned by the Board of Directors and defined in the charted of the NRC formulated in accordance with the Notification of the Bangladesh Securities and Exchange Commission's Corporate Governance Code, 2018

The Nomination and Remuneration Committee of Indo-Bangla Pharmaceuticals Ltd. is comprised of three (3) non-executive Directors of the Board including an Independent Director. The Chairperson of the Committee is an Independent Director of the Company the composition of the present NRC is as follows:

SL	Name	Position
1.	Md. Monirujjaman (Independent Director)	Chairman
2.	Mrs. Sayeda Huq (Director)	Member
3.	Md. Mizanur Rahman (Director)	Member
4.	In Attendance	-Chairman -Managing Director -External Advisers – by invitation -Any Non-Executive Director shall be entitled to attend the Committee's meetings.
5.	Mr. Mohi Uddin, QCS	Secretary

Mr. Mohi Uddin, QCS Company Secretary is the Secretary to the Nomination & Remuneration Committee. The number of the meeting held during year ended June 30, 2020 were 2 (two). Mr. Mohi Uddin, Company Secretary attends the Committee's meeting as the Secretary of the Committee. The Managing Director and Head of Human Resources and Administration attends the meeting by invitation. The Chief Financial Officer attends the meeting as and when invited.

MAINTANING WEBSITE

The company has been maintaining an official website www.indo-banglapharma.com which is linked with the website of the stock exchanges.

SUBSIDIARY COMPANY

The company has no subsidiary company.

CORPORATE GOVERNANCE

Corporate Governance is the practice of good citizenship, through which the Company is governed by the Board, keeping in view its accountability to the stakeholders and to the society. In accordance with the requirement of Bangladesh Securities and Exchange Commission (BSEC) Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June, 2018, a statement in pursuance to Clause 1 (5), resume of the Directors who shall be appointed, Audit Committee Report as per clause 5 (7), Certificate from the CEO & CFO to the Board, Certificate on Compliance of Condition of Corporate Governance Code & Status of Compliance in depicted in the Annexure-I, II, III, IV, V, A, B & C respectively.

GOING CONCERN

While approving the financial statements, the directors have made appropriate inquiries and analyzed the significant financial, operating as well as other indicators for enabling them to understand the ability of the Company to continue its operation for a conceivable period. Directors are confident and have a reasonable expectation that the Company has adequate resources to continue its operation consistently for the predictable future. Therefore, the company adopted the going concern basis in preparing the financial statement.

MANAGEMENT GRATITUDE

Finally, on behalf of the Board, I would like to take this opportunity to thank all the employees of Indo-Bangla Pharmaceuticals Ltd for their tremendous efforts. I would also like to express sincere gratitude to the shareholders as well as all Stakeholders of the company for their continued support.

The Board is also grateful to the Officers, Staff, Workers, Customers, Creditors, Banks, Insurance Companies, Utility Providers, BSEC, DSE, CSE, CDBL and the Government of Bangladesh and other business partner for their cooperation extended to the Company during the year.

Thanking you.

On behalf of the Board of Directors

Sd/-

(Mrs. Aziza Yeasmin)

Chairman

MANAGEMENT'S DISCUSSION & ANALYSIS

Pursuant to the Corporate Governance Code 2018 [Condition # 1 (5) (xxv)] of the Bangladesh Securities and Exchange Commission, the Management's Discussion & Analysis for the year ended 30 June, 2020 has been depicted hereunder:

Accounting Policies and Estimation for preparation of Financial Statements:

Indo-Bangla Pharmaceuticals Ltd. follows International Financial Reporting Standards (IFRS) and International Accounting Standards (IAS) along with prevailing local rules and regulations applicable for preparation of financial statements. Detail description of accounting policies and estimation used for preparation of the financial statements of Indo-Bangla Pharmaceuticals Ltd., are disclosed in the Notes No. 2.05, 2.06, 2.07, 2.08 and 2.09 to the Standalone Financial Statements (Page No. 76).

Changes in Accounting Policies and Estimation:

Indo-Bangla Pharmaceuticals Ltd., has been following consistent policies and estimation and there is no such changes in accounting policies or estimation which has material impact on financial statements.

Comparative Analysis of Financial and Operational Performance:

The Directors' Report provides the analysis of financial performance and position during the year under review and also a detail comparison of financial performance and position as well as cash flows are presented as part of the financial statements including notes. However, major areas of financial performance, financial position as well as cash flows with immediate preceding five years are presented as follows:

Particulars	2019-2020	2018-2019	2017-2018	2016-2017	2015-2016
Turnover	866,097,783	740,714,183	659,917,100	616,711,210	444,777,724
Gross Profit	346,450,050	296,550,952	260,400,732	234,910,917	182,248,732
Profit from Operation	222,667,522	178,281,873	153,178,111	132,222,600	94,497,109
Net Profit (Before Tax)	217,005,550	180,778,346	151,529,230	135,957,956	90,807,238
Net Profit (After Tax)	156,243,664	155,226,689	98,493,999	88,372,671	59,024,705
Net Operating Cash Flows per share	1.57	1.70	1.20	1.09	0.19

Financial Position	2019-2020	2018-2019	2017-2018	2016-2017	2015-2016
Non-Current Assets	1,126,809,674	818,523,321	654,019,821	536,553,973	330,469,857
Current Assets	612,456,404	767,224,351	565,947,614	541,115,957	614,908,956
Shareholder's Equity	1,517,598,176	1,374,627,332	1,036,100,643	937,606,643	849,233,972

FINANCIAL AND ECONOMIC SCENARIO OF BANGLADESH AND THE GLOBAL (IN BRIEF):

Bangladesh is the 41st largest in the world in nominal terms and 30th largest by purchasing power parity (PPP); it is classified among the Next Eleven emerging market middle income economies and frontier market. GDP growth is accelerating gradually. Along with the current FY2019-2020, the GDP growth rate of the economy of Bangladesh surpassed the 7 percent mark for consecutive five times since FY2015-16. According to Estimated Bangladesh Bureau of Statistics (BBS), the GDP growth stood at 8.13 percent in FY2019-2020, which was 7.86 percent in previous fiscal year. High growth of manufacturing sector under broad industry sector has contributed significantly to achieve high GDP growth in this fiscal year. Per capita GNI (Gross National Income) and GDP (Gross National Product) stood at US\$1,909 and US\$1,827 respectively in FY2018-19 compared to US\$1,751 and US\$1,675 respectively in FY2017-18. On the basis of PPP (Purchasing Power Parity), calculated by UNDP, the per capita GNI stood at US\$3,524. The real GDP growth for World economy stands at 3.3% (Source: IMF). Bangladesh registered the fastest growth rate in the Asia-Pacific economies comprised of 45 countries, according to Asian Development Bank. Bangladesh will continue to be the fastest growing economy in the Asia-Pacific, the bank said in its Asian Development Outlook (ADO). Public and private investment were important contributors to the high GDP growth rate in 2019. Real investments increased by 13.88%. Public investment to GDP ratio increased while private investment to GDP ratio decreased. According to the UNCTAD's 2019 World Investment Report, Foreign Direct Investment (FDI) inflows to Bangladesh closed at USD 3.61 billion in 2018 (an increase compared to USD 2.15 billion in 2017). The main investors in the country are China, South Korea, India, Egypt, the United Kingdom, the United Arab Emirates and Malaysia. Total FDI stock was estimated USD 17 billion (5.9% of the country's GDP) in 2018 by the UNCTAD. The country ranked 176th out of 190 economies in the World Bank's 2019 Doing

Business ranking, rising one point compared to last year. The country's Logistics Performance Index has dropped over the last two years, signaling a significant concern for local and foreign investors. One of the most densely populated economies in the world, Bangladesh has continued making impressive strides in achieving social development goals for its 165.55 million citizens. The resilience of the country's economy is commendable. However, sound economic policy must be implemented to mitigate under performance of the financial sector, diversify exports and create better employment opportunities by increasing private investment. It also requires to mitigate the infrastructure bottlenecks, insufficient power and gas supplies, bureaucratic corruption, political instability, natural calamities and a lack of skilled workers.

Future plan or projection or forecast:

The Management of Indo-Bangla Pharmaceuticals limited is very sincere in adoption of necessary feasible plans and strategy in respect of sustainability in its performances & financial position and to continue the operations for foreseeable future.

STATEMENT OF DIRECTORS ON FINANCIAL REPORTS

Annexure- I To the Directors Report

In accordance with the Bangladesh Securities and Exchange Commission Notification No. BSEC/CMRRCD/2006- 158/207/Admin/80 dated 03 June, 2018 the Directors also report that:

- The financial statements together with notes thereon have been drawn up in conformity with the Companies Act, 1994 and The Securities and Exchange Rules 1987. The Financial Statement of the Company present true and fair view of the Company's state of affairs, result of its operations, cash flows and changes inequity.
- Proper books of accounts of the company as required prevailing Law have been maintained.
- Appropriate accounting policies have been applied consistently in preparation of the financial statements and the accounting estimates are based on reasonable and prudent judgment.
- The Financial Statement was prepared in accordance with International Accounting Standards (IAS)/ International Financial Reporting Standards (IFRS)/Bangladesh Accounting Standard (BAS).
- The internal control system is sound in design and is effectively implemented and monitored.
- Minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress.
- There is no significant doubt about the Company's ability to continue as a going concern.
- There is no significant deviation from the last year's operating result of the Company.
- The system of internal control is sound and has been implemented and monitored effectively.
- Remuneration of Directors including Independent Director have been shown in Note No. in the Notes of standalone Account.
- The key operating and financial data for the last five years. (Page 34)

Board Meeting and Attendance: The number of Board meeting and the Attendance of Directors during the year 2019-2020 were as follows:

Name of the Directors	Position	Meeting held	Attended
Mrs. Aziza Yeasmin	Chairman	10	10
Mr. A.F.M Anowarul Huq	Managing Director	10	10
Mrs. Hafiza Yeasmin	Director	10	0
Mrs. Aysha Siddika	Director	10	*0
Mrs. Sayeda Huq	Director	10	9
Mrs. Fatima Parvin	Director	10	10
Md. Golam rabbani	Director	10	6
Md. Mizanur Rahman	Director	10	10
Mr. Md. Monirujjaman	Independent Director	10	9
Mr. Md. Iftikhar-Uz-Zaman	Independent Director	10	**1
Md. Amin-Ur-Rashid	Director	10	***3
Mrs. Shahanaz Akter	Director	10	****3
Mr. S. M. Harun Or rashid	Independent Director	10	****3
Mr. Mad. Firoz Khan	Independent Director	10	****2

*Appointed on 16 August, 2020 ** Appointed on 30 January, 2020 ***Resigned on 12 December 2019 **** Resigned on 30 January, 2020.

DIRECTORS PROFILE

Who are seeking appointment

Annexure- II
To the Directors Report

RE-APPOINTMENT OF DIRECTORS



MRS. SAYEDA HUQ is a Non-Executive and Sponsor Director of Indo-Bangla Pharmaceuticals Ltd., since 2014. She is the wife of late Azizul Haque, Founder of Indo-Bangla Pharmaceuticals Works. She has a rich experience of more than 18 years in the Pharmaceuticals and other sector. In addition, her present role, she is a member of Nomination and Remuneration Committee of the Company and has been playing role to assist the Board in formulation of the nomination policy for determining qualifications, positive attributes, experiences and independence of directors and top level executives as well as a policy for formal process of considering remuneration of directors, top level executives.



MRS. FATIMA PARVIN is a Director of Indo-bangla Pharmaceuticals Ltd., since 2016, Daughter of Dr. Ali Akbar Mia. She obtained L.L.B (Hon's) and L.L.M from the Dhaka International University and has an experience of more than 13 years in the pharmaceuticals sector. In addition, her present role, she is a member of Audit Committee of the Company and has been playing role to review and recommend to the Board to approve the quarterly and annual financial statements prepared for statutory purpose. She is also the columnist of the Bangladesh Protidin, Daily Samakal, DailyJaiJai Din and Daily Aurtho-nitiprotidin.

APPOINTMENT OF INDEPENDENT DIRECTORS



MR. MD. IFTIKHAR-UZ-ZAMAN joined as Independent Director on the Board of Indo-Bangla Pharmaceuticals Limited in January 2020. He is the Chairperson of Audit Committee of Indo-Bangla Pharmaceuticals Ltd. He obtained B.A. (Hon's) and M.A. in Statistics from the University of Rajshahi.

Mr. Zaman has a rich experience of more than 33 in corporate arena. He was appointed as the Managing Director (additional Charge) of Investment Corporation of Bangladesh (ICB) in December, 2015. Thereafter, he has been appointed as the Managing Director of Investment Corporation of Bangladesh (ICB) on 4 February 2016. He joined ICB in 1983 as Senior Officer. During his 33 years long professional career he rendered his duties as the CEO of ICB Capital Management Ltd. (ICML), GM of ICB, Chairman of ICB Securities Trading Company Ltd. (ISTCL) & ICB Asset Management Company Ltd. (IAMCL), DMD of Janata Bank Ltd. & ICB.




MRS. AYSHA SIDDIKA, has been appointed as a Non-Executive Director on the Board of Directors of Indo-Bangla Pharmaceuticals Limited in August 2020. Mrs. Siddika is also a sponsor of the company. She obtained Master's and has a rich experience of more than 13 years in Administration, Human Resources and the pharmaceuticals sector.

SHAREHOLDING PATTERN

Annexure- III
Pattern of Shareholding
as on June 30, 2020

	Name of the Shareholders	Status	Share held	%
A.	Parent/Subsidiary /Associated Companies and otherrelated parties	-	-	-
B.	Directors & Sponsors:			
1.	Mrs. Aziza Yeasmin	Chairman	2,403,995	2.16%
2.	Mr. A F M Anowarul Huq	Managing Director	14,909,565	13.37%
3.	Mrs. Hafiza Yeasmin	Director	2,403,995	2.16%
4.	Mrs. Aysha Siddika	Director	2,403,995	2.16%
5.	Mrs. Fatima Parvin	Director	2,950,739	2.65%
6.	Mrs. Sayeda Huq	Director	2,399,199	2.15%
7.	Investment Corporation of Bangladesh Represent by Md. Golam Rabbani	Director	17,985,000	16.13%
8.	Mr. Mizanur Rahman	Director	2,459,149	2.21%
9.	Mr. Md. Iftikhar-Uz-Zaman	Independent Director	-	-
10.	Mr. Md. Monirujjaman	Independent Director	-	-
11.	Mr. Md. Bellal Khan	Sponsor	3,764,860	3.38%
12.	Mr. Md. Amin-Ur-Rashid	Sponsor	3,015,485	2.70%
C.	Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance and their spouses and minor children;			
	Mr. A F M Anowarul Huq	Chief Executive Officer	14,909,565	13.37%
	Md. Faruque Hossain	Chief Financial Officer	-	-
	Mohi Uddin QCS	Company Secretary	-	-
	Md. Abu Taleb	Head of Internal Audit and Compliance	-	-
D.	Executives:			
	Mohammed Anwar Hossain	General Manager	-	-
	Mr. Shah-E-Azam	Plant Manager	-	-
	Mr. Mizanur Rahman	Head of Admin.	-	-
E.	Shareholders holding 10% or more voting interest in the company			



REPORT OF AUDIT COMMITTEE FOR THE YEAR 2019-2020

Annexure- IV To The Directors' Report

Indo-Bangla Pharmaceuticals Limited has an Audit Committee as a sub-committee of the Board of Directors in order to assist the Board of Directors in ensuring and fulfilling its oversight responsibilities in compliance with Condition-5 of the Notification of Bangladesh Securities and Exchange Commission (BSEC) No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June, 2018. All members of the audit committee are "financially literate" and having the ability to read and understand the financial statements like statement of financial position, statement of comprehensive income, statement of changes in equity and cash flows statement.

COMPOSITION OF AUDIT COMMITTEE

The Audit Committee of Indo-Bangla Pharmaceuticals limited is comprised of 3 (three) Members of the Board of Directors including 2 (two) Independent Directors. The composition of the present members of Audit Committee as follows:

Md. Iftikhar-Uz-Zaman (Independent Director)	Chairperson
Md. Monirujjaman (Independent Director)	Member
Mrs. Fatima Parvin (Director)	Member

Mohi Uddin, Company Secretary attends the Audit Committee's meeting as the Secretary of the Committee. The Managing Director and Head of Internal Audit and compliance (HIAC) attends the meetings by invitation as specified in ToR of the Audit Committee.

THE SCOPE OF AUDIT COMMITTEE WAS DEFINED AS UNDER:

Role of the Audit Committee directly from the Board of Directors oversight function and the purpose, authority, composition, duties and responsibilities of the Audit Committee are outlined in its terms of references, some of main responsibilities of the Audit Committee are as follows:

- Review and recommend to the Board to approve the quarterly and annual financial statements prepared for statutory purpose;
- Monitor and oversee choice of accounting policies and principles, internal audit and Compliance process, management process, auditing manner, hiring and performance of external auditors;
- Reviewing the corrective measures taken by the Management as regards the incidents relating to the deficiencies, fraud in internal control or other similar issues detected by Internal and External Auditors and inform the Board on a regular basis.
- Review statement of significant related party transactions submitted by the management.
- Carry on a supervision role to safeguard the systems of governance and independence of statutory auditors and
- Review and consider the report of internal auditors and statutory auditors' observations on internal control.

AUTHORITY

The Audit Committee is a committee of the Board as a sub-committee of the Board and responsible to the Board; the Committee has delegated authority from the Board in respect of the functions and power set out in its Terms of Reference. It is authorized to seek any information it requires from and require the attendance at any of its meetings of any Director, Member of Management. The Committee is also authorized to have any information and advice from the Company's Legal Advisors, Statutory Auditor and Compliance Auditor if required.

MEETINGS AND ATTENDANCE

During the year 2019-2020 under review, the Committee held four meetings. The attendance of the Member at these meeting is outlined below:

Name of the Member	Position	No. of Meeting held whilst a Committee Member	Meetings Attend	Remarks
Md. Iftikhar-Uz-Zaman (Independent Director)	Chairperson	1	1	Appointed as a chairman of the Audit Committee on 30 January 2020.
S.M. Harun or Rashid (Independent Director)	Chairperson	3	3	Membership was vacated due to resignation from the Board.
Md. Amin-Ur-Rashid	Member	2	1	Membership was vacated due to resignation from the Board.
Md. Monirujjaman	Member	2	2	Appointed as a member of the Audit Committee on 18 December 2019.
Mrs. Fatima Parvin	Member	4	4	Continuing
Mohi Uddin	Secretary	4	4	Continuing

The Audit Committee of Indo-Bangla Pharmaceuticals Ltd. is pleased to confirm that the following activities have been carried out during the year:

In accordance with the 'Audit Committee Charter' the Audit Committee worked and evaluated items that was raised for consideration as well as discussed issues related to key events of every every financial period

- Enhance good practices in financial reporting and risk management.
- Ensure establishment of adequate internal controls and compliance with laws and regulations.
- Ensure that the preparation, presentation and submission of financial statements have been made in accordance with the prevailing laws, standards and regulations.

In pursuance with Corporate Governance Code, 2018, the Audit Committee also reviewed the internal audit reports, the interim and annual financial statements and the financial performance of Indo-Bangla Pharmaceuticals Ltd. for the year ended June 30, 2020.

The Committee found adequate arrangement to present a true and fair view of the financial status of the company and did not find any material deviation, discrepancies or any adverse finding/observation in the areas of reporting.

(Md. Iftikhar-Uz-Zaman)

Independent Director
Chairman of Audit Committee.

Date: 28 October, 2020

REPORT OF NOMINATION AND REMUNERATION COMMITTEE (NRC)

For the year 2019-2020

Annexure- V
To The Directors' Report

The Board of Directors of Indo-Bangla Pharmaceuticals Ltd. has duly constituted a Nomination and Remuneration Committee (NRC), as per the requirement of the Corporate Governance Code of Bangladesh securities and Exchange Commission (BSEC) to shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executives as well as a policy for formal process of considering remuneration of directors, top level executives.

The statement of Nomination and Remuneration Committee is prepared as per Corporate Governance Code issued by BSEC.

TERMS OF REFERENCES

The Nomination and Remuneration Committee has performed its duties as assigned by the Board of Directors and defined in the chartered of the NRC formulated in accordance with the Notification of the Bangladesh Securities and Exchange Commission's Corporate Governance Code, 2018

COMPOSITION

The Nomination and Remuneration Committee of Indo-Bangla Pharmaceuticals Ltd. is comprised of three (3) non-executive Directors of the Board including an Independent Director. The Chairperson of the Committee is an Independent Director of the Company the composition of the present NRC is as follows:

1. Md. Monirujjaman (Independent Director)	Chairperson
2. Mrs. Sayeda Huq (Director)	Mrmber
3. Md. Mizanur Rahman (Director)	Member

Mr. Mohi Uddin, Company Secretary attends the Committee's meeting as the Secretary of the Committee. The Managing Director and Head of Human Resources and Administration attends the meeting by invitation. The Chief Financial Officer attends the meeting as and when invited.

QUALIFICATION

The members of Nomination and Remuneration Committee of Indo-Bangla Pharmaceuticals Limited possess the adequate knowledge and business management and corporate governance matters.

ROLES AND RESPONSIBILITIES

The roles and responsibilities of the Nomination and Remuneration Committee flow directly from the Board's oversight functions. The purpose, authority, composition, duties and responsibilities of the Nomination and Remuneration Committee are delineated in its Charter. Some of the major responsibilities of the NRC are as follows:

- The Committee shall be independent, responsible and accountable to the Board and the Shareholders.
- Recommend a policy to the Board relating to the remuneration of the Directors, and top level executives;
- Recommend a policy on Board's diversity taking into consideration age, gender, experience, education and nationality;
- Formulate the criteria for determining qualification and independence of Directors;
- Identify persons who are qualified to become Directors and in top level executives and recommend their appointment and removal;
- Formulate the criteria for evaluation of performance of Independent Directors;
- Assess that the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable Directors to run the company successfully;
- Evaluate that remuneration to Directors and top level executives involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;
- Identify the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria;
- Recommend and review annually the Company's human resources and training policies;
- Recommend the remuneration policy of the Company, particularly in relation to the yearly increment principle; and
- Recommend the Code of Conduct for the Chair of the Board, other Board Members and Chief Executive Officer of the Company.
- Reporting to the Board of Directors on the Committee's activities and findings

NOMINATION, RECRUITMENT AND SELECTION STANDARDS

Recruitment and selection processes for Board members identify candidates with the most suitable skills, knowledge, experiences and personal values. The NRC is responsible to ensure that the procedures for appointing new Directors are transparent and rigorous. The Board places great emphasis on ensuring its membership reflecting diversity in broader sense. A combination of age, gender, experience, ethnicity, educational background, nationality and other relevant personal attributes in the Board is important in providing a range of perspectives, insights and challenges needed to support right decision making.

MEETINGS AND ATTENDANCE

During the year 2019-2020 under review, the Committee held four meetings. The attendance of the Member at these meeting is outlined below:

Name of the Member	Position	No. of Meeting held whilst a Committee Member	Meetings Attend	Remarks
Md. Monirujjaman (Independent Director)	Chairperson	2	2	Continuing
Mrs. Sayeda Huq	Member	2	2	Continuing
Md. Mizanur Rahman	Member	2	2	Continuing
Mohi Uddin	Secretary	2	2	Continuing

EVALUATION CRITERIA

The evaluation process is led by the Chairman of the Board and assisted by the Company Secretary. The respective line authority of the Directors, Top level Executives sets the performance measurement criteria based on the respective role profile and responsibilities through the annual appraisal process. The NRC is responsible for ensuring the effectiveness of the Board. The Board shall carry out an evaluation once a year of its work, functions, performance as well as monitoring of internal control over financial reporting for the preparation of external financial statements and the safeguarding of assets. Each Director is required to complete a confidential pre-set questionnaire. The evaluation includes a review of the administration of the Board and its committees covering their operations, agenda, reports, and information produced for consideration, and relationship with Management.

AUTHORITY

The Nomination and Remuneration Committee has carried out its duties with due care, due diligence, transference and independence and as an act of good faith for the betterment of the Company and shareholders. The Committee has authorized to seek any information if requires from and require the attendance at any of it meetings of any Director, member of Management and all employees are expected to cooperate with any quest made by the Committee.

ACTIVITIES CARRIED OUT DURING FINANCIAL YEAR 2019-2020.

In accordance with the 'Terms of Reference' of Nomination and Remuneration Committee, the Committee carried out the following activities during the financial year 2019-2020.

SELECTION & REMUNERATION CRITERIA OF TOP LEVEL EXECUTIVE

The performance of the Company depends upon the quality of its Directors and Top Level Executives. To prosper, the Company must attract, motivate and retain highly skilled Directors and Executives. The recruitment process for Top Level Executives shall be transparent, non-discriminatory, diversified and in alignment with the Codes of Conduct.

REMUNERATION FOR BOARD OF DIRECTORS.

Each Director shall receive reasonable remuneration from the Company for every meeting attended, plus travelling expenses from and to usual place of residence and an allowance per day for the number of days spent attending, travelling to and returning from Board meetings. The amounts will be determined by the Shareholders at the General Meeting.

- Consider the Terms of Reference (ToR) of NRC as approved by the Board of Directors;
- Formulate the policy relating to the remuneration of the Directors and top-level executives;
- Formulate the criteria for determining qualifications, positive attributes and independence of the Directors;
- Adopt Code of Conduct for the Chairman, Directors and Top-level Executive as per BSEC Notification;
- Criteria for evaluation of performance of Independent Directors;

For and on behalf of the Nomination and Remuneration Committee of Indo-Bangla Pharmaceuticals Ltd.

Sd/-

(Adv. Md. Monirujjaman)

Independent Director

Chairman of the Nomination and Remuneration Committee.

27 October 2020

DECLARATION BY CEO AND CFO

Under Condition # 1(5)(xxvi) of CGC

Annexure-A
Report to the Shareholders

The Board of Directors
Indo-Bangla Pharmaceuticals Ltd.
Bashundhara R/A, Baridhara,
Dhaka-1229

Date: 27 October, 2020

Subject: Declaration on Financial Statements for the year ended on 30 June, 2020.

Dear sir(s),

Pursuant to the condition No. 1(5)(xxvi) imposed vide the Commission's Notification No. BSEC/ CMRRCD/2006 -158/207/Admin/80 Dated 3 June, 2018 under section 2CC of the Securities and Exchange Ordinance, 1969, we do hereby declare that:

1. The Financial Statements of Indo-Bangla Pharmaceuticals Ltd. for the year ended on 30th June, 2020 have been prepared in compliance with International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in the Bangladesh and any departure there from has been adequately disclosed;
2. The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, in order for the financial statements to reveal a true and fair view;
3. The form and substance of transactions and the Company's state of affairs have been reasonably and fairly presented in its financial statements;
4. To ensure above, the Company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;
5. Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the Company were consistently followed; and
6. The management's use of the going concern basis of accounting in preparing the financial statements is appropriate and there exists no material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.

In this regard, we also certify that: -

- (i) We have reviewed the financial statements for the year ended on 30th June, 2020 and that to the best of our knowledge and belief:
 - (a) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - (b) These statements collectively present true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable laws.
- (ii) There are, to the best of knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely yours,


(A F M Anowarul Huq)
Managing Director


(Md. Faruque Hossain)
Chief Financial Officer

CERTIFICATE ON COMPLIANCE

with the condition No. 1(5)(XVII) of
Corporate Governance Code

Annexure –B

Certificate as per condition
No. 1(5)(xxvii)



শফিক বসাক এন্ড কোং
SHAFIQ BASAK & CO.

CHARTERED ACCOUNTANTS

Partners:

Md. Shafiqul Islam, FCA
Sampad Kumar Basak, FCA
Md. Enayet Ullah, FCA
Sarwar Mahmood, FCA
Sheikh Zahidul Islam, MBA, FCA

CHATTOGRAM OFFICE :

National House (1st Floor),
109, Agrabad Commercial Area,
Chattogram -4100, Bangladesh.
Phone :880-31-711561
Pho/Fax :880-31-723680
Web :www.shafiqbasak.com
E-mail: basak_sbc@yahoo.com
basak@shafiqbasak.com

DHAKA OFFICE -(1):

Shatabdi Centre (4th & 6th Floor)
292, Inner Circular Road,
Fakirapool, Motijheel, Dhaka.
Phone/Fax : 880-2-7192098,
Cell: 01730-080666
E-mail : skzislam86@gmail.com
shafiq_basak@yahoo.com
Web : www.shafiqbasak.com

Ref. No. : SB/IBPL-297/2020

Report to the Shareholders of Indo-Bangla Pharmaceuticals Ltd. on compliance on the Corporate Governance Code

We have examined the compliance status to the Corporate Governance Code by **Indo-Bangla Pharmaceuticals Ltd.** for the year ended on 30 June 2020. This Code relates to the Notification No.BSEC/CMRRCD/2006-158/207/Admin/80, dated 3 June 2018 of the Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the Company. Our Examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.

This is a scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Corporate Governance Code.

We state that we have obtained all the information and explanations, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion:

- The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above mentioned Corporate Governance Code issued by the Commission;
- The company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code;
- Proper books and records have been kept by the company as required under the Companies Act, 1994, the securities laws and other relevant laws;
- The governance of the company is highly satisfactory.

Place: Dhaka

Dated: 25 November, 2020




(Sheikh Zahidul Islam, MBA, FCA)
Partner
SHAFIQ BASAK & CO.
CHARTERED ACCOUNTANTS



INDEPENDENT MEMBER OF
ABACUS
WORLDWIDE

DHAKA OFFICE -(2): House - 42 (1st Floor), Road - 01, Book - A, Niketan, Gulshan - 01, Dhaka.
Phone : 88-02-99859602-3, 01819-285196, E-mail:mahmoods.bd@gmail.com

In Practice Since 1993

Status of compliance with the conditions imposed by the Commission's Notification No.SEC/CMRRCD/2006-158/207/Admin/80 dated 3 June 2018 issued under section 2CC of the Securities and Exchange Ordinance, 1969:

(Report under Condition No. 9)

Condition No.	Title	Complied	Not Complied	Remarks (IF ANY)
1	Board of Directors			
1(1)	Size of the Board of Directors			
	The total number of the board members of the company shall not be less than 5 (five) and more than 20 (twenty)	√		
1(2)	Independent Directors			
1(2)(a)	At least one fifth (1/5) of the total number of directors in the company's board shall be independent directors.	√		
1(2)(b)	<i>For the purpose of this clause 'independent director' means a director-</i>			
1(2)(b)(i)	Who either does not hold any share in the company or holds less than one percent (1%) shares of the total paid-up shares of the company;	√		
1(2)(b)(ii)	who is not a sponsor of the company or is not connected with the company's any sponsor or director or nominated director or shareholder of the company or any of its associates, sister concerns, subsidiaries and parents or holding entities who holds one percent (1%) or more shares of the total paid-up shares of the company on the basis of family relationship and his or her family members shall not hold above mentioned shares in the company;	√		
1(2)(b)(iii)	who has not been an executive of the company in immediately preceding 2 (two) financial years;	√		
1(2)(b)(iv)	who does not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary or associated companies;	√		
1(2)(b)(v)	who is not a member or TREC (Trading Right Entitlement Certificate) holder, director or officer of any stock exchange;	√		
1(2)(b)(vi)	who is not a shareholder, director excepting independent director or officer of any member or TREC holder of stock exchange or an intermediary of the capital market;	√		
1(2)(b)(vii)	who is not a partner or an executive or was not a partner or an executive during the preceding 3 (three) years of the concerned company's statutory audit firm or audit firm engaged in internal audit services or audit firm conducting special audit or professional certifying compliance of this Code;	√		
1(2)(b)(viii)	who is not independent director in more than 5 (five) listed companies;	√		

1(2)(b)(ix)	who has not been convicted by a court of competent jurisdiction as a defaulter in payment of any loan or any advance to a bank or a Non-Bank Financial Institution (NBFi);	√		
1(2)(b)(x)	who has not been convicted for a criminal offence involving moral turpitude;	√		
1(2)(c)	The independent director(s) shall be appointed by the Board and approved by the shareholders in the Annual General Meeting (AGM);	√		
1(2)(d)	The post of independent director(s) cannot remain vacant for more than 90 (ninety) days;	√		
1(2)(e)	The tenure of office of an independent director shall be for a period of 3 (three) years, which may be extended for 1 (one) tenure only.	√		
1(3)	Qualification of Independent Director			
1(3)(a)	Independent Director shall be a knowledgeable individual with integrity who is able to ensure compliance with financial laws, regulatory requirements and corporate laws and can make meaningful contribution to business;	√		
1(3)(b)	Independent Director shall have following qualifications			
1(3)(b)(i)	Business leader who is or was a promoter or director of an unlisted company having minimum paid up capital of Tk. 100.00 million or any listed company or a member of any national or international chamber of commerce or business association; or	-	-	N/A
1(3)(b)(ii)	Corporate leader who is or was a top level executive not lower than Chief Executive Officer or Managing Director or Deputy Managing Director or Chief Financial Officer or Head of Finance or Accounts or Company Secretary or Head of Internal Audit and Compliance or Head of Legal Service or a candidate with equivalent position of an unlisted company having minimum paid up capital of Tk. 100.00 million or of a listed company;	√	-	
1(3)(b)(iii)	Former official of government or statutory or autonomous or regulatory body in the position not below 5th Grade of the national pay scale, who has at least educational background of bachelor degree in economics or commerce or business or law;	√		
1(3)(b)(iv)	University Teacher who has educational background in Economics or Commerce or Business Studies or Law;	-	-	N/A
1(3)(b)(v)	Professional who is or was an advocate practicing at least in the High Court Division of Bangladesh Supreme Court or a Chartered Accountant or Cost and Management Accountant or Chartered Financial Analyst or Chartered Certified Accountant or Certified Public Accountant or Chartered Management Accountant or Chartered Secretary or equivalent qualification;	√	-	
1(3)(c)	The independent director shall have at least 10 (ten) years of experiences in any field mentioned in clause (b);	√		

1(3)(d)	In special cases, the above qualifications or experiences may be relaxed subject to prior approval of the Commission;			No such issue arose
1(4)	Duality of Chairperson of the Board of Directors and Managing Director or Chief Executive Officer			
1(4)(a)	The positions of the Chairperson of the Board and the Managing Director and/ or Chief Executive Officer (CEO) of the company shall be filled by different individuals;	√		
1(4)(b)	The Managing Director (MD) and/ or Chief Executive Officer (CEO) of a listed company shall not hold the same position in another listed company;	√		
1(4)(c)	The Chairperson of the Board shall be elected from among the non-executive directors of the company;	√		
1(4)(d)	The Board shall clearly define respective roles and responsibilities of the chairperson and the Managing Director and/ or Chief Executive Officer;	√		
1(4)(e)	In the absence of the chairperson of the Board, the remaining members may elect one of themselves from non-executive directors as Chairperson for that particular Board's meeting; the reason of absence of the regular Chairperson shall be duly recorded in the minutes.	√		
1(5)	The Directors' Report to Shareholders:			
	The Board of the company shall include the following additional statements or disclosures in the Directors' Report prepared under section 184 of the companies Act, 1994 (Act No. XVIII of 1994):-			
1(5)(i)	An industry outlook and possible future developments in the industry;	√		
1(5)(ii)	The Segment-wise or product-wise performance;	√		
1(5)(iii)	Risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment, if any;	√		
1(5)(iv)	A discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin, where applicable;	√		
1(5)(v)	A discussion on continuity of any Extra-Ordinary activities and their implications (gain or loss);			No such issue arose
1(5)(vi)	A detailed discussion on related party transactions along with a statement showing amount, nature of related party, nature of transactions and basis of transactions of all related party transactions;	√		
1(5)(vii)	A statement of utilization of proceeds raised through public issues, rights issues and/or any other instruments;	√		
1(5)(viii)	An explanation if the financial results deteriorate after the company goes for Initial Public Offering (IPO), Repeat Public Offering (RPO), Rights Share Offer, Direct Listing, etc;			No such issue arose
1(5)(ix)	An explanation on any significant variance that occurs between Quarterly Financial performance and Annual Financial statements;			No such matter to explain
1(5)(x)	A statement of remuneration paid to the directors including independent directors	√		

1(5)(xi)	The financial statements prepared by the management of the issuer company present fairly its state of affairs, the result of its operations, cash flows and changes in equity;	√		
1(5)(xii)	Proper books of account of the issuer company have been maintained;	√		
1(5)(xiii)	Appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment;	√		
1(5)(xiv)	International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh, have been followed in preparation of the financial statements and any departure there from has been adequately disclosed;	√		
1(5)(xv)	The system of internal control is sound in design and has been effectively implemented and monitored;	√		
1(5)(xvi)	Minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;	√		
1(5)(xvii)	There is no significant doubt upon the issuer company's ability to continue as a going concern, if the issuer company is not considered to be a going concern, the fact along with reasons there of shall be disclosed;	√		
1(5)(xviii)	An explanation that significant deviations from the last year's operating results of the issuer company shall be highlighted and the reasons thereof shall be explained;			No such matter to explain
1(5)(xix)	Key operating and financial data of at least preceding 5 (five) years shall be summarized;	√		
1(5)(xx)	An explanation on the reasons if the issuer company has not declared dividend (cash or stock) for the year;			The BOD declared dividend
1(5)(xxi)	Board's statement to the effect that no bonus share or stock dividend has been or shall be declared as interim dividend;			N/A
1(5)(xxii)	The total number of Board meetings held during the year and attendance by each director;	√		
1(5)(xxiii)	A report on the pattern of shareholding disclosing the aggregate number of shares (along with name-wise details where stated below) held by:-	√		
1(5)(xxiii)(a)	Parent or Subsidiary or Associated Companies and other related parties (name-wise details);	√		
1(5)(xxiii)(b)	Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance and their spouses and minor children (name-wise details);	√		
1(5)(xxiii)(c)	Executives; and	√		
1(5)(xxiii)(d)	Shareholders holding ten percent (10%) or more voting interest in the company (name-wise details);	√		
1(5)(xxiv)	In case of the appointment or reappointment of a director, a disclosure on the following information to the shareholders:-	√		
1(5)(xxiv)(a)	a brief resume of the director	√		

1(5)(xxiv)(b)	nature of his or her expertise in specific functional areas;	√		
1(5)(xxiv)(c)	names of companies in which the person also holds the directorship and the membership of committees of the Board;	√		
1(5)(xxv)	Management's Discussion and Analysis signed by CEO or MD presenting detailed analysis of the company's position and operations along with a brief discussion of changes in the financial statements, among others, focusing on:	√		
1(5)(xxv)(a)	accounting policies and estimation for preparation of financial statements;	√		
1(5)(xxv)(b)	changes in accounting policies and estimation, if any, clearly describing the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes;	√		
1(5)(xxv)(c)	comparative analysis (including effects of inflation) of financial performance or results and financial position as well as cash flows for current financial year with immediate preceding five years explaining reasons thereof;	√		
1(5)(xxv)(d)	compare such financial performance or results and financial position as well as cash flows with the peer industry scenario;	√		
1(5)(xxv)(e)	briefly explain the financial and economic scenario of the country and the globe;	√		
1(5)(xxv)(f)	risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the company;	√		
1(5)(xxv)(g)	future plan or projection or forecast for company's operation, performance and financial position, with justification thereof, i.e., actual position shall be explained to the shareholders in the next AGM;	√		
1(5)(xxvi)	Declaration or certification by the CEO and the CFO to the Board as required under condition No. 3(3) shall be disclosed as per Annexure-A;	√		
1(5)(xxvii)	The report as well as certificate regarding compliance of conditions of this Code as required under condition No. 9 shall be disclosed as per Annexure-B and Annexure-C.	√		
1(6)	Meetings of the Board of Directors:			
	The company shall conduct its Board meetings and record the minutes of the meetings as well as keep required books and records in line with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Code.	√		
1(7)	Code of Conduct for the Chairperson, other Board members and Chief Executive Officer			

1(7)(a)	The Board shall lay down a code of conduct, based on the recommendation of the Nomination and Remuneration Committee (NRC) at condition No. 6, for the Chairperson of the Board, other board members and Chief Executive Officer of the company;	√		
1(7)(b)	The code of conduct as determined by the NRC shall be posted on the website of the company including, among others, prudent conduct and behavior; confidentiality; conflict of interest; compliance with laws, rules and regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency.	√		
2	Governance of Board of Directors of Subsidiary Company			
2(a)	Provisions relating to the composition of the Board of the holding company shall be made applicable to the composition of the Board of the subsidiary company;	-	-	N/A
2(b)	At least 1 (one) independent director on the Board of the holding company shall be a director on the Board of the subsidiary company;	-	-	N/A
2(c)	The minutes of the Board meeting of the subsidiary company shall be placed for review at the following Board meeting of the holding company;	-	-	N/A
2(d)	The minutes of the respective Board meeting of the holding company shall state that they have reviewed the affairs of the subsidiary company also;	-	-	N/A
2(e)	The Audit Committee of the holding company shall also review the financial statements, in particular the investments made by the subsidiary company.	-	-	N/A
3	Managing Director (MD) or Chief Executive Officer (CEO), Chief Financial Officer (CFO), Head of Internal Audit and Compliance (HIAC) and Company Secretary (CS)			
3(1)	Appointment			
3(1)(a)	The Board shall appoint a Managing Director (MD) or Chief Executive Officer (CEO), a Company Secretary (CS), a Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC);	√		
3(1)(b)	The positions of the Managing Director (MD) or Chief Executive Officer (CEO), Company Secretary (CS), Chief Financial Officer (CFO) and Head of Internal Audit and Compliance (HIAC) shall be filled by different individuals;	√		
3(1)(c)	The MD or CEO, CS, CFO and HIAC of a listed company shall not hold any executive position in any other company at the same time;	√		
3(1)(d)	The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS;	√		
3(1)(e)	The MD or CEO, CS, CFO and HIAC shall not be removed from their position without approval of the Board as well as immediate dissemination to the Commission and stock exchange(s).	√		
3(2)	Requirement to attend Board of Directors' Meetings:			

	The MD or CEO, CS, CFO and HIAC of the company shall attend the meetings of the Board provided that CS, CFO and HIAC shall not attend such part of a meetings of the Board relating to their personal matter.	√		
3(3)	Duties of Managing Director (MD) or Chief Executive Officer (CEO) and Chief Financial Officer (CFO)			
3(3)(a)	The MD or CEO and CFO shall certify to the Board that they have reviewed financial statements for the year and that to the best of their knowledge and belief:	√		
3(3)(a)(i)	these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading; and	√		
3(3)(a)(ii)	these statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws;	√		
3(3)(b)	The MD or CEO and CFO shall also certify that there are, to the best of knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board or its members	√		
3(3)(c)	The certification of the MD or CEO and CFO shall be disclosed in the Annual Report.	√		
4	Board of Directors' Committee:- For ensuring good governance in the company, the Board shall have at least following subcommittees:			
4(i)	Audit Committee	√		
4(ii)	Nomination and Remuneration Committee	√		
5	Audit Committee			
5(1)	Responsibility to the Board of Directors			
5(1)(a)	The company shall have an Audit Committee as a sub-committee of the Board;	√		
5(1)(b)	The Audit Committee shall assist the Board in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and in ensuring a good monitoring system within the business;	√		
5(1)(c)	The Audit Committee shall be responsible to the Board; the duties of the Audit Committee shall be clearly set forth in writing.	√		
5(2)	Constitution of the Audit Committee			
5(2)(a)	The Audit Committee shall be composed of at least 3 (three) members;	√		
5(2)(b)	The Board shall appoint members of the Audit Committee who shall be non-executive directors of the company excepting Chairperson of the Board and shall include at least 1 (one) independent director;	√		
5(2)(c)	All members of the audit committee should be "financially literate" and at least 1 (one) member shall have accounting or related financial management background and 10 (ten) years of such experience;	√		

5(2)(d)	When the term of service of any Committee member expires or there is any circumstance causing any Committee member to be unable to hold office before expiration of the term of service, thus making the number of the Committee members to be lower than the prescribed number of 3 (three) persons, the Board shall appoint the new Committee member to fill up the vacancy immediately or not later than 1 (one) month from the date of vacancy in the Committee to ensure continuity of the performance of work of the Audit Committee;	√		
5(2)(e)	The company secretary shall act as the secretary of the Committee;	√		
5(2)(f)	The quorum of the Audit Committee meeting shall not constitute without at least 1 (one) independent director.	√		
5(3)	Chairperson of the Audit Committee			
5(3)(a)	The Board shall select 1 (one) member of the Audit Committee to be Chairperson of the Audit Committee, who shall be an independent director;	√		
5(3)(b)	In the absence of the Chairperson of the Audit Committee, the remaining members may elect one of themselves as Chairperson for that particular meeting, in that case there shall be no problem of constituting a quorum as required under condition No. 5(4)(b) and the reason of absence of the regular Chairperson shall be duly recorded in the minutes.			No such Incident arose
5(3)(c)	Chairperson of the Audit Committee shall remain present in the Annual General Meeting (AGM);	√		
5(4)	Meeting of the Audit Committee			
5(4)(a)	The Audit Committee shall conduct at least its four meetings in a financial year	√		
5(4)(b)	The quorum of the meeting of the Audit Committee shall be constituted in presence of either two members or two third of the members of the Audit Committee, whichever is higher, where presence of an independent director is a must.	√		
5(5)	Role of Audit Committee: The Audit Committee shall:-			
5(5)(a)	Oversee the financial reporting process;	√		
5(5)(b)	monitor choice of accounting policies and principles;	√		
5(5)(c)	monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance Plan and review of the Internal Audit and Compliance Report;	√		
5(5)(d)	oversee hiring and performance of external auditors;	√		
5(5)(e)	hold meeting with the external or statutory auditors for review of the annual financial statements before submission to the Board for approval or adoption;	√		
5(5)(f)	review along with the management, the annual financial statements before submission to the Board for approval;	√		
5(5)(g)	review along with the management, the quarterly and half yearly financial statements before submission to the Board for approval;	√		
5(5)(h)	review the adequacy of internal audit function;	√		
5(5)(i)	review the Management's Discussion and Analysis before disclosing in the Annual Report;	√		

5(5)(j)	review statement of all related party transactions submitted by the management;	√		
5(5)(k)	review Management Letters or Letter of Internal Control weakness issued by statutory auditors;	√		
5(5)(l)	oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors;	√		
5(5)(m)	oversee whether the proceeds raised through Initial Public Offering (IPO) or Repeat Public Offering (RPO) or Rights Share Offer have been utilized as per the purposes stated in relevant offer document or prospectus approved by the Commission;	√		
5(6)	Reporting of the Audit Committee			
5(6)(a)	Reporting to the Board of Directors			
5(6)(a)(i)	The Audit Committee shall report on its activities to the Board.	√		
5(6)(a)(ii)	The Audit Committee shall immediately report to the Board on the following findings, if any:-			
5(6)(a)(ii)(a)	report on conflicts of interests;			No such Incident arose
5(6)(a)(ii)(b)	suspected or presumed fraud or irregularity or material defect identified in the internal audit and compliance process or in the financial statements;			No such Incident arose
5(6)(a)(ii)(c)	suspected infringement of laws, regulatory compliances including securities related laws, rules and regulations;			No such Incident arose
5(6)(a)(ii)(d)	any other matter which the Audit Committee deems necessary shall be disclosed to the Board immediately;			No such Incident arose
5(6)(b)	Reporting to the Authorities:			
	If the Audit Committee has reported to the Board about anything which has material impact on the financial condition and results of operation and has discussed with the Board and the management that any rectification is necessary and if the Audit Committee finds that such rectification has been unreasonably ignored, the Audit Committee shall report such finding to the Commission, upon reporting of such matters to the Board for three times or completion of a period of 6 (six) months from the date of first reporting to the Board, whichever is earlier.			No such reportable incident arose
5(7)	Reporting to the Shareholders and General Investors:			
	Report on activities carried out by the Audit Committee, including any report made to the Board under condition No. 5(6)(a)(ii) above during the year, shall be signed by the Chairperson of the Audit Committee and disclosed in the annual report of the issuer company.	√		Activities of Audit Committee are disclosed in the Annual Report.
6	Nomination and Remuneration Committee (NRC)			
6(1)	Responsibility to the Board of Directors			
6(1)(a)	The company shall have a Nomination and Remuneration Committee (NRC) as a subcommittee of the Board;	√		

6(1)(b)	The NRC shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executive as well as a policy for formal process of considering remuneration of directors, top level executive;	√		
6(1)(c)	The Terms of Reference (ToR) of the NRC shall be clearly set forth in writing covering the areas stated at the condition No. 6(5)(b).	√		
6(2)	Constitution of the NRC			
6(2)(a)	The Committee shall comprise of at least three members including an independent director;	√		
6(2)(b)	All members of the Committee shall be non-executive directors;	√		
6(2)(c)	Members of the Committee shall be nominated and appointed by the Board;	√		
6(2)(d)	The Board shall have authority to remove and appoint any member of the Committee;	√		
6(2)(e)	In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) days of occurring such vacancy in the Committee;			No such Incident arose
6(2)(f)	The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee;			No such Incident arose
6(2)(g)	The company secretary shall act as the secretary of the Committee;	√		
6(2)(h)	The quorum of the NRC meeting shall not constitute without attendance of at least an independent director;	√		
6(2)(i)	No member of the NRC shall receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than Director's fees or honorarium from the company.	√		
6(3)	Chairperson of the NRC			
6(3)(a)	The Board shall select 1 (one) member of the NRC to be Chairperson of the Committee, who shall be an independent director;	√		
6(3)(b)	In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for that particular meeting, the reason of absence of the regular Chairperson shall be duly recorded in the minutes;			No such Incident arose
6(3)(c)	The Chairperson of the NRC shall attend the annual general meeting (AGM) to answer the queries of the shareholders.	√		
6(4)	Meeting of the NRC			
6(4)(a)	The NRC shall conduct at least one meeting in a financial year;	√		
6(4)(b)	The Chairperson of the NRC may convene any emergency meeting upon request by any member of the NRC;	√		

6(4)(c)	The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher, where presence of an independent director is must as required under condition No. 6(2)(h);	√		
6(4)(d)	The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC.	√		
6(5)	Role of the NRC			
6(5)(a)	NRC shall be independent and responsible or accountable to the Board and to the shareholders;	√		
6(5)(b)	NRC shall oversee, among others, the following matters and make report with recommendation to the Board;	√		
6(5)(b)(i)	formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend a policy to the Board, relating to the remuneration of the directors, top level executive, considering the following:	√		
6(5)(b)(i)(a)	the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the company successfully;	√		
6(5)(b)(i)(b)	the relationship of remuneration to performance is clear and meets appropriate performance benchmarks;	√		
6(5)(b)(i)(c)	remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;	√		
6(5)(b)(ii)	devising a policy on Board's diversity taking into consideration age, gender, experience, ethnicity, educational background and nationality;	√		
6(5)(b)(iii)	identifying persons who are qualified to become directors and who may be appointed in top level executive position in accordance with the criteria laid down, and recommend their appointment and removal to the Board;	√		
6(5)(b)(iv)	formulating the criteria for evaluation of performance of independent directors and the Board;	√		
6(5)(b)(v)	identifying the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria;	√		
6(5)(b)(vi)	developing, recommending and reviewing annually the company's human resources and training policies;	√		
6(5)(c)	The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual Report.	√		
7	External or Statutory Auditors			
7(1)	The issuer company shall not engage its external or statutory auditors to perform the following services of the company, namely:-			
7(1)(i)	appraisal or valuation services or fairness opinions;	√		
7(1)(ii)	financial information systems design and implementation;	√		
7(1)(iii)	book-keeping or other services related to the accounting records or financial statements;	√		
7(1)(iv)	broker-dealer services;	√		
7(1)(v)	actuarial services;	√		

7(1)(vi)	internal audit services or special audit services;	√		
7(1)(vii)	any service that the Audit Committee determines;	√		
7(1)(viii)	audit or certification services on compliance of corporate governance as required under condition No. 9(1);	√		
7(1)(ix)	any other service that creates conflict of interest.			No such incident arose
7(2)	No partner or employees of the external audit firms shall possess any share of the company they audit at least during the tenure of their audit assignment of that company; his or her family members also shall not hold any shares in the said company	√		
7(3)	Representative of external or statutory auditors shall remain present in the Shareholders' Meeting (AGM or EGM) to answer the queries of the shareholders.	√		
8	Maintaining a website by the Company			
8(1)	The company shall have an official website linked with the website of the stock exchange.	√		
8(2)	The company shall keep the website functional from the date of listing.	√		
8(3)	The company shall make available the detailed disclosures on its website as required under the listing regulations of the concerned stock exchange(s).	√		
9	Reporting and Compliance of Corporate Governance			
9(1)	The company shall obtain a certificate from a practicing Professional Accountant or Secretary (Chartered Accountant or Cost and Management Accountant or Chartered Secretary) other than its statutory auditors or audit firm on yearly basis regarding compliance of conditions of Corporate Governance Code of the Commission and shall such certificate shall be disclosed in the Annual Report.	√		
9(2)	The professional who will provide the certificate on compliance of this Corporate Governance Code shall be appointed by the shareholders in the annual general meeting.	√		
9(3)	The directors of the company shall state, in accordance with the Annexure-C attached, in the directors' report whether the company has complied with these conditions or not.	√		

Independent Auditor's Report

To the Shareholders of INDO-BANGLA PHARMACEUTICALS LTD

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of **Indo-Bangla Pharmaceuticals Ltd**, which comprise the statement of financial position as at June 30, 2020 and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended and notes to the financial statements including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as at June 30, 2020, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRS).

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these ethical requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

- a) We draw attention to Note 2.14 (c) of the financial statements, which describes that the Nomination and Remuneration Committee (NRC) of the company reviewed all post employee benefits and the policies are under process for final review of the Board. Our opinion is not modified in respect of this matter.
- b) We draw attention to Note 2.20 of the financial statements, which describes that a number of transactions entered into by the company were cash transactions with prior board approval and this was due to suppliers' demand. Our opinion is not modified in respect of this matter.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon; we do not provide a separate opinion on these matters.

Risk	Our responses to the risk
<p>Revenue recognition</p> <p>Revenue recognition has significant and wide influence on financial statements.</p> <p>The Company has reported revenue of BDT 866.1 million in the financial statements (30th June, 2019: BDT 740.71).</p> <p>Revenue is recognized when the amounts and the related costs are reliably measured, and the performance obligation is complete through passing of control to the customers. Revenue from the sale of goods is recognized at the time when the goods are dispatched for delivery to the customers.</p> <p>We identified revenue recognition as a key audit matter because revenue is one of the key performance indicators of the Company and therefore there is an inherent risk of manipulation of the timing of recognition of revenue by management to meet specific targets or expectations.</p>	<p>We read the assessed compliance of company's revenue recognition policy in terms of IFRS 15: Revenue from Contracts with Customers'. Our audit procedures included the following:</p> <ul style="list-style-type: none"> ▪ We have evaluated and validated the key controls related to the Company's sales process from end to end, from contracts approval and sign-off, recording of sales through to cash receipts and customers' outstanding balances. ▪ We assessed the design and implementation of these controls. We tested a sample of individual sales transactions and traced to dispatch notes and subsequent cash receipt or other supporting documents; ▪ Assessed the invoicing and measurement systems up to entries in the general ledger; ▪ Examined customer invoices and receipts of payment on test basis; ▪ Assessed the design of the processes set up to account for the transactions in accordance with the company policy; ▪ Assessed whether any adjustments are required.
Refer to note 16 to the financial statements	
<p>Measurement of deferred tax liability</p> <p>Company reported net deferred tax liability totaling BDT 94.72 million in the financial statements as at 30 June, 2020. (30th June, 2019: BDT 66.76),</p> <p>Significant judgment is required in relation to deferred tax liability as their recoverability is dependent on forecasts of future profitability over a number of years.</p>	<p>We obtained an understanding, evaluated the design and tested the operational effectiveness of the Company's key controls over the recognition and measurement of deferred tax liability and the assumptions used in estimating the Company's future taxable income.</p> <p>We also assessed the completeness and accuracy of the data used for the estimations of future taxable income.</p> <p>We also assessed the appropriateness of presentation and disclosures in relation to deferred tax.</p>
Refer to note 11 to the financial statements	

Other Information

Management is responsible for the other information. The other information comprises the information included in the Annual Report other than the financial statements and our auditor's report thereon. The Annual Report is expected to be made available to us after the date of this auditor's report.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

When we read the Annual Report, if we conclude that there is a material misstatement therein of this other information, we are required to communicate the matter to those charged with governance.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgments and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Company' financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994 and the Securities and Exchange Rules 1987, we also report the following:

- a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) in our opinion, proper books of accounts as required by law have been kept by the Company so far as it appeared from our examination of these books;
- c) the statements of financial position and statements of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts and returns; and
- d) the expenditure incurred was for the purposes of the Company's business.

Place: Dhaka, Bangladesh
Dated: 27 October, 2020


Md. Abu Kaiser FCA
Mahfel Huq & Co.
Chartered Accountants

INDO-BANGLA PHARMACEUTICALS LTD
STATEMENT OF FINANCIAL POSITION
As at 30 June 2020

Particulars	Notes	Amounts in Taka	
		30th June 2020	30th June 2019
ASSETS:			
Non-current Assets:			
		1,126,809,674	818,523,321
Property, Plant and Equipment	3.00	1,061,759,460	743,134,778
Capital Work In Progress	4.00	65,050,214	75,388,543
Current Assets:			
		612,456,404	767,224,351
Inventories	5.00	190,289,732	202,867,111
Trade & Other Receivables	6.00	226,078,126	180,041,951
Advance, Deposits and Prepayments	7.00	182,249,756	223,733,862
Cash and Cash equivalents	8.00	13,838,790	160,581,427
TOTAL ASSETS		1,739,266,078	1,585,747,672
EQUITY AND LIABILITIES			
Shareholders' Equity:			
		1,517,598,116	1,374,627,332
Share Capital	9.00	1,115,070,000	1,023,000,000
Retained Earnings	10.00	402,528,176	351,627,332
NON-CURRENT LIABILITIES			
		94,720,685	66,759,081
Deferred Tax Liability	11.00	94,720,685	66,759,081
Current Liabilities:			
		126,947,217	144,361,259
Provision for WPPF	12.00	10,850,277	9,038,917
Trade Payables	13.00	371,989	6,108,271
Provision for Taxes	14.00	107,770,381	123,615,998
Liabilities for Expenses	15.00	7,954,570	5,598,073
TOTAL OWNER'S EQUITY AND LIABILITIES		1,739,266,078	1,585,747,672
Net Asset Value (NAV) Per Share	23.00	13.61	13.44

Annexed notes form an integral part of these financial statements.

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Sd/-
Director

Sd/-
Managing Director

Signed in terms of our separate report of even date annexed.

Place: Dhaka
Date: October 27, 2020


Mahfel Huq & Co.
Chartered Accountants

INDO-BANGLA PHARMACEUTICALS LTD
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
For the year ended 30 June, 2020

Particulars	Notes	Amount In BDT	
		30-Jun-20	30-Jun-19
Net Sales Revenue	16.00	866,097,783	740,714,183
Less: Cost of Sales	17.00	519,647,733	444,163,230
Gross Profit		346,450,050	296,550,952
Less: Operating Expenses:		123,782,527	118,269,079
Administrative Expenses	18.00	36,382,303	36,552,436
Selling & Distributing Expenses	19.00	87,400,224	81,716,643
Profit from Operations		222,667,522	178,281,873
Add: Non Operating Income:	20.00	5,188,305	11,535,389
Profit before Contribution to WPPF & Welfare Fund		227,855,827	189,817,263
Less: Contribution to WPPF & Welfare Fund	12.00	10,850,277	9,038,917
Profit before Tax		217,005,550	180,778,346
Less: Income Tax Expenses:		60,761,886	25,551,656
Current Tax	21.00	26,808,614	26,042,176
Deferred Tax	11.00	27,961,604	(490,520)
Short Provision	14.01	5,991,668	-
Net Profit for the year		156,243,664	155,226,689
Earnings per share (EPS)	22.00	1.40	1.39

Annexed notes form an integral part of these financial statements.

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Sd/-
Director

Sd/-
Managing Director

Signed in terms of our separate report of even date annexed.

Dated: Dhaka
Date: October 27, 2020


Mahfel Huq & Co.
Chartered Accountants

INDO-BANGLA PHARMACEUTICALS LTD
STATEMENT OF CHANGES IN EQUITY
For the year ended 30 June 2020

Particulars	Share Capital	Retained Earnings	Total Equity
	Note - 09	Note : 10	
Balance as at 01-07-2019	1,023,000,000	351,627,332	1,374,627,332
Issue of share Capital (Bonus)	92,070,000	(92,070,000)	-
Cash Dividend	-	(13,272,820)	(13,272,820)
Net Profit for the period	-	156,243,664	156,243,664
Balance as at 30-06-2020	1,115,070,000	402,528,176	1,517,598,176

STATEMENT OF CHANGES IN EQUITY
For the year ended 30 June 2019

Particulars	Share Capital	Retained Earnings	Total Equity
	Note - 09	Note : 10	
Balance as at 01-07-2018	730,000,000	306,100,643	1,036,100,643
Issue of share Capital (IPO)	200,000,000	-	200,000,000
Issue of share Capital (Bonus)	93,000,000	(93,000,000)	-
IPO Expenses		(16,700,000)	(16,700,000)
Net Profit for the period	-	155,226,689	155,226,689
Balance as at 30-06-2019	1,023,000,000	351,627,332	1,374,627,332

Annexed notes form an integral part of these financial statements.

Sd/-
Chief Financial Officer
Place: Dhaka

Sd/-
Company Secretary

Sd/-
Director

Sd/-
Managing Director

Date: October 27, 2020

INDO-BANGLA PHARMACEUTICALS LTD
STATEMENT OF CASH FLOWS
For the year ended 30 June, 2020

Particulars	Notes	Amount in Taka	
		30-Jun-20	30-Jun-19
Cash Flows from Operating Activities			
Cash receipts from customers	26.00	818,823,799	750,125,650
Cash receipts from others income	27.00	6,426,113	14,564,437
Cash payment to Suppliers	28.00	(464,492,478)	(429,631,922)
Cash payment to Employees		(99,507,644)	(63,290,278)
Cash payment to Others		(50,070,916)	(79,684,302)
Cash Generate from operation		211,178,874	192,083,585
Cash payment against income Tax		(35,648,753)	(25,294,755)
Net Cash generated from Operating Activities	32.00	175,530,121	166,788,830
Cash Flow from Investing Activities			
Acquisition of property, plant and equipment		(239,213,724)	(84,235,781)
Paid for Capital Work In Progress		(65,050,214)	(69,842,623)
Paid for land (Gazipur)		-	(100,000,000)
Advance paid for L/C Margin Machinery		(4,736,000)	(27,908,618)
Net Cash used in Investing Activities		(308,999,938)	(281,987,022)
Cash Flows from Financing Activities			
Proceeds from issue of share capital		-	200,000,000
Cash Payment to IPO Expenses		-	(15,900,000)
Cash payment to Dividend		(13,272,820)	-
Net Cash Used in Financing Activities		(13,272,820)	184,100,000
Net increase/(Decrease) in Cash and Cash equivalents		(146,742,637)	68,901,808
Cash and Cash Equivalents at beginning of the period		160,581,427	91,679,619
Cash and Cash Equivalent at end of the Period		13,838,790	160,581,427
Net Operating Cash Flows Per Share (NOCFPS)		1.57	1.70

Annexed notes form an integral part of these financial statements.

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Sd/-
Director

Sd/-
Managing Director

Place: Dhaka

Date: October 27, 2020

INDO-BANGLA PHARMACEUTICALS LTD.

Notes to the Financial Statements and other explanatory information.

As at and for the year ended June 30, 2020

1.00 REPORTING ENTITY

1.01 Background of the Company

Indo-Bangla Pharmaceuticals Limited was incorporated as a private Limited Company under the Companies Act-1994 on 18 June 2014 vide registration no.C-116665/14 through takeover of M/S. Indo-Bangla Pharmaceutical Works, a proprietorship business since pre-liberation period. The company has been converted into public limited company on 21-10-2014. Registered office of the company and Factory is at Aziz Bhaban, College Road, Barisal. Authorized capital of the company is Tk.1, 500,000,000 divided into 150,000,000 ordinary shares of Tk.10 each. Paid up capital of the company Tk.1, 115,070,000 divided into 111,507,000 ordinary shares of Tk. 10 each.

1.02 Registered Office of the Company

The registered office of the Company and the Factory is located at 729, College Road, Barisal Sadar, Barisal and having its Corporate office at Polt-183 (7th floor) Block-B, Road-4, Ahmed Akbar Sobhan Road, Basundhara R/A, Baridhara, Dhaka-1229.

1.03 Nature of the business

The Company is engaged in manufacturing and selling of all kinds of medicine (excluding Antibiotic), medical preparations drugs & chemicals (Human Health) with due approval of Drug Administration Authority. The company applied for permission for production and selling of veterinary medicine also.

2.00 BASIS OF PREPARATION AND PRESENTATION OF FINANCIAL STATEMENTS:

2.01 Presentation of Financial Statements

The Financial Statements of the Company are prepared on a going concern Basis under historical cost convention and in accordance with the International Accounting Standards (IAS), International Financial Reporting Standards (IFRS), the Companies Act, 1994, the Securities and Exchange Rules, 1987 and other laws & regulation in Bangladesh applicable to the Company.

2.02 Going Concern

The company has adequate resources to continue its operation for the foreseeable future. The current credit facilities and resources of the company provides sufficient fund to meet the present requirements of its existing business. As such, the directors intended to adopt the going concern Basis in preparing the financial statements.

2.03 Accrual Basis

The financial statements have been prepared, except Statements of Cash Flows, using the accrual Basis of accounting.

2.04 Reporting Period

The financial Statements have been prepared covering one year from July 01, 2019 to June 30, 2020

2.05 Components of the Financial Statements

According to IFRS-1 “presentation of the Financial Statements” the complete set of financial statements includes the following components;

- a) Statement of Financial Position as at June 30, 2020;
- b) Statement of Profit or Loss and other Comprehensive Income for the period from 1st July 2019 to 30th June, 2020;
- c) Statement of Changes in Equity for the year ended June 30, 2020;
- d) Statement of Cash Flows for the year ended June 30, 2020; and
- e) Notes comprising a summary of significant accounting policies and other explanatory information.

2.06 Accounting Policies & Estimates

The preparation of these financial statements is in conformity with IAS and IFRS which require management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Estimates and underlying assumptions are reviewed on an ongoing basis and used for accounting of certain terms such as provision for expenses and depreciation.

2.07 Responsibility for Preparation and Presentation of Financial Statements

The Board of Directors is responsible for the preparation of financial statements under section 183 of the Companies Act, 1994 and as per the provision of “the Framework for the preparation and Presentation of Financial Statements” issued by the International Accounting Standards (IASs) and Bangladesh Securities and Exchange Commission (BSEC) guideline.

2.08 Statement of Cash flows

Statement of Cash flows have been prepared in accordance with IAS-7 "Statement of Cash Flows" and the cash flows from the operating activities have been presented under direct method considering the provisions of Paragraph 19 of IAS-7 which provides that "Entities are encouraged to report cash flows from operating activities using the direct method".

2.09 Applicable accounting standards

The following IAS and IFRS are applicable for the financial statements for the year under review:

IASs:

IAS -1	Presentation of Financial Statements
IAS -2	Inventories
IAS -7	Statements of Cash flows
IAS -8	Accounting Policies, Changes in Accounting Estimates and Errors
IAS-10	Events after the Reporting Period
IAS-12	Income Taxes
IAS-16	Property, Plant and Equipment
IAS -19	Employee Benefits
IAS-24	Related Party Disclosures
IAS- 32	Financial Instruments Presentation
IAS-33	Earnings Per Share
IAS-36	Impairment of Assets
IAS- 37	Provisions, Contingent Liabilities and Contingent Assets

IFRSs:

IFRS 7	Financial Instruments: Disclosures
IFRS 8	Operating Segments
IFRS 9	Financial Instruments
IFRS 15	Revenue from Contracts with Customers
IFRS 16	Leases

2.10 Property, Plant and Equipment**2.10.1 Recognition and Measurement**

All Property, Plant and Equipment are stated at cost less accumulated depreciation as per IAS-16 “Property, Plant and Equipment”. The cost of acquisition of an asset comprises of its purchase price and any directly attributable cost of bringing the asset to its working condition for its intended use inclusive of inward freight, duties and non- refundable taxes.

The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its costs can be measured reliably. The cost of the day to day maintaining cost on PPE is recognized in the Statements of Profit or Loss and other Comprehensive Income as incurred.

2.10.2 Depreciation

Depreciation on Property, Plant and Equipment other than Land has been computed during the year using the reducing balance method. Depreciation has been charged on addition when the related Property, Plant and Equipment are available for use as per management intention. Depreciation has been charged at following rates:

Name of Assets	Rate	Rate
	As at 30 th June 2020	As at 30 th June 2019
Land and Land Development	0%	0%
Building	2.50%	2.50%
Civil Works	5%	-
Machineries & Equipment	3%	3%
Micro biological Lab	3%	3%
Factory Air Condition	10%	10%
Generator	3%	3%
Furniture & Fixture	10%	10%
Office Equipment	10%	10%
SEP Decoration	10%	10%
Office Decoration	10%	10%
Computer	10%	10%
Air Condition	10%	10%
Transport	10%	10%
Water Plant	10%	10%
ETP Plant	10%	10%

2.10.3 Retirement and Disposals

An asset is derecognized on disposal or when no future economic benefits are expected from its use and subsequent disposal. Gain or loss arising from the retirement or disposal of an asset is determined as the difference between the net disposal proceeds and the carrying amount of the assets and is recognized as gain or loss from disposal of asset under other income in the statement of profit or loss and other comprehensive income.

2.10.4 Impairment

All fixed assets have been reviewed and it was confirmed that no such fixed assets have been impaired during the period and for this reason no provision has been made for Impairment of assets as per IAS 36.

2.11 Revenue Recognition

As per IFRS-15: "Revenue from Contracts form Customers" the company accounts for a contract with a customer only when all of the following criteria are met:

- (a) The parties to the contract have approved the contract (in writing, orally or in accordance with other customary business practices) and are committed to perform their respective obligations;
- (b) The company can identify each party 's rights regarding the goods or services to be transferred ;
- (c) The company can identify the payment terms for the goods or services to be transferred
- (d) The contract has commercial substance (i.e. the risk , timing or amount of the entity `s future cash flows is expected to change as a result of the contract); and
- (e) It is probable that the company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.

2.12 Valuation of Current Assets

Trade and Other Receivable

These are carried forward at their original invoiced value amount and represents net realizable value. Management considered the entire bills receivable as good and is collectable and therefore, no amount has been provided for as bad debt in the current year's account.

Inventories

In compliance with the requirements of IAS-2 "Inventories", the inventories have been valued at Cost or Net Realizable value whichever is lower, which is consistent with the previous period's practice. Net realizable value is based on estimated selling price in the ordinary course of business less any further cost expected to be incurred to make the sale.

2.13 Provisions:

Provisions were made considering risk and un-certainties at best estimate of the probable expenditure that would require to meet the current obligation at the date of statement of financial position.

2.14 Employees' Benefit

The company maintains defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective deeds.

The company has accounted for and disclosed employee benefits in compliance with the provisions of IAS 19: "Employee Benefits".

The cost of employee benefit is charged off as revenue expenditure in the year to which the contributions relate.

The company's employee benefits include the following.

a) Short Term Employee Benefit

Short-term employee benefits include wages, salaries, festival bonuses etc. Obligations for such benefits are measured on an undiscounted basis and are expensed as the related service is provided.

b) Contribution to Workers' Profit Participation and Welfare Funds

This represents 5% of net profit before tax but after charging such expenses by the company as per provisions of the Bangladesh Labor Act, 2006, & Bangladesh Labor (amendment) Act, 2013.

c) Post Employment Benefit

The Nomination and Remuneration Committee (NRC), a sub-committee of Board formed to ensure good governance in the company as per Corporate Governance Code in notification No. BSEC/CMRRCD/2006 of Bangladesh Securities and Exchange Commission reviewed all post employee benefits to comply with IAS 19 Employee Benefits and the policies are under process for final review of the Board.

2.15 Advances, Deposits and Prepayments

Advances are initially measured at cost. After initial recognition advances are carried at cost less deductions, adjustments or charges to other account heads such as PPE or inventory etc.

2.16 Functional and Presentational Currency:

The financial statements are prepared in Bangladeshi Taka which is the Company's functional currency.

2.17 Income Tax Expenses:

Income Tax expense comprises current and deferred tax. It is recognized in profit or loss except to the extent that it relates to items recognized directly in equity and profit or loss.

Current Income Tax

Current income tax is excepted tax payable on the taxable income for the year and any short fall of provision for previous years. The company (IBPL) is a "Publicly Traded Company"; hence Tax rate is applicable @ 25%.

Deferred Tax

Deferred tax expenses is considered for taxable temporary differences may arise for the reporting year, adjustments for prior years accumulated differences and changed in tax rate.

2.18 Earnings per Share

The company calculates Earnings per Share (EPS) in accordance with IAS-33 "Earnings per Share" which has been shown on the face of the Profit or Loss and other Comprehensive Income.

Basic Earnings

This represents profit or loss at the end of the period attributable to ordinary shareholders of the entity.

Basic Earnings per Share

This has been calculated by dividing profit or loss attributable to ordinary shareholders of the entity by the weighted average number of ordinary shares outstanding during the year.

2.19 Financial Instruments

A financial instrument is any contract that gives rise to a financial asset to one entity and a financial liability or equity instrument to another entity as per IAS-39 "Financial Instruments Recognition and Measurement."

Financial Assets

Financial assets of the company include cash and cash equivalents, Trade receivables and other receivables. The company initially recognizes a financial asset in its statement of financial position when, and only when, the company becomes a party to the contractual provision of the instrument. The company derecognizes a financial asset when, and only when; the contractual rights to the cash flows from the financial asset expire or transfer the contractual rights to receive the cash flows of the financial asset.

Financial Liabilities

Financial liabilities of the company include trade payables and liabilities for expenses. The company initially recognizes a financial liability in its statement of financial position when, and only when, the company becomes a party to the contractual provision of the instrument. The company derecognizes a financial liability from its statement of financial position when, and only when, it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires.

2.20 Cash and Cash Equivalents

According to IAS-7 'Statement of Cash Flows', cash comprises cash in hand, short term deposit and highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in values.

A number of transactions entered into by the company were cash transactions with prior board approval. This was due to suppliers' demand.

2.21 Events after the Reporting Period

Events after the reporting period are those events, favorable and unfavorable, that occur between the end of the reporting period and the date when the financial statements are authorized for issue. Two types of events can be identified:

Adjusting Events are those that provide evidence of conditions that existed at the end of the reporting period.

Non-adjusting Events are those that are indicative of conditions that arose after the reporting period.

2.22 Authorization date for issuing Financial Statements

The financial statements were authorized by the Board of Directors on October 27, 2020.

2.22 Comparative Information

Comparative information has been disclosed in the respect of previous year for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current year's financial statement.

2.23 Segmental Reporting

The company essentially provides similar products to customers across the country and the products essentially have the similar risk profile. As there is a single business and geographic segment within which the company operates as such no segment reporting is felt necessary.

2.24 Related Party Disclosure

The company carried out a number of transactions with related parties in the normal course of business and on arms' length basis. The information as required by IAS-24: Related Party Disclosures has been disclosed in a separate note to the financial statements.

2.25 Leases

The Company has short term lease facilities and recognized them as operating lease facilities by complying with Para 5 of IFRS 16: "Leases, Lease payments and lease receipts under operating lease are recognized as rental expense from lease in the statement of profit or loss and other comprehensive income on a straight-line basis over the lease term.

2.26 General

The figure has been rounded off to the nearest taka.

Indo-Bangla Pharmaceuticals Ltd

Notes to the Financial Statements

As at and for the year ended 30 June 2020

Particulars	Amount in Taka	
	30 June'2020	30 June'2019
3.00 Property, Plant and Equipment		
These have arrived at as under:		
(A) At Cost		
Opening balance	801,514,939	686,464,201
Add: Addition during the Period	347,522,885	126,821,731
Less: Disposal during the Period	-	(11,770,992)
Total	1,149,037,824	801,514,939
(B) Accumulated Depreciation		
Opening balance	58,380,161	37,990,300
Add: Depreciation Charged for the period	28,898,203	21,974,546
Less: Adjusted during the period	-	(1,584,685)
Total :	87,278,364	58,380,161
WDV as on 30.06.2020 (a-b)	1,061,759,460	743,134,778
A schedule of Property, Plant and Equipment is given in Annexure-A		
4.00 Capital Work in Progress		
These have arrived at as under:		
A. Machineries & Equipment:		
Opening balance	67,266,943	-
Add: Addition during the period	211,648,406	67,266,943
Less: Transfer to Fixed Assets	(213,865,135)	-
Closing Plant & Machinery	65,050,214	67,266,943
B. Land Development:		
Opening balance	8,121,600	5,545,920
Earth fill-up	33,250	2,575,680
Less: Transfer to Fixed Assets of Land & Land Development	(8,154,850)	-
	-	8,121,600
Total (A+B)	65,050,214	75,388,543

Particulars	Amount in Taka	
	30 June'2020	30 June'2019
5.00 Inventories :		
This consists of the following;		
Raw Material	97,025,425	89,645,280
Finished Goods	63,366,292	76,485,251
Work - in - Process	12,376,500	20,585,480
Maintenance of Machine & Consumable Items	3,025,650	4,625,650
Packing Materials	14,495,865	11,525,450
	190,289,732	202,867,111

Inventories in hand have been valued at lower of cost or/and net realizable value as per IAS-2 and have been certified by management.

6.00 Trade & Others Receivable:

These have arrived at as under:

A. Trade Receivable

Opening balance	178,804,143	188,215,610
Add: Sales during the period	866,097,783	740,714,183
Total	1,044,901,925	928,929,793
Less:Recovery	818,823,799	750,125,650
Closing balance (Trade Receivable) A schedule of Receivable is given in Annexure-B	226,078,126	178,804,143

B. Other Receivable (Interest on FDR)

	-	1,237,808
Total:	226,078,126	180,041,951

Ageing of Accounts Receivable

More than six months		-
Less than six month	226,078,126	178,804,143
	226,078,126	178,804,143

The classification of receivables as required by the schedule XI of the Companies Act, 1994 are given below:

Receivable considered good in respect of which the company is fully secured.	-	-
	226,078,126	178,804,143
Receivable considered good in respect of which the company holds no security other than the debtor personal security.		
Receivables considered doubtful bad.	-	-
Receivable due by directors or others or other offers of the company or any of them either severly or jointly with any other person or debts due by firms or private companies respectively in which any director is a partner or a director or a member.	-	-
Receivables due by common under the same management.	-	-
The maximum amount of receivable due by any director or other officer of the company at any time during the period.	-	-
Total:	226,078,126	178,804,143

Particulars	Amount in Taka	
	30 June'2020	30 June'2019
7.00 Advance, deposit and prepayments:		
This consists of the following;		
Advance		
Advance Income Tax	75,097,055	88,094,202
Advance to Employees	2,025,000	2,156,450
Advance to others	105,127,701	133,483,210
	182,249,756	223,733,862

The classification of Advances, Deposits and Prepayments as required by Schedule-XI, Part-I of the Companies Act, 1994

Advance, Deposit and pre-payments considered good and fully secured;	182,249,756	223,733,862
Advance, deposit and pre-payments considered good and company holds no security other than personal security;	-	-
Advance, deposit and pre-payments considered doubtful and bad;	-	-
Advance, deposit and pre-payments due by directors or other officers;	-	-
Advance, deposit and pre-payments due from companies under common management; and	-	-
Maximum advance, deposit and pre-payments due by Directors or other officers at any time.	-	-
	182,249,756	223,733,862
7.01 Advance Tax paid		
Opening	88,094,202	62,799,447
Less: Adjustment Income Tax Expenses Assessment year 2017-2018	22,986,703	-
Less: Adjustment Income Tax Expenses Assessment year 2018-2019	24,460,348	-
Add: Advance Tax paid during the year	34,449,904	25,294,755
	75,097,055	88,094,202
7.02 Advance to Others		
Goods and services	1,205,000	1,523,425
Tour	485,000	652,850
Office Rent	300,000	288,000
Land (Gazipur)	95,000,000	100,000,000
L/C Margin for Raw-materials	2,335,800	1,677,247
L/C Margin for Machinery	4,736,000	27,908,618
Prepaid Insurance	12,219	-
VAT current account	1,053,682	1,433,070
	105,127,701	133,483,210

Advances are initially measured at cost. After initial recognition, advances are carried at cost less deductions, adjustments or charges to other account heads such as inventory, land or any recurring expenses.

Particulars	Amount in Taka	
	30 June'2020	30 June'2019
8.00 Cash and Cash equivalents:		
These have arrived at as under:		
Cash in Hand	9,942,202	7,354,880
Cash at Bank	3,896,588	53,226,547
Short Term FDR	-	100,000,000
	13,838,790	160,581,427
8.01 Cash at Bank	3,896,588	53,226,547
Pubali Bank Ltd. Barishal Sadar Branch A/C 54490	1,705,467	100,444
Sonali Bank Ltd.Barishal Corporate Branch A/C. 3953	144,937	127,531
Islami Bank Bangladesh Ltd. Barishal Branch A/C no.10807	20,197	46,356,137
Islami Bank Bangladesh Ltd. Bhanga Branch A/C no.01405	196,589	192,028
Islami Bank Bangladesh Ltd.Bhanga Branch A/C no.01506	84,388	82,976
Islami Bank Bangladesh Ltd. Bhanga Branch A/C no.79513	33,621	34,312
One Bank Ltd. Barisal Branch A/C no.02579	3,455	4,146
Mercantile Bank ltd. rampura Br. A/C: 56998	12,502	17,131
Mercantile Bank ltd. Elephant road Br. A/C: 88298	3,000	2,611,111
Dutch-Bangla Bank Ltd. Barisal Branch A/C 1271100014683	24,682	1,221,187
Dutch-Bangla Bank Ltd. Bashundhara 1471100016286	449,815	-
City bank A/C no. 3102631598001	3,253	1,260,067
Standard Bank ltd.Green Road Brance, A/C '05133000333	-	388,760
First Security Islami Bank Ltd. Bashundhara Br. A/C 302	1,167,735	-
First Security Islami Bank Ltd. Bashundhara Br. A/C 315	15,489	-
Eastern Bank Ltd Principal Branch A/C 1011360459420	31,458	830,718
9.00 Share Capital :		
Authorized Capital		
150,000,000 Ordinary Shares		
of Tk. 10 each	1,500,000,000	1,500,000,000
Issued, Subscribed & Paid-up Capital:		
73,000,000 Ordinary Shares of Tk. 10each	730,000,000	730,000,000
29,300,000 Bonus Shares issued in 2018	293,000,000	293,000,000
9,207,000 Bonus Shares issued in 2019	92,070,000	-
111,507,000 Ordinary Shares of Tk. 10 each fully paid up.	1,115,070,000	1,023,000,000
10.00 Retained Earnings:		
This amount consists of as follows:		
Opening balance	351,627,332	306,100,643
Add :Net Profit for the year	156,243,664	155,226,689
Less: IPO Expenses	-	16,700,000
Less: Transfer to Share capital	92,070,000	93,000,000
Less:Cash Dividend	13,272,820	-
	402,528,176	351,627,332

Particulars	Amount in Taka	
	30 June'2020	30 June'2019
11.00 Deferred Tax Liability:		
This amount consists as follows:		
Carrying Value of Property, Plant & Equipment (Annexure-A)	1061759460	851,486,378
As Tax Base	682,876,720	584,450,053
Temporary Difference	378,882,740	267,036,325
Deferred Tax Liabilities @25%	94,720,685	66,759,081
Opening Deferred Tax Liability	66,759,081	67,249,601
Deferred Tax Liability/Expenses (Income)	27,961,604	(490,520)
12.00 Provision for WPPF:		
Opening WPPF	9,038,917	7,576,461
Add: Addition during the year	10,850,277	9,038,917
Less: Transfer to WPPF Bank Accounts	(9,038,917)	(7,576,461)
Total:	10,850,277	9,038,917
Profit before contribution for WPPF	227,855,827	189,817,263
Provision for contribution @5% Profit After WPPF(For the year)	10,850,277	9,038,917
13.00 Trade Payables :		
Opening balance;	6,108,271	6,541,572
Add: Purchase during the year	458,416,068	441,592,349
Total:	464,524,339	448,133,921
Less: Adjustment during the year	464,152,350	442,025,650
Closing balance	371,989	6,108,271
14.00 Provision for Taxes		
This has been arrived as at under;		
Balance b/d	123,615,998	97,573,822
Add: Short Provision Note : 14.01	5,991,668	-
Less: Adjusted Income Tax Expenses Assessment year 2017-2018	22,986,703	-
Less: Adjusted Income Tax Expenses Assessment year 2018-2019	24,460,348	-
Less: Tax Payment cash for assesment year 2018-19	1,198,848	-
Add : Provision during the year	26,808,614	26,042,176
	107,770,381	123,615,998
14.01 Short Provision for Taxes:		
Assessment Year 2017-2018	4,298,292	-
Assessment Year 2018-2019	1,693,376	-
	5,991,668	-
15.00 Liabilities for Expenses :		
This consists of the following		
Telephone Bill	346	399
Electricity Bill	398,538	198,928
Directors Remuneration	250,000	150,000
Salary & Wages	5,256,554	4,487,096
Repairs and Maintenance	-	123,585
Audit Fees	287,500	287,500
Others	1,761,632	350,565
	7,954,570	5,598,073

		Amount in BDT	
		30 June 2020	30 June 2019
16.00	Net Sales Revenue:		
	Gross Sales Sales	996,012,450	851,821,310
	Less: VAT @ 15%	129,914,667	111,107,127
	Net Sales revenue	866,097,783	740,714,183
17.00	Cost of Sales :		
	This has been arrived as under;		
	Raw Material Consumed	347,640,353	337,300,529
	Add: Work in process (Opening)	20,585,480	20,123,650
	Less: Work in Process (Closing)	12,376,500	20,585,480
	Total Consumption	355,849,333	336,838,699
	Add: Manufacturing Overhead	68,916,166	58,435,912
	Add: Direct expenses	85,988,425	84,053,870
	Cost of Production	510,753,924	479,328,481
	Add: Finished Goods (Opening balance)	76,485,251	45,215,650
	Finished Goods Available	587,239,175	524,544,131
	Less: Finished Goods (Closing)	63,366,292	76,485,251
	Less: Sample Costs	4,225,150	3,895,650
	Cost of Sales:	519,647,733	444,163,230
17.01	Material Consumed :		
	Opening balance	89,645,280	78,512,350
	Add: Material Purchased	355,020,498	348,433,459
	Import	311,012,229	310,243,449
	Local	44,008,269	38,190,010
	Less: Closing Materials	97,025,425	89,645,280
	Total	347,640,353	337,300,529
17.02	Manufacturing Overhead:		
	Salary & Wages	11,379,576	7,607,936
	Cork & Cap	2,412,530	2,359,150
	Carton & Label	3,185,750	3,140,070
	Hand Glove, Tape, Gum Etc	235,420	218,920
	Quality Control Expenses	768,550	750,970
	Accessories	2,684,120	2,669,180
	Apron & Uniform	621,530	599,230
	Carriage Inward	1,141,095	1,275,475
	Water bill	7,650	7,215
	Washing Expenses	3,425	3,375
	Maintenance of Machine & Consumable Items	17,850,320	17,748,260
	Electricity Bill Factory	2,748,281	1,991,775
	Maintenance of Factory Building	1,125,360	1,118,050
	Insurance Expense	134,406	15,525
	Depreciation (Annexure-A)	24,618,153	18,930,781
	Total	68,916,166	58,435,912

		Amount in BDT	
		30 June 2020	30 June 2019
17.02.1	Maintenance of Machine & Consumable Items		
	Opening balance	4,625,650	8,025,460
	Purchase during the period	16,250,320	14,348,450
	Closing balance	(3,025,650)	(4,625,650)
	Consumption	17,850,320	17,748,260
17.03	Direct expenses :		
	Delivery Charges	725,680	746,890
	Packing Materials	84,174,835	82,160,670
	Medical Bag Expenses	432,150	420,680
	Cost of Literature	135,620	206,605
	Remission Settlement	520,140	519,025
	Total	85,988,425	84,053,870
17.03.1	Packing Materials		
	Opening balance	11,525,450	14,875,680
	Purchase during the period	87,145,250	78,810,440
	Less: Packing Materials(Closing balance)	(14,495,865)	(11,525,450)
	Consumption	84,174,835	82,160,670
18.00	Administrative Expenses		
	Salary & allowance	13,046,776	12,536,746
	Director Remuneration	2,400,000	1,800,000
	Board Meeting Fee	370,000	525,000
	Travelling & Conveyance	2,914,750	2,900,620
	Entertainment	2,215,630	2,116,670
	Office Rent	662,400	662,400
	Printing & Stationery	1,972,860	1,959,155
	News Paper & Megazine	82,560	62,425
	Post & Telegram	421,560	445,905
	License & Legal Fee	969,449	3,887,980
	Telephone & Mobile Bill	183,216	72,510
	Internet Bill	95,310	81,867
	Audit Fee	287,500	287,500
	Company Secretarial, Regulatory Fee and AGM Expenses	2,136,076	2,112,931
	Electricity Bill & others charge	92,782	131,952
	Maintenance of Transport	1,923,520	1,844,905
	Securities service	762,520	757,160
	Bank Charge	539,985	359,115
	Others expenses	1,025,360	963,830
	Depreciation (Annexure-A)	4,280,050	3,043,765
	Total	36,382,303	36,552,436

	Amount in BDT	
	30 June 2020	30 June 2019
19.00 Selling & Distributing Expenses		
Salary & allowance(Including Depot Staff)	40,484,604	38,187,574
Incentive Bonus	3,482,680	3,217,774
TA & DA of Field Staff	3,995,850	3,659,725
Carriage Outward	2,956,410	2,863,130
Packing Materials-Selling & Distribution	3,651,530	3,531,510
Sales Promotion	3,698,240	3,521,605
Training & seminar Expenses	4,991,530	4,805,815
Entertainment for Conference	2,935,620	2,714,575
Gift & Presentation(Promotional Materials)	3,415,360	3,264,670
Sample expense	4,225,150	3,895,650
Travelling & Conveyance	13,563,250	12,054,615
	87,400,224	81,716,643
20.00 Non Operating Income:		
Misc Sales	3,029,350	4,827,050
Interest on FDR	2,137,192	10,413,431
Interest on Bank	21,763	481,216
Profit/(Loss) on Sale of Fixed Assets	-	(4,186,308)
	5,188,305	11,535,389
21.00 Current Tax:		
Profit before tax as per account	217,005,550	180,778,345
Accounting depreciation	28,898,203	21,974,546
Tax base depreciation	(140,744,617)	(103,198,343)
Non Operating Income	(5,188,305)	(11,535,389)
Taxable profit	99,970,830	88,019,159
Current Tax for Operating Income@ 25%	24,992,708	22,004,790
Add: Tax on Non Operating Income @ 35%	1,815,907	4,037,386
	26,808,614	26,042,176

22.00 Basic Earnings Per Share :

This has been calculated in compliance with the requirements of IAS 33: Earnings Per Share, is the basic earning dividing by the weighted average number of ordinary shares outstanding at the end of the Period.

The composition of earnings per shares (EPS) is given below:

Earnings Per Share (EPS)

Net profit for the year	156,243,664	155,226,689
Weighted Average number of ordinary shares outstanding	111,507,000	111,507,000
Earnings Per Share (EPS)	1.40	1.39

Weighted Average Number of Shares

73000000	Shares	1.00	73,000,000	73,000,000
20000000	Shares	1.00	20,000,000	20,000,000
9300000	Shares	1.00	9,300,000	9,300,000
9207000	Shares	1.00	9,207,000	9,207,000
Weighted Average Number of Shares			111,507,000	111,507,000

Amount in BDT	
30 June 2020	30 June 2019

23.00 Net Assets Value Per Share :

The composition of net assets value per share is given below:

Total Assets	1,739,266,078	1,585,747,672
Less: Non-Current Liabilities+Current Liabilities	221,667,902	211,120,340
Net Assets Value	1,517,598,176	1,374,627,332
Number of ordinary shares outstanding	111,507,000	102,300,000
	13.61	13.44

24.00 Net Operating Cash Flows Per Share (NOCFPS)

Net Cash from operating activities	Notes: 32	175,530,121	166,788,830
Weighted Average Number of Shares		111,507,000	111,507,000
		1.57	1.70

Amounts in Taka	
30 June 2020	30 June 2019

25.00 Utilization of IPO Fund

Utilization position of IPO proceeds up to 30 June 2020 was as under;

The company raised Tk. 200,000,000 divided into 20,000,000 ordinary shares of Tk. 10 each through IPO on September 13, 2018. The company fully utilized Tk. 20,00,00,000/- in total up to June 30, 2020 for the purposes described above as certified by independent auditor, Shafiq Basak & Co, Chartered Accountants.

26.00 Cash receipts from customers

Opening receivable

Add: Sales during the year

Less: Closing receivable

178,804,143	188,215,610
866,097,783	740,714,183
(226,078,126)	(178,804,143)
818,823,799	750,125,650

27.00 Cash receipts from others income

Misc. Sales

FDR and Bank Interest

3,029,350	4,827,050
3,396,763	9,737,387
6,426,113	14,564,437

28.00 Cash payment to suppliers

Purchase (RM,spare,packing)

Opening Accounts Payable

Closing Accounts Payable

Opening Advance goods

Closing Advance goods

458,416,068	441,592,349
6,108,271	6,541,572
(371,989)	(6,108,271)
(3,200,672)	(15,594,400)
3,540,800	3,200,672
464,492,478	429,631,922

29.00 Cash Flow for Acquisition of property, plant and equipment

Property, Plant & Equipment addition during the year

Less: Adjustment:

Closing Advance L/C Margin for Machinery

Opening Advance L/C Margin for Machinery

Opening WIP Machinery

Closing Advance for Land

Opening Advance for land

Opening land Development

Sale of Machinery

347,522,885	126,821,731
113,033,161	42,585,950
4,736,000	36,585,950
27,908,618	-
67,266,943	-
(95,000,000)	-
100,000,000	-
8,121,600	-
-	6,000,000
234,489,724	84,235,781

30.00 Paid for Work In Progress

65,050,214	69,842,623
-------------------	-------------------

31.00 Advance paid for L/C Margin Machinery

4,736,000	27,908,618
------------------	-------------------

32.00 Reconciliation of Net Profit with cash flows from Operating Activities:

Profit before Tax

Add: Depreciation on property, plant and equipment

Add/(Less):

Less: Increase in Trade & Other Receivables

Add: Decrease in Inventories

Less: Decrease in Trade Payables

Add: Increase in Liabilities for Expenses

Add: Increase in Liability for contribution to W.P.P.F

Add:Decrease in Advance, Deposit & Prepayments

Add: Capital Loss for Sale of Machinery

Less: Income Tax Paid

217,005,550	180,778,346
28,898,203	21,974,546
245,903,752	202,752,892
(46,036,176)	8,254,207
12,577,379	(36,114,321)
(5,736,282)	(433,301)
2,356,497	672,736
1,811,360	1,462,456
302,341	11,302,608
-	4,186,308
(35,648,753)	(25,294,755)
175,530,121	166,788,830

33.00 Related parties disclosure:**Key Management Personnel:**

As per Schedule-XI, part-II, Para 4 of the Companies Act, 1994, the profit and loss account will give by way of a note detailed information, showing separately the following payments provided or made during the financial year to the directors, including managing director, the managing agents or manager, if any, by the company, subsidiaries of the company and any other person:-

No.	Particulars	30.06.2020	30.06.2019
(a)	Managerial Allowances paid or payable during the period to the directors, including managing directors, a managing agent or manager;	2,400,000	1,800,000
(b)	Expenses reimbursed to Managing Agent;	Nil	Nil
(c)	Commission or Remuneration payable separately to a managing agent or his associate;	Nil	Nil
(d)	Commission received or receivable by the managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company;	Nil	Nil
(e)	The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the financial period;	Nil	Nil
(f)	Any other perquisite or benefits in cash or in kind stating, approximate money value where applicable;	Nil	Nil
(g)	Other allowances and commission including guarantee commission;	Nil	Nil
(h)	Pensions etc.	-	-
	(i) Pensions;	Nil	Nil
	(ii) Gratuities;	Nil	Nil
	(iii) Payments from a provident funds, in excess of own subscription and interest thereon;	Nil	Nil
	(iv) Compensation for loss of office;	Nil	Nil
	(v) Consideration in connection with retirement from office.	Nil	Nil
(i)	Share Based payments	Nil	Nil

Related parties Transactions:

The company carried out a number of transactions with related parties. The following are the related parties transactions of

the Indo-Bangla Pharmaceuticals Ltd has been disclosed as required by BAS 24 Related Party Disclosures.

(a) Remuneration

Name	Designation	Nature of Transaction	Amount in (BDT)	
			2019-2020	2018-2019
Mr. A.F.M Anowarul Huq	Managing Director	Remuneration	2,400,000	1,800,000

(b) Board meeting fee

Name	Designation	Nature of Transaction	Amount in (BDT)	
			2019-2020	2018-2019
Mrs. Aziza Yeasmin	Chairman	Board Meeting fee	50,000	50,000
Mr. A.F.M Anowarul Huq	Managing Director		50,000	55,000
Mrs. Hafiza Yeasmin	Director		-	20,000
Md. Amin-Ur-Rashid	Director		15,000	50,000
Sayeda Huq	Director		45,000	50,000
Fatima Parvin	Director		50,000	55,000
Mst.Shanaj Akter	Director		15,000	40,000
Mizanur Rahman	Director		45,000	50,000
Md. Golam Rabbani	Director (Represented)		30,000	20,000
S.M. Harun Or Rashid	Independent Director		15,000	50,000
Md. Monirujjaman	Independent Director		45,000	45,000
Md. Firoz Khan	Independent Director		10,000	40,000

34.00 Production Capacity and Utilization

Item	Unit	Production Capacity		Actual Production	Capacity Utilization	
		2020	2019	2019	2020	2019
Tablet	Million Pcs	3500	2700	2250	79%	83%
Capsule	Million Pcs	735	535	450	75%	84%
Liquid/Phs	Million ML	350	350	330	97%	94%

35.00 The requirements of schedule XI, Part II, note-5 Para 3, of the company Act.1994.

	2020	2019
Employees		
Number of employees whose salary was below Tk. 3,000.00	-	-
Number of employees whose salary was above Tk. 3,000.00	309	224

36.00 Disclosure as per Schedule XI, Part – II, Para 8 of the companies Act, 1994.

a) Import of raw materials and packing materials on CIF basis are as follows:

The company did not import any raw and packing materials at CIF price in 2020 and 2019. All purchase of raw materials by the company was at C&F price.

During the period 1st July 2019 to 30th June 2020 total Value of import in respect of raw materials stands equivalent USD **3,389,428** on CIF basis. Details are as follows:

Particulars	Amount In BDT	
	2020	2019
Import of raw Materials	311,012,229	310,243,449
Import of Packing Materials	-	15,787,180
Import of Capital goods	197,872,985	75,307,366
Total:	508,885,214	401,337,995

b) The Company did not incur any expenditure in foreign currency during the financial year on account of royalty, Know-how, professional Consultation fees, Interest and other matters.

(c) The value of both imported and Indigenous raw materials, Spare parts, Packing materials and Consumption thereof are as follows;

For the year 30 June 2020

Raw Materials:	Indigenous	Total
Opening balance	13,119,430	89,645,280
Add: Purchase during the year	44,008,269	355,020,498
	57,127,699	444,665,778
Less: Closing balance	4,499,075	97,025,425
Consumption during the year	52,628,624	347,640,353
Percentage of total Consumption during the year	15.14%	100%

Spare Parts	Indigenous	Total
Opening balance	4,625,650	4,625,650
Add: Purchase during the year	16,250,320	16,250,320
	20,875,970	20,875,970
Less: Closing balance	3,025,650	3,025,650
Consumption during the year	17,850,320	17,850,320
Percentage of total Consumption during the year	100.00%	100.00%

Packing Materials	Indigenous	Total
Opening balance	11,525,450	11,525,450
Add: Purchase during the year	87,145,250	87,145,250
	98,670,700	98,670,700
Less: Closing balance	14,495,865	14,495,865
Consumption during the year	84,174,835	84,174,835
Percentage of total Consumption during the year	100%	100.00%

For the year 30 June 2019

Raw Materials:	Indigenous	Total
Opening balance	10,963,985	78,512,350
Add: Purchase during the year	38,190,010	348,433,459
	49,153,995	426,945,809
Less: Closing balance	13,119,430	89,645,280
Consumption during the year	36,034,565	337,300,529
Percentage of total Consumption during the year	10.68%	100%

Spare Parts	Indigenous	Total
Opening balance	8,025,460	8,025,460
Add: Purchase during the year	14,348,450	14,348,450
	22,373,910	22,373,910
Less: Closing balance	4,625,650	4,625,650
Consumption during the year	17,748,260	17,748,260
Percentage of total Consumption during the year	100.00%	100.00%

Packing Materials	Indigenous	Total
Opening balance	14,875,680	14,875,680
Add: Purchase during the year	63,023,260	78,810,440
	77,898,940	93,686,120
Less: Closing balance	11,525,450	11,525,450
Consumption during the year	66,373,490	82,160,670
Percentage of total Consumption during the year	80.78%	100.00%

(d) No amount was remitted during the year in foreign currencies on account of dividend to non-residents shareholders. It is mentioned that the company does not have any non-resident shareholders.

(e) Earnings in foreign exchange classified under the following heads:

Heads	30.06.2020	30.06.2019
i. export of goods on FOB basis	Nil	Nil
ii. Royalty, know-how, professional and consultation fees	Nil	Nil
iii. Interest and dividend	Nil	Nil
iv. Other income	Nil	Nil
	Nil	Nil

37.00 Impact of Covid 19 on Our Business:

Worlds' most of the country have been badly affected by the Corona pandemic and Bangladesh is no exception to that, for which Economy and Companies all are affected at certain ranges whether that is significant or insignificant. Indo-Bangla Pharmaceuticals Limited also effected by COVID-19 pandemic since its outbreak, is mostly dependent on India and China for raw materials, with 80 per cent of Raw Materials coming from these two countries. We opened several L/C to import raw materials with different banks on regular basis, but the shipment was delayed and the import of raw materials remained suspended since the beginning of January this year a mid the outbreak of coronavirus thus the supply chain disrupted, production hampered as well as reduced sales by the ongoing coronavirus crisis, has triggered uncertainties of a shortage of raw materials.

38.00 Events after the Reporting Period

The Board of Directors at its board meeting held on 27 October 2020 recommended Cash 4.5% for all Shareholders excluding the Sponsors & Directors (including ICB) and Bonus 2% for all shareholder of the paid up Capital for the year ended 30 June 2020. This dividend is subject to final approval by the shareholders at the forthcoming annual General Meeting (AGM) of the company.

39.00 Financial Risk Management

The management of company has overall for the establishment and oversight of the company's risk management framework. Risk management policies, procedures and systems are reviewed regularly to reflect changes in market conditions and the company's activities. The company has exposure to the following risk for its use of financial instruments.

Credit Risk
Liquidity Risk
Market Risk

Credit Risk

Credit risk is the risk of a financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the company's receivables. Management has a credit policy in place and exposure to credit risk monitored on an ongoing basis. As at 30th June 2020 substantial part of the receivables are those from its related company and subject to insignificant credit risk. Risk exposures from other financial assets. i.e. Cash at bank and other external receivables are nominal.

Liquidity Risk

Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall due. The company's approach to managing liquidity (cash and cash equivalents) is to ensure as far as possible, that it will always have sufficient liquidity to meet its liabilities when due under both normal and stressed conditions without incurring unacceptable losses or risking damage to the company's reputation. Typically, the company ensures that it has sufficient cash and cash equivalent to meet expected operational expenses including financial obligation through preparation of the cash flow forecast with due consideration of time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date. In extreme stressed conditions the company may get support from the related company in the form of short term financing.

Trade and Other Payables (Notes: 13)

Total

Amounts in Taka	
30-Jun-20	30-Jun-19
371,989	6,108,271
371,989	6,108,271

Market Risk

Market risk is the risk that any changes in market prices such as foreign exchange rates and interest will affect the company's income or the value of its holdings financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters.

(a) Currency risk

The company is exposed to currency risk on certain revenues and purchases such as revenue from foreign customers and import of raw materials, machineries and equipment. Majority of the company's foreign currency transactions are denominated in USD and relate to procurement of raw materials, machineries and equipment from abroad.

(b) Interest rate risk

Interest rate risk is the risk that arises due to changes in interest rates on borrowing. The foreign currency loan is subject to floating rates of interest. Local loans are, however, not significantly affected by fluctuations in interest rate risk. The company has not entered into any type of derivative instrument in order to hedge interest rate risk as at the reporting date.

40.00 Compensation of Key Management Personnel

During the period, Compensation of key management personnel in total has been set below in accordance with the provisions of IAS 24: Related Party Disclosures.

	Amounts in Taka	
	30-Jun-20	30-Jun-19
Short-term employee benefits*	2,400,000	1,800,000
Post-employment benefits	-	-
Other long-term benefits	-	-
Termination benefits	-	-
Share-based payments	-	-
Total	2,400,000	1,800,000

*Short-term employee benefits comprise of Directors' remuneration that has been fixed up by the BOD having regard to the performance of the individuals and market trends.

INDO-BANGLA PHARMACEUTICALS LTD
Schedule of Property Plant & Equipment
As at 30 June 2020

Particulars	COST			Rate	DEPRECIATION				Written Down Value as on 30.06.2020
	Balance as on 01.07.2019	Addition during the Period	Disposal during the period		Total Cost as at 30.06.2020	Balance as on 01.07.2019	Adjusted during the period	Charge during the period	
Land & Land Development	45,487,485	45,900,128	-	91,387,613	-	-	-	-	91,387,613
Building	190,766,572	39,126,302	-	229,892,874	11,831,038	-	4,962,467	16,793,505	213,099,369
Civil Works	-	16,082,250	-	16,082,250	-	-	81,513	81,513	16,000,737
Machineries & Equipment	496,751,459	213,865,135	-	710,616,594	36,502,262	-	17,976,300	54,478,561	656,138,033
Micro biological Lab	11,548,735	7,525,680	-	19,074,415	331,236	-	355,339	686,576	18,387,839
Factory Air Condition	6,525,480	-	-	6,525,480	750,430	-	577,505	1,327,935	5,197,545
Air Compressor	-	2,325,900	-	2,325,900	-	-	135,678	135,678	2,190,223
Generator	4,352,879	6,250,350	-	10,603,229	501,045	-	240,562	741,607	9,861,622
Furniture & Fixture	9,900,194	2,530,560	-	12,430,754	2,532,765	-	821,095	3,353,860	9,076,894
Office Equipment	4,962,146	-	-	4,962,146	1,408,296	-	355,385	1,763,681	3,198,465
SEP Decoration	12,054,850	3,565,250	-	15,620,100	1,386,308	-	1,185,696	2,572,004	13,048,096
Office Decoration	2,106,500	3,825,650	-	5,932,150	267,016	-	407,111	674,127	5,258,023
Computer	639,990	-	-	639,990	99,688	-	54,030	153,718	486,272
Air Condition	354,170	-	-	354,170	72,265	-	28,190	100,456	253,714
Transport	11,606,144	6,525,680	-	18,131,824	1,127,372	-	1,428,541.84	2,555,914	15,575,910
Water Plant	2,512,960	-	-	2,512,960	905,426	-	160,753	1,066,179	1,446,781
ETP Plant	1,945,375	-	-	1,945,375	665,015	-	128,036	793,051	1,152,324
Balance as on 30 June,2020	801,514,939	347,522,885	-	1,149,037,824	58,380,161	-	28,898,203	87,278,364	1,061,759,460
Balance as on 30 June,2019	686,464,201	126,821,731	11,770,992	801,514,939	37,990,300	1,584,685	21,974,546	58,380,161	743,134,778

Allocation of Depreciation

Factory	24,618,153
Administration	4,280,050
	28,898,203

INDO-BANGLA PHARMACEUTICALS LTD
Schedule of Property Plant & Equipment
As at 30 June 2019

Particulars	COST				Rate	DEPRECIATION			Written Down Value as on 30.06.2019
	Balance as on 01.07.2018	Addition during the year	Disposal during the year	Total Cost as at 30.06.2019		Balance as on 01.07.2018	Adjusted during the year	Charge during the year	
Land & Land Development	45,487,485	-	-	45,487,485	0%	-	-	-	45,487,485
Building	154,040,627	36,725,945	-	190,766,572	2.5%	-	3,874,771	11,831,038	178,935,534
Machineries & Equipment	433,215,086	75,307,366	11,770,992	496,751,460	3%	1,584,685	13,664,726	36,502,261	460,249,199
Micro biological Lab	8,652,165	2,896,570	-	11,548,735	3%	-	309,606	331,236	11,217,499
Factory Air Condition	6,525,480	-	-	6,525,480	10%	-	641,672	750,430	5,775,050
Generator	4,352,879	-	-	4,352,879	3%	-	119,129	501,045	3,851,834
Furniture & Fixture	7,774,694	2,125,500	-	9,900,194	10%	-	720,200	2,532,765	7,367,429
Office Equipment	4,962,146	-	-	4,962,146	10%	-	394,872	1,408,296	3,553,850
SEP Decoration	12,054,850	-	-	12,054,850	10%	-	1,185,394	1,386,308	10,668,542
Office Decoration	2,106,500	-	-	2,106,500	10%	-	204,387	267,016	1,839,484
Computer	399,490	240,500	-	639,990	10%	-	48,899	99,688	540,302
Air Condition	354,170	-	-	354,170	10%	-	31,323	72,265	281,905
Transport	2,080,294	9,525,850	-	11,606,144	10%	-	458,689	1,127,372	10,478,772
Water Plant	2,512,960	-	-	2,512,960	10%	-	178,615	905,426	1,607,534
ETP Plant	1,945,375	-	-	1,945,375	10%	-	142,262	665,015	1,280,360
Balance as on 30 June,2019	686,464,201	126,821,731	11,770,992	801,514,940		1,584,685	21,974,546	58,380,161	743,134,778
Balance as on 30 June,2018	557,442,914	129,021,287	-	686,464,201		-	17,101,359	37,990,300	648,473,901

Allocation of Depreciation

Factory	18,930,781
Administration	3,043,765
	21,974,546

Indo-Bangla Pharmaceuticals Ltd
College Road, Barisal sadar, barisal.
Accounts Receivable
As at 30th June 2020

Annexure-B

SL No.	Name of Debtors	Address	Amount in Taka	
			30-Jun-20	30-Jun-19
1	Barendra Marketing House	181/A, Upo shohor, Newmarket, Rajshahi.	2,041,445	6,025,465
2	Saimun Drug, Khulna	17/3, Durgabari Road, Maymansing.	-	5,568,450
3	Shafi Medical Hall	25, BCDS Market, Maik Potti, Jessore	11,500,865	5,145,685
4	Mannan Pharmacy	BRTC Bus Station, 87, Shamoli Para, Ulla Para	-	5,521,350
5	Shah Pharmacy	Ranjit Shaha, Taramoni Medical Hall, 12, College Mor, Sherpur	-	6,025,480
6	Rakibul Medical Hall	Rakibul Hasan, 65, Hatirkumrul, Oil Pump, Sirajgong	-	6,523,470
7	Khokon Medical Hall	75, Sarder Super Market, Satkhira, Khulna	-	5,542,650
8	Rafiq medical hall	85, Kadamtala Bazer, Nator.	-	2,521,860
9	Deep medical hall	60, Hisan Medicine Market, Rangpur.	-	5,241,850
10	Iqbal medical hall	27, Sadar Road, Kishoregong.	-	4,523,650
11	City Pharmacy	Bishnu podo Shaha, 12, Thana More Golachipa.	9,610,300	6,584,700
12	Badal pharmacy	Sumit Sikder, 67, Natun Bazar, Gopalganj.	4,870,000	3,568,950
13	Kanai Lal Pharma	Kanai Lal Das, 102, Laheri Para, Faridpur.	-	65,210
14	Rumman Medical	110, Nodi Bangla Market, 2 nd floor, Shatmata, Bogura.	-	3,541,250
15	Ali Medical	Soroware Hossain, 115, Sadar Road, Kishoregonj.	-	2,565,820
16	Shahin Medical Hall	76, Nurpur Market, Babubazar, Dhaka	-	3,256,250
17	Sundorban Pharmacy	Tofazzel Hossen, 24, Station Road, Comilla.	-	4,875,620
18	Jannat Medical	Kayser Ahmed, 45, Station Road, Natore.	-	3,265,410
19	Bangladesh Medical	17, Durgabari Road, Moymonsing.	8,268,465	2,568,945
20	City Medical Hall	33, Datta Building, Infront of Town Hall, Magura.	-	3,925,420
21	Tanvir Medical Hall	Golam Soroware Hossain, 21, Station Road, Hatia.	-	3,562,895
22	Asha Drug	Mr. Azad, 42/A Heraj Market, Khulna.	-	2,254,165
23	Shams pharmacy	167, Bijoy Bitan, Hali Shohor, Hazari Lane, Chittagong.	453,355	3,521,450
24	Aroga Niketon	Monorangon Pal, 12, Sadar Road, Dohar, Dhaka.	-	1,754,875
25	Basin Medical Hall	M.A Mannan, 55, Madhabpur, Narshingdi.	-	3,526,980
26	Lovely Enterprise	Mr. Bimal, 34, Station Road, Feni.	349,830	1,625,420
27	Janata Medical Hall	15, Hazi Super Market, Rangpur.	120,850	3,526,985
28	Rup Saj Corner	Mr. Arif, 27, Bazar Road, Sayedpur.	-	5,241,350
29	Helal Drug	Md. Issa, 55, Laxmipur Mor, Rajshahi.	429,660	3,512,475
30	Utsab Meideal	Deb Dulal Shaha, 15, Sadar Road, Kishoregong.	94,350	4,012,650
31	Taramoni Medical Hall	Biplob Das, 7, Khoda Box Road, Faridpur.	-	5,874,230
32	Prodip Medical Store	Md. Rakibul Islam, 18, M.K Road, Jessore.	-	5,214,780
33	Tanzila Medical Hall	19, Merina Nodi Bangla Market, Bogura.C25	219,420	4,523,150
34	Badhon Pharmacy	28, Bangabandhu Sarak, Jhinaidah.	8,472,120	2,135,620
35	Lia Aroggo Niketon	G.C Market, 170 Hazari Lane, Chittagong.	-	2,251,480
36	Kanai Lal Medical Hall	Rajon Lal Das, 11 Bhanga Bazar, Bhanga Faridpur.	-	1,520,150
37	Shah Medical hall	320, Chandina bazar, Comilla	68,575	523,625
38	Dottho Pharma	120, Fai bazar, Chandina, Comilla	-	1,052,865
39	Johir pharma	Rammohon bazar, 25 Pan potti, Borora, Comilla	151,175	1,256,850
40	Shades Pharma	135, Chatkhil, Noakhali	-	215,420
41	Sheto Medical hall	75, Jatrabari, Dhaka.	-	25,450
42	Bayewan Medical hall	118, Shonir Akhra, Jatrabari, Dhaka	88,515	250,320
43	Alia Pharma	54, Aziz supermarket, Khulna	191,560	2,325,120
44	Nazmul Pharma	120, Laksam bazar, Comilla	312,319	250,150
45	Mayer Doa Medical hall	135, Kadamtala Bazer, Nator	157,042	165,230
46	Asif pharma	120, Durgabari Road, Moymonsing.	66,295	120,420
47	Priya Medical hall	25, Nurpur Market, Babubazar, Dhaka	-	375,450
48	Alif Medical hall	120, Merina Nodi Bangla Market, Bogura.	-	1,150,250
49	Billal Pharma	Alikamura Bazar, Chandina, Comilla	383,862	425,630
50	Rayhan Medical hall	Batagashi Bazar, Chandina, Comilla	297,487	250,480
51	Monjur Pharma	129 Akborsha, Khalshe, Chittagong	-	2,245,168
52	Shapla Medical hall	Konapara, Paradogar, Jatrabari, Dhaka	2,591,589	1,020,099

53	Tabassume Medical hall	Rarikandi,Matlab,Chandpur	-	2,215,460
54	Onanna Pharma	Changarchor, Matlab, Chandpur	-	611,241
55	Jonokollan Distribution	Durga bari Road, Moymonshing	1,003,912	2,025,480
56	Sattar Distribution	Haji Abdul Ali Super Market, 2nd Floor, Babubazar, Dhaka.	96,625	2,025,450
57	S.T.Barakas	Sector 12,Road no.14. Uttara, dhaka	5,343,551	5,536,965
58	Mizan Distribution	Barisal Sadar, Barisal	6,210,452	6,125,630
59	Shahid Distribution	Nathollabad station road, Barisal Sadar, Barisal	6,227,227	7,695,250
60	Waliullah Medicine	Chandpur	2,899,810	-
61	Uzzal Pharmacy	Narayangong	1,425,195	-
62	Wasu Pharmacy	Tangail.	1,846,400	-
63	Town Pharmacy	Chottogram	1,158,810	-
64	Bidico	ANZ Huq Eleven Square,House-1,Block-H,Road-11,Level-12,Banani, Dhaka-1212.	2,500,000	-
65	Tarak Medical Hall	Khalshe	267,105	-
66	Tajul Pharmacy	Rangpur	3,470,721	-
67	Mr.Tofayel Medicine	Rajshahi	3,317,044	-
68	Sylhet Medical Hall	Famous Market,Sylhet.	977,210	-
69	Sumona Clinic	Sagolnaya,Feni	2,931,675	-
70	Sirajul Medicine	Narayangong	3,838,695	-
71	Shamol Pharmacy	Kurigram	2,379,700	-
72	Mr.Shahin Medicine	Mymansing	605,185	-
73	Safa Dawakhana	Gazipur	936,280	-
74	Rony Medical Store	Kabirajhat, Birganj, Dinajpur	1,418,600	-
75	Robin Pharmacy	Khan Market, Bagura	4,207,800	-
76	Ritu Pharmacy	Hisan Market, Rangpur	1,264,300	-
77	Ranjan Pharmacy	Pabna	1,173,900	-
78	Rakibul Hasan Medicine	Dhaka	455,600	-
79	Rajib Roy Medicine	B. Baria	1,437,550	-
80	R.K.Deb Medicine	Zila Parishod Market, Panchagarh.	1,846,000	-
81	Q Zaman Pharmacy	Rajbari	1,023,000	-
82	Paul Pharmacy	Khalshe	872,000	-
83	Nowshad Medicine	Tangail.	1,455,775	-
84	Nishad Medical Hall	Cumilla	1,229,985	-
85	Nil Kamol Enterprise	Khulna	1,496,420	-
86	Mr. Nazmul Medicine	Chandpur	2,095,505	-
87	Nasirudin Medicine	Cumilla	1,551,420	-
88	Totul Pharmacy	Madrassa Market Shop-03.Hazari Lane.Chittagong	1,563,980	-
89	SD Pharmacy	Bhairab	1,898,250	-
90	Sujoy Pharmacy	Hazari Lane, Chittagong	1,872,535	-
91	2 Star Medicine Shop	Feni Mddicine Market,Shop--15,Bash Para,Trank Road.	261,875	-
92	4 Star Drug	40/1-Sen Para,Parbota,Mirpur-10	432,985	-
93	A.K Tarkise Medicine	Natrkona	382,955	-
94	Khokon Pharmacy	Joypurhat	736,000	-
95	Khokon Pharmacy	Joypurhat	641,970	-
96	Ma Medical Center	Khagrachari	554,240	-
97	Ma Medicine Center	Pabna	2,081,500	-
98	Ma Pharmacy	Magura	775,750	-
99	Ma Podma Pharmacy	Tangail.	792,020	-
100	Medicine Mart	Thakurgaon.	1,554,630	-
101	Mahabuba Pharmacy	Thakurgaon Road.	398,800	-
102	Matree Sheba Medico	Cox,s Bazar	1,319,900	-
103	Medicine House	Jessore	1,690,760	-
104	Mr.Monirul Medicine	Gobindogong	531,650	-
105	Moon Star Pharmacy	Hazari Lane, Chittagong	2,794,648	-
106	Mr.Makbaul Medicine	Sariatpur.	990,320	-
107	Muslim Medico	Cox's Bazar	727,750	-
108	Nackdee Pharmacy	Tangail.	1,420,205	-
109	MR.Nasir Medicine	Saver.	2,717,647	-
110	Labib Pharmacy	Hazari Lane, Chittagong	2,428,647	-
111	Mazumder Pharmacy	Safina Medicine Market, Sylhet	2,900,147	-
112	Mr. Kartik Medicine	Takerhut	1,129,900	-

113	Ma mone Pharmacy	Khalshe	4,321,120	-
114	Mahabub Medical Store	Jeshore	1,452,650	-
115	Modhon Modok Medicine	Manikgong	1,977,175	-
116	Mr.Robin Medicine	Gulshan-2.	1,938,425	-
117	Gohira Medical Hall	Chattagram	1,267,300	-
118	Green Pharmacy	Bhairab.	8,845,360	-
119	Md.Harouner Rashid Medicine	Laxmipur	2,155,495	-
120	Gouri Pharmacy	Durgabari, Mymensingh	461,000	-
121	Joy Pharma	Jahangir Market, Hazari Lane, Chittagong	498,492	-
122	Famaus Pharmacy	Rangpur	2,559,992	-
123	Firoz Alom Medicine	Chowmone	1,180,312	-
124	Juthy Pharmacy	Dinazpur	1,083,950	-
125	D K Shaha	Noakhali	659,100	-
126	Dada Pharmacy	Kustia	3,217,350	-
127	Desh Medico	Cox's Bazar	5,493,970	-
128	Durgha Pharamcy	Madhabpur	1,732,370	-
129	Fahim Pharmacy	Rangpur	432,820	-
130	Care & Cure Pharmacy	Alekhar Char Medical Market, Comilla	1,745,000	-
131	Chaya Medical Hall	Kamona Market.Sherpur.	1,298,000	-
132	Bismillah Harbal	Bhairab	985,700	-
133	Chondinin Pharmacy	Chittagong	845,700	-
134	Bisti Pharmacy	Rongpur	656,850	-
135	Care Medical Hall	Gazipur	1,004,520	-
136	Babul Drug House	Heraz Markey, Khulna	1,696,500	-
137	Biplob Pharmacy	Cumilla	1,105,130	-
138	Babul Medicine	Tonghi	638,600	-
139	Baral Markating	Nator	3,719,990	-
140	Anowar Pharmacy	Moulavibazar	388,000	-
141	Aoishi Pharmacy	Hisan Markat, Rangpur	1,073,295	-
142	Ararafat Pharmacy	Fulbari.	938,674	-
143	Asia Pharmacy	Golkuthi Road, Dinajpur	3,350,309	-
144	Asrafuddin Medicine	Chowmone	1,075,675	-
145	Aman Pharmacy	Terminal Road, Sylhet	970,420	-
146	Amir Foysal	Bera.	4,962,481	-
147	Amdadur Rahman	Bhairab.	2,044,500	-
148	Amin Pharmacy	Syrajgonj.	3,713,339	-
149	Ankur Pharmacy	Sabila Complex, 1st Floor, Shopno-01, Hazari Lane, Chittagong	2,286,971	-
	Total:		226,078,126	178,804,143

INDO-BANGLA PHARMACEUTICALS LTD.

Trade Paybles

As at 30th June, 2020

Annexure-C

Sl. No	Name of the Medical Hall	Address	Amounts in Taka	
			30-Jun-20	30-Jun-19
1	Pirojpur Printing & Packing	185, Fakirapul, Motijhil, Dhaka.	-	850,250
2	S.T.S Foil Corporation	Fakirapul, Motijhil, Dhaka.	82,103	1,214,560
3	M.K.Printers	103, Arambag, Motijhil, Dhaka.	-	565,850
4	Jass Corporation	Asulia, Savar.	34,838	1,350,250
5	Oni Printers	240/3, Fakirapul Motijhil, Dhaka.	-	523,560
6	Nahid Perfumary & Chemical	47/C, Midford, Dhaka.	-	336,980
7	Riya Perfumary	Midford, Dhaka.	-	125,470
8	Brothers Hood Chemical	Agrabad, Chittagong.	-	121,585
9	Desh Foil Limited	Sabujbag, Dhaka.	54,750	254,750
10	Banik Stors	Bazar Road, Barisal.	-	98,316
11	Padma Cap	Oponin Mor, Barisal.	15,470	215,470
12	Global Capsul	Rupatoli, Barisal.	-	154,820
13	Rouf Medical Hall	Babu Bazar, Dhaka	-	250,630
14	Rabby Cartoon	Barisal	60,000	45,780
15	Shahin enterprise	Hospital Road, Barisal	32,350	-
16	Rifat Plastic	2/3, Raj Raj Narayan Dhar Road,	6,250	-
17	Arabian Carton	Lalbagh, Dhaka	76,320	-
18	Boishaki Product	Barisal.	9,908	-
	Total Taka		371,989	6,108,271



INDO-BANGLA PHARMACEUTICALS LTD.

Bashundhara R/A, Baridhara, Dhaka-1229

PROXY FORM

I/We.....
of.....
being ashareholders of Indo-Bangla Pharmaceuticals Limited and entitle to vote, hereby appoint

Mr./Mrs./Miss.....
.....

as my/our proxy to attend and vote for me/us and on my/our behalf att he 6th Annual General Meeting of the Company to be held on **Thursday, 24 December, 2020 at 11:00 a.m.** at virtually by using digital platform and/ or at any adjournment thereof.

As witness my hand this.....day of.....2020.

Revenue
Stamp
Tk. 20.00

(Signature of the Shareholder)

(Signature of Proxy)

BO ID No.

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

No. of Shares held

Dated.....

Notes:

1. A Member entitled to attend and vote at the Annual General Meeting may appoint a proxy to attend and vote on his/her behalf. The Proxy Form duly completed must be sent through email to Registered Office at info@indo-banglapharma.com not letter 72 hours before the time fixed for the meeting.
2. Signature of the shareholder(s) should be in accordance with the specimen signature recorded with the company/.



Corporate Office: Plot# 183 (7th Floor) Block#B
Ahmed Akbar Sobhan Road, Basundhara R/A, Baridhara
Dhaka-1229. Phone- 09678777995.
E-mail : info@indo-banglapharma.com
Web : www.indo-banglapharma.com
Factory : College Road, Barisal, Phone: 0431-61028, 0431-2174977.

